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Treatment of head and neck cancer with radiation therapy is associated with adverse 
side effects to the oral cavity and surrounding areas.  These complications include 
mucositis, mucosal fibrosis and atrophy, salivary gland dysfunction, increased risk of 
dental caries, increased susceptibility to infections, tissue necrosis, taste dysfunction, and 
muscular and/or cutaneous fibrosis.  The often permanent nature of the radiation-induced 
damage necessitates the maintenance of a strict oral care program, involving frequent 
flossing and brushing in addition to daily fluoride applications, for the rest of the patient’s 
life.  An additional concern among patients with head and neck cancer is the use of 
tobacco and alcohol.  Both are known risk factors in the development of head and neck 
cancers and failure to abstain from either after diagnosis increases the risk for relapse and 
development of secondary cancers.   The present study was a longitudinal investigation of 
several factors that may influence patients’ consistency in following their prescribed oral 
care program and abstaining from alcohol and tobacco use, including, but not limited to, 
vii
patient satisfaction with the doctor-patient communication, patient coping, and patient 
illness perceptions.  The study examined an integrative model seeking to explain patient 
adherence to the oral care regimen as well as tobacco and alcohol use.  While results were 
inconclusive with respect to the model, there were several interesting findings, which 
were consistent with previous literature examining doctor-patient communication and 
illness perceptions among other cancer populations.  Results from this study suggested 
that both satisfaction with doctor-patient communication and coping play an important 
role in forming patients’ illness perceptions.  Furthermore beliefs about the severity of 
oral complications emerged as a predictor of oral care at follow-up.   
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Common to all of the head and neck cancers is the use of radiation therapy both as 
initial and adjuvant treatment.  Besides the general side effects associated with 
radiotherapy, head and neck cancer patients being treated with radiotherapy often endure 
additional complications involving the oral cavity and surrounding areas (Dreizen, 1990). 
These complications arise from damage to fast growing cells in the mucosal tissue. 
 It is estimated that most patients with head and neck cancer who are being treated with 
radiation therapy will develop oral complications.  As a consequence of these 
complications, patients with head and neck cancers who are being treated, or have been 
treated, with radiation therapy are required to follow a strict oral care regimen for the rest 
of their lives. 
 Further as both tobacco and alcohol use are know risk factors in the development of 
head and neck cancers, failure to restrict, or terminate, the use of both increases the risk 
for relapse and development of secondary cancers.  This study is a longitudinal 
investigation of several factors that may influence patients’ ability and consistency in 
following their prescribed oral care program.   
The specific aims of the project were to: 
1. Describe the pattern of adherence to a dental hygiene program and recommendations
to restrict tobacco and alcohol use among head and neck cancer patients receiving
radiation therapy.
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2. Examine patients’ perceptions of both the affective quality of the doctor-patient
communication and the instrumental information provided during the consultation in
relation to patient adherence, patients’ illness perceptions, and patients’ coping.
3. Examine the relationships between patients’ coping, patients’ illness perceptions, and
patient adherence.
4. Examine the relationship between patients’ illness perceptions and patient adherence.
5. Determine whether patients’ coping moderate the relationship between patients’
illness perceptions and patient adherence.
6. Determine whether patients’ illness perceptions act as a mediator between patients’
perceptions of doctor-patient communication and patient adherence.
The following chapters will provide a broad review of the epidemiology, biology, and 
treatment of cancer (chapter 1), discuss the concept of adherence and review predictors of 
adherence among cancer patients (chapter 2), discuss epidemiology and treatment of head 
and neck cancer specifically, present the current study (chapter 3), and describe the 
methods of the present study (chapter 4). Chapter 5 presents the findings of the study, and 
Chapter 6 provides a discussion of the results in the context of previous research. 
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CHAPTER 1:  LITERATURE REVIEW 
The aim of this chapter is to provide information about cancer and cancer treatment in 
order to better understand the context within which cancer patients find themselves. The 
chapter provides a general overview of the epidemiology, biology, and treatment of 
cancer.  The first section, cancer as a public health concern, discusses the epidemiology of 
cancer, the cost to society of cancer, and cancer prevention efforts.  The second portion of 
the chapter presents a brief overview of the development and biology of cancer, and 
common risk factors.  Finally, the chapter provides an overview of the most common 
cancer treatment modalities, and the importance of cancer treatment adherence in relation 
to clinical outcomes. 
Cancer as a Public Health Concern 
 Cancer is the second leading cause of death in the U.S.  Recent advances in medical 
technology have significantly reduced mortality rates; however, approximately 533,000 
people still die from cancer each year (Cancer Prevention & Early Detection, 2003). 
Moreover, cancer incidence rates continue to rise with an estimated 1.2 million new cases 
diagnosed each year (Ries et al., 2003; Cancer Prevention & Early Detection, 2003).  The 
life time prevalence of cancer is about 33% for women and 50% for men and currently 
8.9 million Americans have a history of cancer (Cancer Prevention & Early Detection, 
2003).
These numbers are alarming considering that a number of environmental risk factors
such as smoking, exposure to ultraviolet light, poor diet, alcohol use, exposure to certain 
chemicals (Cancer Prevention & Early Detection, 2003), and the contraction of viruses 
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such as HIV, HPV, Cytomegalovirus, and the hepatitis B virus can be reduced if not all 
together eliminated.  Not only does cancer take a huge toll in terms of human lives, the 
illnesses that fall within this category are also vastly expensive for society (Greenwald, 
2002).  According to estimates the overall financial cost of cancer is $150 billion a year. 
This number includes $50 billion a year spent on direct medical costs, $10 billion in lost 
worker productively due to cancer and $75 billion due to premature death. 
 Research on cancer has covered both the treatment and prevention of cancer. 
Advances in medical research and technology have been highly successful and despite the 
increase in incident rates over the last 20 years, survival rates have improved from 50% in 
1973 to 62% in 1998 (Greenwald, 2002).  Two other key elements in the fight against 
cancer are the focus on prevention through the reduction of risk factors and the promotion 
of early diagnosis through regular screening of high risk populations (Greenwald, 2002). 
The sedentary lifestyle adapted by many inhabitants of western society, along with poor 
dietary choices and other maladaptive health behaviors, such as smoking, are among the 
most common risk factors for cancer (Cohen & Baum, 2001; Baum & Posluszny,1999) 
and primary interventions have been focused on educating the public at large about these 
(Robertson, Bound, &  Segal, 1998; Greenwald, 2002).  In addition, the implementation 
of regular screening procedures such mammograms for women, prostate exams for men, 
and colonoscopies for both sexes, have significantly increased the proportion of cancers 
that are diagnosed in the early stages (Baum & Posluszny, 1999).  However, early 
detection through cancer screening is only effective when recommended screening 
schedules are adhered to.  Despite efforts on the public health level, an increasing number 
of people are living with cancer and within the last two decades more and more research 
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has focused on the psychosocial aspects of being diagnosed with cancer, treated for 
cancer, living with cancer, and surviving cancer.        
 The broad diagnosis of cancer encompasses many different illnesses; however, for the 
purpose of this study a general description of the illness and its treatment is discussed to 
better understand the context within which the cancer patients must cope.  
Cancer Facts 
Biology of Cancer
The term cancer covers a broad category of illnesses characterized by the presence of 
one or more neoplastic growths.  A neoplasm is a cell, or group of cells, which have lost 
the mechanism that normally controls the cell cycle and consequently grow at an 
abnormally increased rate, often invading surrounding tissues and organs (Duckett & 
Belldegrun, 1992).  The first step during which a cell is primed, through the exposure to 
carcinogens, to become cancerous is known as the initiation phase.  Once primed, the 
cell’s DNA changes and the cell is considered cancerous.  This phase is known as 
promotion.  The change in DNA is what causes the uncontrolled growth, or dividing, of 
the cell, which ultimately results in a tumor (Stockhorst, Klosterhalfen, & Steingrueber, 
1998; Duckett & Belldegrun, 1992). 
 Not all tumors are malignant.  There are two main differences between benign and 
malignant tumors (Duckett & Belldegrun, 1992).  First, malignant tumors have no clearly 
defined borders and directly invade surrounding tissue, whereas benign tumors are clearly 
defined and do not spread to surrounding tissue.  Second, malignant tumors have the 
ability to spread throughout the body by shedding malignant cells that travel through 
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blood and lymph vessels to other tissues where they establish new growths, whereas 
benign tumors do not (Dollinger, Rosenbaum, & Cable, 1997).  This shedding of cells is 
what is known as metastasis.  As a general rule, malignant tumors are what we are 
concerned about when we talk about cancer.  There are a few exceptions to this rule 
involving benign tumors that, either because of their size or location, are causing 
functional impairment necessitating treatment.  The stage of cancer is classified by the 
TNM System which indexes 4 stages of severity, reflecting tumor size (T), degree of 
spread to lymph nodes (N), and metastasis (M) (Fleming et al, 1997).   
 Normally, the immune system, which is the body’s natural defense against cancerous 
cells, is proficient in detecting and eliminating cancer cells before they can replicate 
(Duckett & Belldegrun, 1992).  One of the most important features of the immune system 
is its ability to recognize foreign cells or tissue (Naftzger & Houghton, 1991; Bancroft B., 
1994).  All of the cells in our body carry what is known as a “self-marker,” however, 
microorganisms such as virus and bacteria lack this marker and can thus be labeled as 
foreign to the host (Bancroft B., 1994).  Once a cell has been recognized as foreign it is 
either killed immediately (Natural Killer Cells) or tagged for later destruction 
(Macrophages) (Bancroft B., 1994).  White blood cells, such as macrophages and natural 
killer cells, are the first line of response (Bancroft B., 1994).  These cells circulate 
throughout the body constantly and, when they come across a foreign cell alert the rest of 
the immune system to the presence of foreign cells in two ways (Naftzger & Houghton, 
1991; Bancroft B., 1994).  First, they produce and release small proteins known as 
cytokines, which stimulates other cells collectively known as lymphocytes.  Lymphocytes 
fall into two broad categories: B cells, which produce antibodies (proteins that attach 
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themselves to the markers of foreign cells), and T cells, which serve two functions.  T 
cells produce and release cytokines that stimulate the growth and activation of: (1) B cells 
and (2) a subset of T cells known as cytotoxic T cells, which can destroy foreign cells on 
direct contact (Pardoll & Topalian, 1998).  The immune system is able to kill a majority 
of cancerous cells because these cells, as a result of their altered DNA display markers, 
which label them as foreign to the host (Duckett & Belldegrun, 1992; Post-White, 1996). 
However, for any given cell to elicit an immune response the marker displayed must be 
sufficiently different from the self-marker (Duckett & Belldegrun, 1992; Naftzger, 1991). 
Cancer often develops when the markers of a cancerous cell do not elicit an immune 
response (Post-White, 1996; Naftzger, 1991).   Further, any condition that weakens the 
immune system, such as HIV+ status, AIDS, autoimmune diseases, and 
immunosuppressive medications, make the host more susceptible to developing cancer. 
Ironically, the most common forms of cancer treatment, such as radiation therapy and 
chemotherapy, adversely affect the immune system; the very system that normally 
defends against cancerous growths. 
Risk Factors for Cancer
Factors disrupting the mechanism controlling normal cell growth are known as 
carcinogens.  Some common carcinogens are chemicals, such as those found in tobacco 
smoke and alcohol, radiation (e.g. sunlight), poor diet (high in fat and low in fiber), and 
viruses such as HIV, HPV, Cytomegalovirus, and the hepatitis B virus all of which can 
cause cancer (Meng, Maskarinec, Lee, & Kolonel, 1999, Cancer Prevention & Early 
Detection, 2001).  Carcinogens often play a role in the initiation phase by either 
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promoting mutations in the cell’s normal cycle or by reducing the immune system’s 
ability to recognize and eliminate cancerous cell.  However, carcinogens are typically not 
sufficient in causing cancer (Schull, 1991).  Most cancerous growths result from a 
combination of the introduction of a carcinogen and inherent genetic flaws (known as 
promoters) within the cell, which makes the cell more susceptible to becoming cancerous 
(Tomatis, 1998).  Genetic risk factors encompass having a family history of cancer or 
chromosomal abnormalities, such as Down’s syndrome (Schull, 1991).   
 Once the diagnosis of cancer has been given, treatment is usually prompt and 
aggressive.  The following section will discuss the different cancer treatments in more 
detail along with adherence rates to each treatment. 
Cancer Treatment 
 Cancers that are in the early stages can be treated very successfully (van Dongen & 
Snow, 1997), and one of the key predictive factors of successful treatment is early 
diagnosis.  However, early detection of cancer is often difficult.  For example, a tumor is 
usually not detectable until it has divided into 1 billion cells, or gone through 30 
doublings, and most people do not experience any symptoms of illness prior to this point 
(Naftzger, 1991).  The time between promotion and detectable size is known as the 
“silent” period and can last from many months to several years, thus, further complicating 
early detection of malignant tumors (Dollinger, Rosenbaum, & Cable, 1997; Naftzger, 
1991). 
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The four most common treatment modalities for cancer are surgery, chemotherapy, 
radiation, and immunotherapy.  All of these treatments have been proven highly 
successful in treating cancer depending on stage, site, and metastasis.  
Surgery
Surgery is the oldest form of cancer treatment and involves the surgical removal of 
tumors (Mocellin, Rossi, Lise, and Marincola, 2002).  Two factors determine the 
appropriateness of surgery as a treatment option.  One factor is the degree to which the 
cancer has spread (Lenhard, Osteen, & Gansler, 2001).  Tumors that are localized and 
have not spread are usually good candidates for surgical removal, whereas tumors that 
have metastasized often complicate surgery or make surgical removal of several tumors 
inappropriate.  The other factor, which must be considered when evaluating surgery as a 
treatment option, is the question of whether tumors can be removed without damage to 
vital organs such as the liver or the brain (Lenhard, Osteen, & Gansler, 2001; Mocellin, 
Rossi, Lise, and Marincola, 2002). 
 Surgery is often used in combination with other treatment modalities such as 
chemotherapy and radiation therapy (Pazdur, Coia, Hoskins, & Wagman, 1996).  Either 
of these may be given prior to surgery to shrink tumors and, thus, simplify the surgical 
procedure.  This is known as neoadjuvant therapy.  Adjuvant therapy, treatment with 
either chemo or radiation after surgery, is given to insure that tumor cells that are too 
small to be visible or tumor cells that could not be removed through surgery do not cause 
later recurrence (Dollinger, Rosenbaum, & Cable, 1997).   For head and neck cancer 
patients the side effects of surgery not only involve the general concerns of recovery and 
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pain management, they often have to cope with permanent disfigurement of the face and 
neck, that can not be hidden by clothing (Hagedoorn & Molleman, 2006; Pruzinsky, 
Levine, & Persing, 2006).  In addition, there is always a risk involved when undergoing 
general anesthesia and having surgery that involves vital organs and/or their surrounding 
tissue. 
Chemotherapy   
Chemotherapy is the use of chemical agents to destroy cancer cells.  While there are 
many different anticancer drugs, most agents used in chemotherapy kill cancer cells by 
affecting their DNA synthesis or metabolic processes (Stockhorst, Klosterhalfen, & 
Steingrueber, 1998). Chemotherapy is in particular appropriate for cancers that have 
metastasized, or leukemias, as the drugs act on a systemic level (Burke, Wilkes, 
Ingwersen, Bean, & Berg, 1996).  The flip side of this important property is coincidently 
one of the main problems in the use of chemotherapy as these agents not only affect 
cancer cells but also normal healthy cells.  The balance between a therapeutic dose and a 
toxic dose is a delicate matter (Dollinger, Rosenbaum, & Cable, 1997) and many of the 
common side effects of chemotherapy are a direct consequence of the toxicity of these 
drugs to normal cells (Camp-Sorrell, 1997).   
 Chemotherapy is most commonly administrated by mouth, through a vein, or into 
muscle tissue (Burke, Wilkes, Ingwersen, Bean, & Berg, 1996).  Recently, however, new 
methods have been applied to increase the local concentration of chemotherapy at the 
tumor site itself leading, not only, to more efficient treatment, but also a reduction in 
some of the systemic side effects (Jurcic & Scheinberg, 1994).  Such methods include 
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administration directly into a specific cavity, the abdomen, the lung, the central nervous 
system, or application directly onto the skin (Jurcic & Scheinberg, 1994).  Another 
complication of treatment with chemotherapy is the length and intensity of treatment. 
While there is great variation in treatment regimens due to type of cancer and individual 
response rates, chemotherapy is generally spaced out over an extended period of time 
with the average treatment regimen lasting anywhere from to 4 to 12 months (Burke, 
Wilkes, Ingwersen, Bean, & Berg, 1996).  Within this time period treatments are usually 
given on a daily, or weekly, schedule with recovery periods interspersed between 
treatments and most patients receive their chemotherapy every 3 to 4 weeks.  
 Chemotherapy is known for its adverse side effects.  As previously mentioned 
chemotherapy not only destroys cancerous cells but also affects healthy cells.  The 
healthy cells that are most at risk for being destroyed by chemotherapy are those which 
tend to grow at a fast rate, particularly blood cells (Camp-Sorrell, 1997).  There are three 
types of blood cells and each type has a special function.  Red blood cells carry oxygen to 
all of the cells in the body, white blood cells are part of the immune response and are 
important in preventing and fighting off infections, and platelets play a central role in 
stopping bleeding. 
 Chemotherapy can cause a reduction in the red blood cell count leading to anemia 
(Camp-Sorrell, 1997).  Common symptoms of anemia include: fatigue, dizziness, 
headache, shortness of breath or difficulty breathing, chest pain or palpitations, 
irritability, ringing in the ears, and feeling chilled.   
 Another adverse effect of chemotherapy is the reduction of white blood cell counts, a 
condition known as neutropenia (Stockhorst, Klosterhalfen, & Steingrueber, 1998). 
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Patients with neutropenia are at increased risk for opportunistic infections and may also 
have a difficult time recovering from infections.  Signs of neutropenia include: fever, 
coughing, excess mucous, shortness of breath or painful breathing, soreness or swelling of 
the oral cavity, mouth ulcers and fungal infections, pain or burning with urination, 
diarrhea, redness, pain or swelling of the skin, pus or drainage from any open cut or sore, 
and an overall feeling of being sick in the absence of fever or any other sign of an 
infection (Camp-Sorrell, 1997).  
 Chemotherapy is also associated with low platelet counts, a condition known as 
thrombocytopenia (Camp-Sorrell, 1997).  Platelets play an important role in clotting 
blood, and patients with thrombocytopenia are at increased risk of bleeding from minor 
injuries, such as a small cut or bump.  Common symptoms of thrombocytopenia include: 
excessive bruising of the skin, petechiae (tiny red spots on the skin), bleeding gums, 
frequent nosebleeds that are difficult to stop, excessive bleeding from a small cut, and 
blood in the urine and stool. 
 Other fast growing cells include hair cells and cells of the intestinal lining and mucous 
membranes.  The consequence of chemotherapy on these cells, lead to some of side 
effects most commonly associated with chemotherapy such as constipation, diarrhea, hair 
loss, mouth sores, and nausea and vomiting (Cull, 1990; Stockhorst, Klosterhalfen, & 
Steingrueber, 1998).     
 Other studies have cited psychological and cognitive impairments as direct 
consequences of chemotherapy stressing the importance of psychological and/or 
psychiatric consultations with patients receiving chemotherapy (Silberfarb, Philibert, & 
Levine, 1980; Cull, 1990). 
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Radiation Therapy
Radiation is another form of cancer treatment and involves exposing tumors to high-
energy x-rays.  Similarly to chemotherapy, radiation destroys cells by damaging the cells’ 
DNA and preventing them from replicating (Coia, 1998).  Radiation is widely used to 
treat many different types of cancer, sometimes as a primary treatment modality and, at 
other times, in combination with surgery and/or chemotherapy.  Radiation is particularly 
lethal for cells that are in the growing and dividing phase of the cell cycle.  Because, 
cancer cells grow and multiply at a much higher rate than most normal cells, radiation 
therapy is an effective treatment for cancer.  However, as with chemotherapy, normal 
cells are also affected, particularly those that grows fast such as hair cells, cells lining the 
intestines, and blood cells.   
 Radiation can be administered externally (most common) or internally (less common) 
(Coia, 1998).  During external radiation high-energy x-rays are directed to the particular 
area of the body where the tumor resides (Coia, 1998).  In most cases treatments are given 
once a day, Monday through Friday on an outpatient basis, over a period of 3 to 7 weeks. 
During internal radiation treatment the radioactive substance is sealed and held in place at 
site of the tumor by mechanical devices, swallowed by mouth, or injected into the body 
(Coia, 1998).  During treatment with internal radiation most patients are hospitalized for 
3-7 days as they can be considered a radioactive source and necessary precautions must 
be taken.  Side effects are generally limited to the region of the body being treated. Some 
of the most common side effects of radiation are skin irritation, hair loss, discomfort 
swallowing, nausea, altered taste, diarrhea, and fatigue (National Cancer Institute, 2002; 
Miaskowski & Lee, 1999). 
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Immunotherapy
The most recent development in cancer treatment is the use of biological response 
modifiers (BRMs) also known as immunotherapy (Greenwald, 2002; Salgaller, 2000; 
Mocellin, Rossi, Lise, & Marincola, 2002).  BRMs are used to help the patient fight 
cancer by strengthening their immune response to cancer cells (Bremers & Parmiani, 
2000).  The functions of BRMs fall into three major categories.  The first group consists 
of agents that help boost the body’s normal immune response to cancerous cells, the 
second group is comprised of agents that directly affect the tumor, and the third group 
includes agents that reduce a tumor's ability to metastasize and differentiate.  Common 
agents currently used in immunotherapy are interferons (INFs), interleukins (IL-), colony-
stimulating factors (CSFs), and monoclonal antibodies (MoAbs).  The use of T cells and 
tumor necrosis factors (TNFs) are still being investigated (Salgaller, 2000; Pardoll & 
Topalian, 1998).  Both interferons and interleukins belong to the broader category of 
cytokines which are proteins produced by cells of the immune system that regulate the 
activity of B and T cells (Grimm, 2000; Mocellin, Panelli, Wang, Rossi, & Marincola, 
2002; Kintzel & Calis, 1991). 
Interleukin-2 is an immunomodulating agent that stimulates the proliferation, 
activation, and differentiation of important cells of the immune system such as T and B 
cells and natural killer cells (Kintzel & Calis, 1991; Mocellin, Panelli, Wang, Rossi, & 
Marincola, 2002). Most clinical studies of interleukin-2 has involved the treatment of 
patients with renal cell carcinoma, melanoma, and colorectal cancer who historically 
respond poorly to conventional therapy (Kintzel & Calis, 1991).  Results have indicated a 
positive response to therapy with interleukin-2 among these patient (Kintzel & Calis, 
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1991) and suggested that the administration of interleukin-2 (IL-2) to patients with cancer 
may mediate the regression of established cancers (Mocellin, Panelli, Wang, Rossi, & 
Marincola, 2002) 
 Colony-Stimulating factors are growth factors, which mediate the proliferation, 
maturation, regulation, and activation of red and white blood cells as well as platelets 
(Salgaller, 2000).  As discussed previously, one of the major side effects of chemotherapy 
is the destruction of blood cells.  The ability to stimulate the growth of these cells 
provides an opportunity to treat tumors more aggressively with higher doses of 
chemotherapy that under normal circumstances would be highly toxic to the patient.   
 A recent development in immunotherapy involves the use of monoclonal antibodies 
(MoAbs) (Jurcic & Scheinberg, 1994).  In this form of therapy samples of the patient's 
tumor cells are taken and processed to reveal specific antibodies to the tumor-associated 
antigens.  Such antibodies are then developed in a lab and injected back into the patient 
where, it is hoped, they will seek out and attach themselves to the tumor cells (Salgaller, 
2000).  Research in this area is also examining the use of monoclonal antibodies as 
carriers of other therapeutic agents such as chemotherapy or radioactive substances that 
can, by way of the tumor specific antibodies, be delivered directly to the tumor (Bast, 
Zalutsky, Kreitzman, Sausville, & Frankel, 2000).  This approach would be more 
effective and significantly less toxic than the conventional treatment modalities currently 
available. (Greenwald, 2002; Jurcic & Scheinberg, 1994).  
 Most treatment with BRMs is delivered though IV or injections.  Potential side effects 
are numerous.  Some are life threatening (see below), and require that the administration 
of both IL-2 and MoAbs are carried out on an in-patient basis (Bast, Zalutsky, Kreitzman, 
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Sausville, & Frankel, 2000; Kintzel & Calis, 1991).  Treatment with INF is commonly 
associated with fever, chills, tachycardia, muscle aches, malaise, fatigue, headaches, 
decreased white blood cell count, anemia (with prolonged therapy), decreased platelets, 
hair loss, loss of appetite, nausea, vomiting, and diarrhea.  In addition are central nervous 
system toxicities, ranging from mild confusion and sleepiness to serious seizures. Acute 
kidney failure is rare, but can occur.  Side effects of IL-2 treatment include hypotension, 
ascites (the accumulation of fluid in the abdominal cavity), generalized body edema, 
pulmonary edema, chills and fever, headache, malaise, nausea, vomiting, loss of appetite, 
diarrhea, mucositis, liver dysfunction, in addition to CNS effects such as lethargy, 
confusion, disorientation, hallucinations, anxiety, and sometimes depression (Walker, 
Walker, Heys, Lolley, Wesnes, & Eremin, 1997; Smith and Khayat, 1992; Pavol, Meyers, 
Rexer, Valentine et al, 1995). 
 Monoclonal antibody therapy has been associated with side effects such as dyspnea 
(difficulty breathing) and mild wheezing, fever, chills, headache, rash, nausea, vomiting, 
tachycardia, and serious allergic reactions.  In contrast, side effects of treatment with CSF 
are usually benign (Salgaller, 2000). 
Complimentary Measures
Cancer prevention health behaviors such as eating a low fat, high fiber diet, regular 
exercise, low alcohol consumption, and abstaining from tobacco use are also 
recommended for cancer patients (Cohen & Baum, 2001) for three reasons.  First, poor 
health behaviors such as a high fat, low fiber diet, sedentary life style, alcohol use, along 
with use of any form of tobacco have all been found to be risk factors in the development 
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of cancer (American Cancer Society, 2002; Baum & Posluszny, 1999) and thus continue 
to present a threat to cancer patients.  Second, continued use of alcohol and tobacco may 
reduce the effectiveness of cancer treatments (Des Rochers, Dische, & Sounders, 1992; 
Browman, Wong, Hodson, et al, 1993).  Third, as reviewed above, side effects of cancer 
treatments include fatigue, treatment induced food aversion, and anorexia which can be 
relieved by moderate exercise and proper nutrition. 
 In summary, the three most common and effective treatments of cancer are surgery, 
chemotherapy, and radiation therapy.  The use of biological Response Modifiers in cancer 
treatment is still being investigate, but research has showed promising results and some 
potential benefits over chemotherapy and radiation therapy as the allow delivery of both 
treatment modalities at a cellular level, thereby reducing adverse side effects. 
Complimentary measures are another important aspect of cancer treatment.  They support 
overall health of the patients allowing for more aggressive treatment, and may prevent 
relapse or secondary cancers upon the conclusion of treatment. 
Cancer Treatment Outcomes 
 As mentioned earlier, new medical technology has significant improved cancer 
survival rates.  Part of this improvement can be attributed to technology that has made 
early diagnosis possible, but much of the increase in survival rates can be directly 
attributed to advances in treatment options.  This section will provide a brief presentation 
illustrating the effectiveness of cancer treatments.   
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Chemotherapy
When appropriately administered chemotherapy has been found to be a highly 
effective treatment for cancer (Green & Hortobagyi, 2002).  In a study of women being 
treated with chemotherapy for breast cancer (Bonadonna & Valagussa, 1981) results 
revealed a clear dose-dependent effect, indicating that the effectiveness of chemotherapy 
increased among patients who received the full or nearly full dose (greater than or equal 
to 85 per cent of the planned dose). Specifically, patients who received all 12 cycles of 
chemotherapy in addition to radical mastectomy had a five-year relapse-free survival of 
77%.  In contrast, among patients who received less than 65% of the planned dose the 
five-year relapse-free rate of survival was 48%, which is similar to the five-year relapse-
free survival among patients treated only with radical mastectomy, which was found to be 
45%. 
 Similarly, three other studies of cancer patients found that when IV doses of 
chemotherapy received by the patient were less than the standard recommendation, 
disease outcome was negatively compromised (Tannock et al, 1988; Wood et al, 1994). 
The importance of providing the optimal dose and number of treatments with 
chemotherapy has also been demonstrated in studies of children with leukemia (Eden, 
Stiller, & Gerrard, 1988; Bonadonna, Gasparini, & Rossi, 1980).  Here results showed 
that receiving the standard recommendations of dose and number of treatments was 
associated with prolonged survival.   Finally, preliminary results have suggested that 
while the link between neoadjuvant chemotherapy and survival rates remains unclear, 
neoadjuvant therapy has been shown to reduce the need for surgical intervention (Green 
& Hortobagyi, 2002). 
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Radiation Therapy
Consistent results have been found for radiation therapy.  In a retrospective analysis of 
survival rates among patients treated with radiotherapy for head and neck cancers 
Cathcart, Dunican, and Halpern (1997) the outcomes and treatments of 69 patients were 
analyzed. Patients who completed less than 80% of the prescribed treatment were 
categorized as non adherent.  The overall five year survival of patients who completed 
treatment was 38% versus 12% for patients who failed to complete treatment and the 
mean survival time for the compliant group was 24.2 months versus 12.6 months for the 
noncompliant group.   Authors concluded that the length of patient survival from head 
and neck cancer is directly related to compliance to radiation treatment. 
 Compliance appears to be directly related to better overall survival and mean survival 
time.  These results are supported by another study of women undergoing radiation 
therapy for early stage breast cancer (Li, Brown, Ampil, Burton, Yu, & McDonald, 2000). 
In this study full compliance was defined as completion of the entire course of radiation 
therapy and clinical follow-up.  The authors reported that among patients who failed to 
complete the entire radiation regimen, 53% did not improve with treatment, whereas only 
5% of patients who completed their radiotherapy failed to show improvement.  Another 
study examining the role of radiation scheduled in overall survival (Alden, O'Reilly, 
Topham, Lowry, Brodovsky, & Curran, 1996) concluded that the number of days 
between radiation therapy treatments was highly predictive of overall survival. In other 
words delay or disruption of treatment had a negative impact on survival rates. 
Specifically, results showed that among patients who received treatments less than 55 
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days apart survival rates were significantly higher (56%) than survival rates among 
patients whose treatments were more than 66 days apart (15%). 
Immonotherapy
On the other hand, treatment outcomes of immunotherapy vary depending on specific 
agents and form of cancer.  Given the recent development in this field, BRMs are still 
undergoing clinical trials.  However, preliminary research has produced optimistic results. 
The use of interferons in cancer treatment has been found to have response rates from 15-
90% depending on cancer type.  The mechanism by which interferons work in yet 
unclear, but it is believed that they may make tumors appear even more foreign and thus 
increase the likelihood of attack by antibodies and other immune cells.  The only FDA 
approved use of interferons in cancer therapy is the use of INF-α2b (McMasters & 
Swetter, 2003). In trials examining the response rates to INF-α2b, the 5 year relapse-free 
survival among patients with stage II and III melanoma has been reported to be between 
37-44 %. (Kirkwood, Strawderman, Ernstoff, et al., 1996; Kirkwood, Ibrahim, Sondak, et 
al, 2000; Kirkwood, Ibrahim, Sosman, et al, 2000).  The primary barriers in the use of 
INF-α2b are the adverse side effects. 
 The FDA has also approved the use of interleukins (IL-2) in cancer therapy, which act 
by increasing the activity of cytotoxic T cells which can both identify and destroy cancer 
cells (Mocellin, Panelli, Wang, Rossi, & Marincola, 2002).  While general response rates 
to treatment to IL-2 treatment are moderate, IL-2 has been found to be an effective 
treatment for cancers, such as renal cell cancer and melanoma, which historically respond 
poorly to conventional treatment (Kintzel & Calis, 1991).  The usefulness of monoclonal 
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antibodies has also been examined.  In two recent reviews of the developments in the area 
of immunotherapy (Jurcic & Scheinberg, 1994; Cheng, Rieger, von Mehren, Adams, & 
Weiner, 2000) authors concluded that trials examining the effectiveness of radiolabeled 
MoAbs have produced positive results. 
Diet
Adhering to a healthy diet is not only a preventive factor: consuming a healthy diet 
during cancer treatment has been associated with an increase in the body’s ability to 
tolerate treatments in two ways.  As stated previously some common side effects of 
cancer treatment encompass both food aversion and anorexia.  Thus, malnutrition during 
cancer treatment is common and a real concern.  Following a proper diet has been shown 
to reduce the chances of malnutrition by ensuring the presence of important nutrients. 
Second, certain nutrients have been associated with improved immune status (Lowell, 
Parnes, & Blackburn, 1990; Simone, Simone, & Simone, 1997).  Specifically, studies 
have suggested that the both omega-3 polyunsaturated fatty acids and the amino acid 
arginine may significantly enhance immune function (Lowell, Parnes & Blackburn, 
1990).  In a study examining the effects of nutritional supplements in late stage cancer 
(See, Mason, & Roshan, 2002) results revealed a positive effects of the addition of milk 
whey protein, ascorbic acid, Immune Modulator Mix (a combination of vitamin, minerals, 
antioxidants and immune-enhancing natural products) and soy extract on titers of natural 
killer cells and tumor necrosis factor alpha. The underlying mechanisms of these findings 
are still being investigated but some researchers have suggested that the nutrient effects 
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may affect the expression of specific genes, especially cytokine and cytokine receptor 
expression (Sanders & Kline, 1995).   
Exercise
Similar effects have been found in relation to physical activity.  Other studies of the 
effects of physical exercise on quality of life in cancer patients have found that 
participation in an exercise program during hospitalization was significantly correlated 
with several quality of life measures such as physical well-being, psychological well-
being, depression, anxiety and number of days hospitalized. (Courneya, Keats, & Turner, 
2000; Block, 2000; Simone, Simone, & Simone, 1997; Dimeo et al, 1996).  Specifically 
exercise has been found to reduce the severity and duration of side effects such as fatigue, 
neutropenia, thrombocytopenia, diarrhea, and pain (Dimeo, Fetscher, et al, 1997; Mustian, 
Katula, and Gill, 2002; Mock et al, 2001).  One study also found that moderate exercise 
during inpatient treatment reduced the length of hospitalization (Dimeo, Tilmann, et al, 
1997).  In a review (Nieman, 1997) of exercise immunology, data suggests that the 
incidence and mortality rates for certain types of cancer are lower among patients who 
remain physically active and that exercise may increase the rate of with which white 
blood cells (macrophages, NK cells, and lymphocytes) circulate the lymphatic system.  
Tobacco use
Research examining the effects of continued tobacco use after diagnosis of cancer has 
produced disturbing results.  Not only are cancer patients who continue to smoke at an 
increase risk for relapse and secondary malignancies, smoking can also negatively impact 
treatment by significantly reducing the effectiveness of treatment.  In a study of patients 
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with head and neck cancer, Browman et al (1993) found that the rate of complete 
response to radiation therapy was 45% among patients who continues to smoke compared 
to 74% for those who did not smoke during treatment.  In addition patients who continued 
to smoke during treatment also had a significantly poorer two-year survival rate (39% 
versus 66%).  Similar results were observed in another study of patients with carcinoma 
of the bladder (Flesher et al, 1999).  Here authors found a significant decrease disease free 
survival time among continued smokers compared to quitters and ex-smokers.  Other 
studies have supported these results.  In a study investigating the effect of nicotine on the 
cytotoxic effects of anticancer agents (Onoda et al, 2001) results indicated that nicotine 
adversely affects the ability of anticancer agents to kill of cancerous cells.  Research 
focusing on the risk of developing secondary malignancies among continued smokers has 
found that both prolonged and intense smoking prior to diagnosis as well as continued 
smoking after diagnosis greatly increases the odds for secondary cancers or relapse (Day, 
Blot, Shore, MacLaughlin et al, 1994). 
Alcohol use
Alcohol use has also been established as a potent risk factor in the development of 
cancer. Studies examining the effect on treatment outcomes among cancer patients who 
continue alcohol use after diagnosis suggests that the risk of developing secondary 
malignancies is higher among these patients than among non-drinking patients (Day, Blot, 
Shore, MacLaughlin et al, 1994).  In a review (Wynder, Mushinski, & Spivak, 1977) of 
the relationship between tobacco and alcohol consumption and the development of 
additional primary cancers of the upper alimentary tract (oral, oral-pharyngeal, larynx, 
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and lung cancers) authors concluded that chances of developing a second primary 
malignancy (i.e. relapse) is dependent principally on the intensity (i.e., quantity and 
duration) of alcohol consumption prior to diagnosis.  These results were consistent with 
the finding of Day, Blot, Shore, MacLaughlin et al (1994) that alcohol use is a risk factor 
for secondary malignancies. 
Summary 
 In conclusion, adherence to the recommended cancer treatment regimen is highly 
correlated with clinical outcomes among cancer patients.  It should be noted here, that 
what denotes an effective dose varies depending on type of cancer and stage of illness, 
and there is a wide range of individual variability in response rates to what is normally 
considered effective doses or treatments.  Despite evidence that most cancers can be 
treated successfully with standard treatment modalities such as surgery, chemo, radiation, 
or immunotherapy, treatment adherence rates vary greatly.  This chapter has provided a 
brief review of the epidemiology and biology of cancer, cancer treatment modalities and 
cancer treatment outcome.  The next chapter will review the concept of adherence, 
adherence rates to the different forms of cancer treatment, and predictors of adherence to 
cancer treatment. 
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CHAPTER 2: PREDICTORS OF CANCER TREATMENT ADHERENCE 
A brief discussion of the concept of treatment adherence serves as an introduction to 
this chapter. Following the introduction, adherence rates among cancer patients to 
chemotherapy, radiotherapy, diet, exercise, and tobacco/alcohol cessation are considered. 
The second section of the present chapter reviews predictors of adherence that have been 
proposed in the literature such as those relating to type and stage of cancer, demographic 
variables, and psychosocial components. 
The Concept of Adherence 
 Before discussing treatment adherence and predictors of treatment adherence in the 
context of cancer it is important to briefly review the definition of medical treatment 
adherence.  In the medical literature treatment adherence has been defined as “the degree 
to which a patient ‘voluntarily’ follows the (treatment) regimen recommended by a 
(health care) provider” (Barofsky, 1984).  Inherent in this definition is the point that 
treatment adherence involves both the health care provider and the patient.   
 Traditionally, adherence to treatment has been viewed as a necessary step in reaching 
remittance of disease state and, hopefully, long term survival by the patient (Peterman & 
Cella, 1998; Lewis, Linet, & Abeloff, 1983).  This is also the view held by many health 
care providers as this is consistent with their job description.  Thus, a patient who fails to 
follow through with all recommendations may be labeled as ‘non-adherent’.  The health 
care provider perspective often assumes that patients will adhere to treatment 
recommendation 100% as the patient is viewed as the primary beneficiary of adherent 
behavior.  However, research has found that among chronically ill patients the perspective 
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on adherence is more related to the notion of ‘doing one’s best’ under the circumstances 
(Roberson, 1992).  Further, patients often defined adherence in the context of their life 
(i.e. actual ability to follow through with recommendations) as well as their perception of 
what is reasonable and effective (Roberson, 1992).    
 Recently, researchers have begun to examine possible predictors and correlates of 
cancer treatment adherence.  To date most research on treatment adherence in the context 
of cancer has focused primarily on two questions.  One area of research has examined the 
medical and health related consequences of poor adherence, while another area has been 
aimed toward the development of ways to measure adherence and, subsequently, the 
measuring of actual adherence rates among cancer patients (Peterman & Cella, 1998). 
Adherence to Cancer Treatment 
Adherence to Chemotherapy
Studies examining adherence to chemotherapy have suggested that overall 
approximately 8% of patients fail to complete the recommended regimen of 
chemotherapy (Blay et al, 1995; Brown et el, 1994; Moertel et al, 1990; Taylor, 
Lichtman, & Wood, 1984).  In addition, research suggests that the percentage of patients 
who fail to complete the entire treatment regimen is even higher.  For example, one study 
of women with breast cancer (Ayres, Hoon, Franzoni, Matheny et al, 1994) found that 
only 63% of the women kept more than 85% of their scheduled treatment appointments. 
 Non-adherence with chemotherapy also appears to be higher among patients with late 
state cancers.  For example, in a trial examining the effects of adjuvant chemotherapy in 
patients with advanced lung cancer it was found that only 54% of patients actually 
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completed all four courses of recommended chemotherapy (Feld et al, 1993).  In two 
studies of patients with advanced stage leukemia and non-Hodgkin’s lymphoma non-
adherence was reported to range between 10-15% (Jehn, 1994; Verdonck et al, 1992), and 
among women with late stage breast cancer non-adherence has been reported to range 
anywhere from 20-30% (Schumacher et al, 1994; Rivkin et al, 1993). 
 Recently, oral administration of chemotherapy has become more prevalent.  In a 
review of adherence to oral anti-neoplastic agents by Partridge, Avorn, Wang, & Winer 
(2002), the authors reported adherence rates ranging from 16.8% to 97.9% depending on 
type of cancer and the specific agent.  This means that anywhere from 2% to 83% of 
patients could be classified as non-adherent.  Similar results were found in a study 
examining adherence rates, and predictors of nonadherence, in women receiving adjuvant 
treatment with tamoxifen for breast cancer (Partridge, Wang, Winer, & Avorn, 2003). 
Authors found that during their first year of treatment, patients filled prescriptions for 
tamoxifen 87% of the time.  However, after four years adherence rates dropped to 50%. 
This is a significant drop considering that continued use of tamoxifen therapy can prevent 
recurrence and death in women with early-stage breast cancer. 
Radiation Therapy
Relatively few studies have focused on the issue of treatment adherence in the context 
of radiation therapy.  In a study by Hyland et al (1983) the authors suggest that non 
adherence to radiotherapy may take the form of delay in seeking treatment, refusal of 
treatment recommendations, premature termination of treatment, and no show for post 
treatment follow-up appointments. 
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Studies examining actual adherence rates to radiotherapy among cancer patients 
suggest that adherence rates among patients receiving radiotherapy are moderate.  For 
example, in a study of adherence to recommended radiation therapy among head and neck 
cancer patients 47% were found to be compliant (Cathcart, Dunican, & Halpern, 1997). 
Similarly, in a study of women with cervical cancer (Formenti, Meyerowitz, Ell, 
Muderspach, Groshen, Leedham, Klement, & Morrow, 1995) results suggested that up to 
60% of patients failed to complete the regimen of radiation therapy.  In another study 
examining adherence rates and clinical outcome among rural women undergoing 
radiation therapy for early stage breast cancer (Li, Brown, Ampil, Burton, Yu & 
McDonald, 2000), the authors reported that only 36% of the patients were fully 
compliant, i.e. they completed the entire course of radiation therapy and all clinical 
follow-up appointments  
Diet
The benefits of maintaining a low fat high fiber diet in cancer prevention and control 
are well established.  No one study has examined the adherence to such a diet among 
cancer patients in general.  However, several randomized trials examining adherence 
among different experimental conditions have found that adherence among participants 
receiving an intervention targeting diet is higher than adherence among controls.  In one 
such study of 240 women who had been operated for a stage I-II breast cancer (Holm, 
Nordevang, Ikkala, Hallstrom, & Callmer, 1990).  121 were assigned to an intervention 
group receiving dietary counseling to reduce dietary fat and 139 were assigned to a 
control group which received no dietary advice.  All patients were followed for two years. 
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Patients in the intervention group decrease their fat intake by 14% vs. 3.6% in the control 
group suggesting that the intervention increased overall adherence to the recommended 
diet.  However, even among the patients in the intervention group only 52% followed 
through with the dietary regimen for two years. 
 In an overview of adherence to preventive dietary regiments in the general public 
(Brownell & Cohen, 1995) authors concluded that there is evidence that meaningful 
dietary changes can be made and continued adherence to these is possible.  However, the 
authors caution that adherence is influences by several variables such as psychological, 
cultural, environmental, and behavioral factors that may interfere with patients’ ability 
and willingness to change their diet. 
Exercise
A few studies have examined exercise adherence among cancer patients.  A pilot study 
examining adherence to a moderate-intensity exercise program in women receiving 
chemotherapy or radiation for breast cancer (Pickett, Mock, Ropka, Cameron, Coleman, 
& Podewils, 2002) found that 30-50% of women failed to adhere to the recommended 
exercise regimen.  The best predictor of adherence to the exercise regimen turned out to 
be regular exercise prior to the diagnosis.  This finding was supported in another study 
examining exercise adherence rates among cancer survivors  (Courneya, Friedenreich, 
Sela, Quinney, & Rhodes, 2002).  In another study examining the influence of exercise 
discussions during cancer treatment consultations on actual adherence, Jones & Courneya 
(2002) found that patients whose physician had initiated discussions about exercise were 
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much more likely to exercise regularly.  Results also revealed that only about 25% of 
physicians actually discussed the importance of exercise with the patients. 
Tobacco and Alcohol Use
Tobacco use is particularly prevalent among head and neck cancer patients.  Several 
studies have examined the rates of smoking cessation among these patients.  In a study of 
48 patients with advanced head and neck cancer scheduled for radiation therapy Des 
Rochers, Dische, and Saunders (1992) found that no less than 72.9% were smoking at the 
time of diagnosis and that 51% of these patients continued to smoke after diagnosis. 
Another study by Browman et al (1993) found that among 115 head and neck cancer 
patients being treated with radiation therapy 46% continued to smoke during treatment. 
A more recent study examined smoking rates among stage III and IV lung cancer patients 
enrolled in a trial of combined radiation and chemotherapy (Cox et al, 2002).  Among 226 
patients, 215 (95%) of patients had a history of cigarette smoking.  Among these 69% 
stopped smoking prior to entry in the trial and 9% stopped smoking at some point during 
the course of the trial; however, 11% continued smoking throughout the trial.  Authors 
noted that while a majority of lung cancer patients were able to stop smoking, a notable 
subset of patients continued smoking despite diagnosis of lung cancer, enrollment in a 
clinical trial, treatment-related toxicity, and encouragement from clinicians to stop 
smoking.  
 While elevated alcohol use has been implicated as a potent risk factor for cancer, in 
particular among patients with head and neck cancer, no studies to date have examined 
the extent to which alcoholic patients are able to reduce their use of alcohol or completely 
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abstain in the context of cancer.  However, one study (Duffy, Terrell, Valenstein, Ronis, 
Copeland, & Connors, 2002) examining the relationship between smoking, alcohol 
intake, depressive symptoms and quality of life in head and neck cancer patients found 
that results showed that 35% of the respondents had smoked within the last 6 months and 
46% had drunk alcohol within the last 6 months. Interestingly, whereas 32% of smokers 
were interested in smoking cessation services, only 9% of those who drank alcohol 
expressed interest in alcohol services.  Furthermore, other studies have suggested that 
patients who are alcoholics are at an increase risk for co-morbid psychiatric disorders 
which in turn been associated with poor treatment adherence among cancer patients 
(Lundberg & Passik, 1997). 
 The next section of the present chapter provides a review of predictors of treatment 
adherence that have been proposed in the literature.    
Predictors of Treatment Adherence 
 It is clear that no one factor predicts whether a cancer patient will choose to adhere to 
treatment recommendations and while the research on predictors of adherence to cancer 
screening is substantial, there is a paucity of research examining predictors of cancer 
treatment adherence.  Such literature as does exist will be presented here.   
Demographic Predictors 
The financial ramifications of cancer can be significant, particularly for patients 
without insurance and low-income patients who cannot afford the loss of wages.  A study 
exploring factors that may affect medical information seeking, treatment engagement, and 
emotional adjustment among African American cancer patients, found that lack of 
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insurance was a significant predictor of poor adherence (Matthews, Sellergren, Manfredi, 
& Williams, 2002).  Similar studies of other medical populations have suggested that 
patients with incomes below the poverty level are at higher risk for cost-associated non-
adherence and that patients without insurance are significantly more likely to fail to 
adhere than those with insurance (Kennedy & Erb, 2002; Rudman, Gonzales, & Borgida, 
1999).  In a study examining rates of adherence among low-income minority women with 
abnormal screening mammograms women who did not comply with follow up 
appointments cited loss of wages as a reason for non-adherence; however, insurance did 
not differentiate between compliant versus non-compliant women (Rojas, Mandelblatt, 
Cagney, Kerner, & Freeman, 1996). 
 Accessibility to treatment is another potential barrier to treatment.  With the 
centralization of cancer care, concerns about the impact of travel on treatment adherence 
have emerged.  A recent literature review (Payne, Jarrett, & Jeffs, 2000) examined the 
impact of travel on cancer patients' experiences of treatment.  Authors concluded that, 
while travel may be inconvenient and distressing to many patients, the lack of research in 
this area (only 11 studies were deemed appropriate for inclusion in the review) makes it 
impossible to draw any conclusions about the impact of travel on treatment adherence 
among cancer patients.  However, another study found that patients who were referred to 
a local hospital were more likely to complete treatment than those who were referred 
elsewhere (Simmons and Lindsay, 2001). 
 Age has also been proposed as a possible predictor of treatment adherence.  However, 
due to the skewed distribution of cancer (cancer is much more prevalent in the above 60 
yr. population) few studies have examined the moderating effect of age in the context of 
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cancer treatment adherence.  In one such study of women receiving tamoxifen therapy for 
early stage breast cancer (Partridge, Wang, Winer, & Avorn, 2003) results indicated that 
adherence was lowest among the very young and the very old patients.  Similar results 
have emerged among other medical populations (Rudman, Gonzales, & Borgida, 1999). 
However, the influence of age on treatment adherence is at best inconclusive.  Other 
studies examining the predictors of medical adherence have found support for several 
other variables such as race, drug and dosage form, number of medications, cost of 
medications, insurance coverage, and physician-patient communication, but failed to 
show any effect of age on adherence (Balkrishnan, 1998; DiMatteo, Hays, & Sherbourne, 
1992). 
 Educational level has been associated with treatment adherence among cancer patients. 
Siminoff and Fetting (1991) conducted a study examining the decision-making process of 
100 breast cancer patients and their physicians.  They found that a majority (80%) of 
patients accepted their physician's primary treatment recommendation, but surprisingly, 
results revealed that patients who were better educated and who tended to be risk takers 
were less likely to comply with primary treatment recommendation. This is contrary to 
the findings in the cancer screening literature where higher education has been associated 
with better adherence to screening recommendations. However, results from another 
study, which examined the predictors of medication adherence among patients with 
asthma, renal disease, cardiac disease, or cancer, (Horne & Weinman, 1999) indicated 
that while specific beliefs about medicines were related to reported adherence, there was 
no effect of educational level on reported adherence. 
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Data on the role of ethnicity on cancer treatment adherence is scarce.  One study 
examining adherence rates among women diagnosed with early stage breast cancer 
(Partridge, Wang, Winer, & Avorn, 2003) found that non-white patients had lower 
adherence rates than white patients.  However, another study examining adherence rates 
among minority women with breast cancer (Li, Brown, Ampil, Burton, Yu, & McDonald, 
2000) did not find any relationship between ethnicity and treatment adherence. Research 
on the interaction between ethnicity and treatment adherence in other areas has shown 
similar results.  For example, in a study of adherence to anti-depressive medications 
(Sleath, B., Rubin, R., & Huston, S. A., 2003) results revealed that Hispanic patients were 
significantly less adherent to antidepressant therapy than non-Hispanic white patients. 
Another study (Oggins, 2003) investigated the difference in reasons for adherence to 
medication for HIV between ethnic minority groups and European Americans. 
Misinformation about the illness and medications were more prevalent among minority 
groups than European Americans.  However, a similar study of racial differences in 
patient-perceived barriers and reported antiretroviral medication adherence (Ferguson, 
Stewart, Funkhouser, Tolson, Westfall, & Saag, 2002), found no differences on adherence 
among different racial groups. 
Gender differences have been proposed as a possible predictor of adjustment to illness 
and treatment adherence.  No one study has compared adherence rates among men and 
women with cancer.  This may be due, in part, to the paucity of research examining 
adherence rates in cancers other than breast and prostate cancers, which are, by nature, 
restricted to one sex or the other.  A few studies, however, have examined gender 
differences in psychological reactions to cancer diagnosis and cancer treatment. These 
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studies have suggested that women tend to report more overall psychological distress than 
men (Hampton & Frombach, 2000) and that men and women report distress in different 
areas (Peleg-Oren & Sherer, 2001).  As both psychological distress and psychiatric co-
morbidity have been associated with poor adherence, gender differences in psychological 
state may be meaningful, but indirect, predictors of treatment adherence 
Summary
In summary, research examining the influence of demographic variables on cancer 
treatment adherence has been inconclusive.  Demographic variables, such as financial 
barriers, educational level, and ethnicity, have been found to have some association with 
cancer treatment adherence, however, more research is needed to better understand the 
underlying mechanisms of how these variables affects patients’ decisions to adhere to 
cancer treatment recommendations. 
Diagnosis- and Treatment-Related Predictors 
 Among other medical populations side effects have been cited as a primary reason for 
non-adherence (Kennedy & Erb, 2002).  For example, in a study of renal transplant 
patients, side effects of medications were found to be a strong predictor of non-adherence 
(Rudman, Gonzales, & Borgida, 1999).  However, while side effects of many cancer 
treatments are highly adverse and often result in marked physical discomfort, 
psychological distress, and poor quality of life (QOL), non-adherence due to side effects 
is surprisingly low among cancer patients (Richardson, Marks, & Levine, 1988; 
O'Connor, Boyd, Warde, Stolbach, & Till, 1987).  For example in a study of medication 
preferences among cancer patients (O'Connor, Boyd, Warde, Stolbach, & Till, 1987) 
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revealed that patients' pre-treatment preferences for specific anti-neoplastic agents were 
not influenced by the way information about side effects was presented and, further, 
despite significant toxicity following initiation of treatment, patient  preferences remained 
consistent during treatment.  Similarly, another study found that neither the occurrence or 
frequency of side effects, nor the difficulty dealing with any of these, related to non-
adherence with anti-neoplastic medications among cancer patients (Richardson, Marks, & 
Levine, 1988).  
 Other diagnostic factors in treatment adherence are type and stage of cancer.  Studies 
examining the role of type of cancer on treatment adherence have provided overwhelming 
evidence that patients diagnosed with breast cancer show much greater rates of adherence 
to treatment, usually cited as above 90%, than cancer patients in general among whom 
adherence rates fall around 70% (Taylor, Lichtman, & Wood, 1984; Simmons, 2001). 
Adherence rates are typically lowest among cancers that require invasive and prolonged 
treatment with more than one treatment modality.   For example in a study of women with 
breast cancer receiving adjuvant tamoxifen therapy (Partridge, Wang, Winer, & Avorn, 
2003) results revealed significantly lower medication adherence among mastectomy 
patients than among patients who did not have a mastectomy.  In another study by 
Franciosi et al (2003) examining compliance rates to an alternating chemo-radiotherapy 
treatment regiment, a highly complex treatment, in patients with advanced head and neck 
cancer, adherence rates were also found to be poor. Other studies examining the effects 
of multimodal chemo-radiation therapy have also found adherence rates to be lower than 
with either treatment alone.  For example, in two different studies that both examined the 
efficacy of multimodal treatment among head and neck cancers, non-adherence was cited 
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to fall around 20-21% (Schuller et al, 2002; Robbins et al, 2000).  Moreover, these 
numbers did not include patients who discontinued treatment due to side effects.   
 While research has investigated adherence rates among cancer patients with late stage 
disease, few studies have compared these to adherence rates among patients with stage I 
or II illness.  Results from studies examining the effect of stage on cancer on treatment 
adherence indicate that stage of cancer is not a significant predictor of adherence to 
cancer treatment.  For example, in a retrospective study of survival rates among patients 
treated for head and neck cancers (Cathcart, Dunican, & Halpern, 1997), stage of cancer 
was not predictive of treatment adherence.  Specifically, results revealed that the 
adherence rate among patients with stage III or stage IV was 48%, which was not 
significantly different from the adherence rate of 54% among the stage I and II patients. 
Summary
In conclusion, three variables related to diagnosis and treatment has been consistently 
associated with cancer treatment adherence.  These include the type of cancer, 
invasiveness of treatment, and intensity of treatment.  Breast cancer patients have been 
found to be more likely to adhere to treatment than patients with other types of cancer. 
With respect to both invasiveness and intensity of treatment both were negatively related 
to treatment adherence.  The more invasive and the more intense the treatment, the less 
likely patients were to adhere.  To this point, the roles of cancer treatment side effects and 
stage of cancer in relation to cancer treatment adherence remain unclear.   
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Psychosocial Predictors 
Given the significant impact of cancer and cancer treatment, researchers have begun to 
investigate psychological variables, such as co-morbid psychological disorders and social 
support, as possible predictors of cancer treatment adherence.  This section will provide a 
brief review of psychosocial predicators. 
 Psychological Disorders
Studies examining psychiatric co-morbidity as a predictor of treatment adherence have 
provided mixed results.  In one longitudinal study examining the role of psychiatric 
complaints on treatment adherence among patients with head and neck cancer (Girardi, de 
Pisa, Cianfriglia, Perrino, et al, 1992), neither somatic disturbance, anxiety, insomnia, 
social dysfunction, nor depression predicted treatment adherence.  However, other studies 
have provided evidence that psychiatric co-morbidity does indeed affect adherence with 
treatment.  Researchers have examined the effect of co-morbid depression, psychoses, 
cognitive impairment, interpersonal dysfunction, and addiction in relation to treatment 
adherence (Kunkel, Woods, Rodgers, & Myers, 1997; Seddon, Zabora, & Smith, 1992; 
Goldberg, 1983). Results from these studies have confirmed that both psychological and 
psychiatric complaints appear to be linked with poor adherence. 
 Interestingly, in a study of oncologists' views of cancer patient non-adherence 
(Hoagland, Morrow, Bennett, and Carnrike, 1983) doctors, themselves cited 
psychological problems as a prime determinant for non-adherence.  Consistent results 
have emerged from a study examining the influence of mood and adjustment to cancer on 
adherence with chemotherapy among breast cancer patients (Ayres, Hoon, Franzoni, 
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Matheny, et al, 1994).  Findings suggested that non-adherence (defined as keeping fewer 
than 85% of appointments) was related to high scores on measures of guilt and hostility. 
In another study examining adherence to chemotherapy (Gilbar, 1989) results suggested 
that patients who were non-compliant tended to report significantly more adjustment 
problems in a variety of areas.  Specifically, subjects who dropped out of treatment were 
less adjusted and reported more distress than patients who completed treatment. Recent 
studies have focused on the early detection of psychiatric symptoms and appropriate 
treatment and intervention to eliminate these potential barriers to adherence and to 
increase patients’ psychological well-being (Kunkel, Woods, Rodgers, & Myers, 1997; 
Seddon, Zabora, & Smith, 1992).   
 Other research has focused on the psychological impact of cancer on patients in 
contrast to psychiatric disorders (Cohen 2002; Cull, 1990).  Results have suggested that 
the psychological impact of the cancer experience is significant and often traumatic 
(Eakes, Rakfal, Keel, & Gaiser, 1996).  In a study examining the self-reported spiritual 
and existential needs among cancer patients (Moadel et al, 1999) found that patients 
desired help in overcoming fears, finding hope, talking about peace of mind, finding 
meaning in life, and finding spiritual resources, as well as someone to talk to about the 
meaning of life and death.   
Social Support
The cancer screening literature has provided consistent evidence that social support 
plays a significant role in people’s decision to follow through with recommended cancer 
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screening procedures. However, most research on social support among cancer patients 
has focused on the effect of social support on patient adjustment. 
 In a study of breast cancer patients and their spouses, Ben-Zur, Gilbar, & Lev (2001) 
found that the use of emotion-focused coping by the spouse was negatively related to the 
patient’s distress and psychological adjustment, indicating that coping and adjustment of 
the patient happen within a dynamic and interactive social network.  Another study of 
women with breast cancer found that the size a patient’s social network was related to 
greater emotional and instrumental support and that emotional support, but not 
instrumental support, was predictive of better mental well-being (Bloom, Stewart, 
Johnston, Banks, & Fobair, 2001).  Similarly, in a study of adjustment among Hispanic 
women undergoing treatment for breast cancer Alferi, Carver, Antoni, Weiss, and Duran 
(2001) found that emotional support from friends and instrumental support from spouses 
at pre-surgery predicted lower distress post surgery. 
 The context of patients’ social environment has also been linked to patient coping.  In 
a study examining the effect of spouse support, coping, and mood among individuals with 
cancer, results indicated that spouse criticism was associated with avoidant coping 
strategies on behalf of the patient, whereas spouse support was associated with adaptive 
coping (Manne, Pape, Taylor, & Dougherty, 1999).  These findings were supported by a 
study of prostate cancer patients in which the associations between coping and adjustment 
were found to depend on patients’ perception of support (Ptacek, Pierce, & Ptacek, 2002). 
Patients who perceived high levels of support reported more problem-focused coping and 
higher levels of support-seeking as well as less self-blame, wishful thinking, and avoidant 
coping.   
41
While research has suggested that social support is central in psychological adjustment 
and adaptive coping among cancer patients, there is very little research examining the role 
of social support in predicting treatment adherence.  Extensive literature searches resulted 
in only one such study by Gilbar (1990) who found no relationship between family 
environment and patients’ adherence to chemotherapy. 
Summary
In summary, psychological co-morbidities, such as depression, anxiety, and psychosis, 
has been found to be strong predictors of non-adherence.  Results from studies examining 
the role of social support on treatment adherence have been unclear.  These results may, 
in part, be a reflection of the relatively few studies that has explored the relationship 
between coping and treatment adherence.  One source supporting further research into the 
role of coping on treatment adherence is evidence from the cancer screening literature, 
which have suggested that social support is instrumental in adherence to recommended 
cancer screening. 
 The next chapter will present the present study and discuss key variables in the 
proposed model. 
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CHAPTER 3: PRESENT STUDY 
The current chapter provides a review of the epidemiology, biology, etiology, and 
treatment of head and neck cancers.  An overview of the literature on adherence to 
primary medical intervention, tobacco and alcohol cessation, and oral hygiene among 
head and neck cancer patients will ensue.  Then, the proposed model to be examined will 
be presented followed by a discussion of key variables in the model: Doctor-patient 
communication, patients’ coping, and patients’ illness perceptions. 
 The present study examines several factors that may influence head and neck cancer 
patients’ consistency in following the prescribed oral care program and cessation of 
tobacco and alcohol use.  These three terms will hereafter be collectively referred to as 
“oral health regimen” no to be confused with “oral care program” which denotes oral 
hygiene only. 
 Common to all of the head and neck cancers is the use of radiation therapy both as 
initial and adjuvant treatment.  Besides the more general side effects associated with 
radiotherapy, head and neck cancer patients being treated with radiotherapy often endure 
additional complications involving the oral cavity and surrounding areas (Dreizen, 1990). 
These complications arise from damage to fast growing cells in the mucosal tissue and 
salivary glands.   Complications include mucositis, which is the thinning of the mucosa in 
the radiation field, pain, mucosal fibrosis and atrophy, salivary gland dysfunction, 
increased risk of dental caries, increased susceptibility to infections, tissue necrosis, taste 
dysfunction, and muscular and/or cutaneous fibrosis (Silverman, 1990, Chambers, Toth, 
Martin, Fleming, & Lemon, 1995). 
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It is estimated that most, if not all, head and neck cancer patients being treated with 
radiation therapy will develop oral complications (Dreizen, 1990, Chambers, Toth, 
Martin, Fleming, & Lemon, 1995).  As a consequence of these complications head and 
neck cancers patients who are being treated, or have been treated, with radiation therapy 
are required to follow a strict oral care program for the rest of their lives.   Further, use of 
tobacco and/or alcohol during and after treatment can exaggerate the complications in 
addition to significantly increase chance of secondary malignancies. 
Head and Neck Cancers 
Epidemiology
About 3% percent of all cancers are head and neck cancers meaning that around 30,000 
individuals in the US are diagnosed with head and neck cancer each year (Cancer 
Prevention & Early Detection, 2001; Silverman, 2001).  Unfortunately, despite advances 
in surgery, radiation therapy, and chemotherapy five-year survival rates among head and 
neck cancer patients remain low at 50-55% (Silverman, 2001). This is a number that has 
not significantly improved for decades. The death rate for oral cancer is higher than that 
of cervical cancer, Hodgkin’s disease, cancer of the brain, liver, testes, kidney, ovary, or 
skin cancer (malignant melanoma). Oral cancers are particularly dangerous because the 
risk for second, primary tumors is high.  In other words, patients, who survive a first 
encounter with the disease, have up to a 20 times higher risk of developing a second 
cancer (Spitz, 1994; Day, Blot, Shore, Schoenberg et al, 1994).
Head and neck cancers are more common among middle aged and older individuals, 
and a majority of people diagnosed with these cancers are over the age of 40 at the time 
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of discovery, though head and neck cancers do occur in younger populations. Men are 
twice as likely as women to develop oral cancers (Swango, 1996) though this ratio is 
starting to even out, most likely due to the fact that women are increasingly exposing 
themselves to risk factors such as tobacco and alcohol use. These cancers tend to occur 
twice as often in the black population as in whites, and survival statistics for blacks over 
five years are also poorer at 33%, versus 55% for whites.   This difference is most likely 
due to socio-economic factors such as income levels, education, and availability of proper 
health care.   
Biology of Head and Neck Cancer
Head and neck cancers encompass cancers of the lips and oral cavity, paranasal 
sinuses and nasal cavity, salivary glands, oropharynx, nasopharynx, hypopharynx, larynx, 
and lymphnodes in the upper part of the neck.  The images below provide an illustration 
of the potential cancer cites in head and neck cancers. 
Image 1:  Potential cancer sites of the oral cavity.        Image 2:  Potential cancer sites in the neck and posterior oral cavity 
Downloaded from National Cancer Institute’s website     Downloaded from www.hncancer.com        
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Most head and neck cancers are of the squamous cell variety (90%).  Squamous cells are 
found in the tissues that forms the surface of the skin, the lining of the hollow organs of 
the body, and the mucosal lining of the passages of the respiratory and digestive tracts 
(Silverman & Shillitoe, 1998).  Early oral cancers and precancerous lesions are often 
subtle and asymptomatic.  These lesions tend to appear as white or red patches on or 
around the lips, gums, palate, tongue, tonsils, and floor of the mouth, or as smalls 
indurated ulcers, which looks like common canker sores (Silverman & Shillitoe, 1998). 
Later stage oral cancers may take the form of non-healing ulcers and symptoms may 
develop into bleeding, loosening of teeth, dysphagia (the sensation that food isn’t 
progression normally from the throat to the stomach), dysarthria (speech problems due to 
inability to coordinate the muscles of the mouth), odynophagia (pain when swallowing), 
numbness in the oral/facial region, or the development a lump or mass which can be felt 
inside the mouth or neck.
The severity of head and neck carcinomas are determined based on the TNM system 
(Fleming, I. D. et al, 1997), which encompasses four stages. Stage I and II cancers are 
considered early stage cancers and generally have a good prognosis with proper 
treatment.  These cancers are characterized by tumors that are no more than 4 cm in 
dimension and show no evidence of either lymphnode involvement or distant metastasis. 
Stage III and IV cancers are advanced cancers and the prognosis varies depending on the 
size of tumor, spread to lymphnodes and distant metastasis.  Stage III cancers are 
characterized by tumors greater than 4 cm in dimension, or tumors greater than 2 cm in 
dimension with a metastasis (3 cm or less) to a single lymphnode.  Stage IV cancers 
involves a) tumors that invade adjacent structures with or without lymphnode 
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involvement or any size tumor with metastasis (3-6 cm in dimension) to either a single 
lymphnode or metastasis to more than one lymphnode, b) any size tumor with lymphnode 
metastasis greater than 6 cm in dimension, or c) any size tumor with or without 
lymphnode involvement but with distant metastasis.    
Risk Factors
Primary risk factors for head and neck cancers are tobacco use and alcohol use.  It is 
estimated that 85% of head and neck cancers can be linked to past and/or current tobacco 
use, and the risk of developing cancers of the head and neck are 5-9 times higher among 
smokers than non-smokers (Mashberg, Boffetta, & Winkelman, 1993; Jovanovic, 
Schulten, Kostense, Snow, & van der Waal, 1993).  Further, among patients treated for 
head and neck cancer who continue to smoke, chances of developing secondary 
malignancies are 2-6 times higher than among patients who stop smoking at diagnosis 
(Silverman & Shillitoe, 1998).      
 Alcohol use has been identified as another significant contributing factor in head and 
neck cancers.  Research has found that, when controlling for smoking, moderate to heavy 
drinkers have a 3-9 times greater risk of developing oral cancer (Mashberg, Boffetta, & 
Winkelman, 1993; Jovanovic, Schulten, Kostense, Snow, & van der Waal, 1993).  While 
each of these behaviors are significant risk factors on their own, studies examining the 
combined effects of smoking and alcohol use have found a 15 times greater risk of 
developing oral cancer among those who both smoke and drink compared to those who 
neither smokes nor drinks.  Among individuals who are both heavy smokers and heavy 
drinkers this risk increased by 100 times (Blot et al, 1988).   
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Other risk factors for head and neck cancer include chronic sun exposure (cancer of 
the lips), poor oral hygiene, and dietary factors such as little intake of vegetables and 
fruits (Winn, 1995; Spitz, 1994).  Biological factors include viruses and fungi, such as the 
human papilloma virus (HPV) and lichen planus, an inflammatory disease of the oral soft 
tissues. 
Treatment
Oral cancer is a preventable disease, related to behavioral and lifestyle factors, 
including tobacco and alcohol, and prevention and early detection of oral cancer remain 
the goals of national efforts to reduce the impact of this disease on the public (Day, Davis, 
et al., 2003).  While early detection is readily available through direct examination of the 
oral cavity during routine dental visits, these cancers are typically not detected in the early 
stages.  This is often due to a combination of dentists not performing this brief 
examination, and patients failing at getting regular dental exams. 
Treatment modalities 
 Standard treatment modalities for head and neck cancers are surgery, and/or radiation. 
Surgical treatment is the mainstay of therapy for patients with oral cancer, particularly in 
advanced stages of cancer.  External beam radiation therapy has been used successfully as 
the primary modality for treating patients with early stage oral cancer, and is also the 
standard adjuvant therapy in surgically treated patients with advanced stage oral cancer. 
There is an emerging trend for the use of chemotherapy in combination with radiation 
therapy and surgery for patients with advanced, recurrent, and metastatic head and neck 
cancer, although evidence is limited regarding survival benefit. Treatment of head and 
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neck cancers is usually a multidisciplinary approach involving the efforts of surgeons, 
radiation oncologists, chemotherapy oncologists, dental practitioners, nutritionists, and 
rehabilitation and restorative specialists (Harris, Sessions, & Hong, Eds., 1998).   
Treatment phases
The standard treatment schedule for head and neck patients consist of a number of 
different phases.  The first phase is the initial work-up, which includes a review of 
laboratory results, assessment of current symptoms, present illness, treatment, and past 
medical history, along with a general medical examination, an examination of the head 
and neck area in addition to any imaging tests deemed appropriate. 
 When the initial work-up is concluded, a phase of expert consultation ensues.  Patients 
are examined by a dental oncologist to determine the patient’s oral health status, and any 
dental treatments or interventions deemed necessary are performed.  Consultations with 
head and neck surgery and radiation oncology follows to determine the most appropriate 
treatment.  Depending on the site of cancer and expected treatment consequences, patients 
may also meet with speech pathologists and/or plastic surgeons.  Finally, a pre-operative 
consultation with internal medicine covers nutrition, smoking cessation, and other 
medical conditions to be considered during treatment.   
 The next phase is the treatment phase.  If appropriate, neo-adjuvant radiation or 
chemotherapy is given to shrink the tumor.  Primary treatment follows and typically 
involves a combination of surgery and/or radiation.  If indicated, adjuvant therapy in the 
form of radiation or chemotherapy may be given.  Once treatment has been successful, 
regular follow-ups are scheduled to assess recurrence of the primary tumor or the 
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development of secondary tumors.  During the first year patients are scheduled for 
follow-up exams every 3 months, during the second year every 4 months, during the third 
year every 6 months, and then once annually. 
Treatment of early stage cancers
Early cancers (stages I and II) are highly curable (cure rates fall between 90% and 
100%) by surgery, radiation therapy, or a combination of the two (Jones et al, 1992).  The 
choice of treatment is usually dictated by the anticipated functional and cosmetic 
consequences of treatment and efforts are made to minimize these to the extent it is 
possible (Cummings et al, 1998; Wang ed, 1990).   Patients with cancers treated in the 
early stages usually have little post treatment disfigurement.   
Treatment of advanced stage cancers
Standard treatment for Stage III and IV is similar to treatment for early cancers and 
usually involves a combination of surgery and radiation therapy.  In this case, however, 
the determination of treatment regimen is based on the exact tumor site as opposed to 
cosmetic considerations.  Cure rates for advanced head and neck cancers are much lower 
than cure rates for early stage cancers and fall around 50-60%.  In some cases, neo-
adjuvant chemotherapy is given to shrink tumors, thereby rendering them more 
definitively treatable with either surgery or radiation (Cummings et al, 1998).  However, 
research supporting the use of neo-adjuvant chemotherapy in head and neck cancers is 
scarce. In a meta-analysis of 63 randomized prospective trials published between 1965 
and 1993 authors concluded that there is a lack of evidence of any survival advantages 
among patients with advanced head and neck cancers receiving neo-adjuvant 
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chemotherapy (Pignon et al, 2000).  Ongoing trials may further clarify the role of 
concomitant chemotherapy and radiation therapy in the management of oral cavity 
cancer. 
Radiation therapy in head and neck cancers
Among patients whose cancer is caught at a later stage, the results of surgical removal 
of the disease may require reconstruction of portions of their oral cavity or facial features 
(Harris, Sessions, & Hong, 1998). Adjunctive therapy may be required to assist in speech, 
chewing of foods, the problems associated with the lack of salivary function, as well as 
the fabrication of dental or facial prostheses (Harris, Sessions, & Hong, 1998).   
 The use of radiation therapy both as primary or adjuvant treatment is common among 
the head and neck cancers.  Radiation therapy can be administered by external-beam 
therapy or interstitial implantation, but for many sites the use of both modalities produces 
better control and functional results (Harris, Sessions, & Hong, 1998).  Besides the more 
general side effects associated with radiotherapy such as fatigue and nausea, head and 
neck cancer patients being treated with radiotherapy often endure additional 
complications involving the oral cavity and surrounding areas (Dreizen, 1990).   These 
complications arise from damage to fast growing cells in the mucosal tissue and salivary 
glands, and include mucositis, which is the thinning of the mucosa in the radiation field, 
pain, mucosal fibrosis and atrophy, salivary gland dysfunction, increased risk of dental 
caries, increased susceptibility to infections, tissue necrosis, taste dysfunction, and 
muscular and/or cutaneous fibrosis (Silverman, 1990, Chambers, Toth, Martin, Fleming, 
& Lemon, 1995).   The presence of one or more these symptoms are common among 
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head and neck cancer patients treated with radiation therapy, and may, ironically, cause 
additional complication such as malnutrition and, in severe cases, delay of treatment.   
The Oral Health Regimen 
 Because of the severity of oral complications caused by radiation therapy to the oral 
cavity and surrounding areas, good oral health is of utmost importance prior to, during, 
and after treatment.   Prior to treatment initiation all patients undergo a comprehensive 
dental evaluation, by a dental oncologist, to identify risk factors that may unnecessarily 
increase severity of acute and permanent complications (Chambers, Toth, Martin, 
Fleming, & Lemon, 1995).  Treatment and prophylaxis is performed where deemed 
appropriate, and for patients with poor oral health full mouth extraction prior to the 
initiation of radiation therapy is not uncommon (Jansma et al, 1992).  Dentulous patients 
are then introduced to a comprehensive oral care program which involves brushing and 
flossing after each meal and at bedtime, daily application of fluoride gel, daily and 
frequent use of mouth rinse, dietary restrictions, and specific tooth brush care that 
involves the alternate use of two brushes and daily cleansing of brushes in a chlorine 
solution (Chambers, Toth, Martin, Fleming, & Lemon, 1995; Jansma et al, 1992). 
 The chronic nature of some of the oral complications of radiation therapy necessitates 
the maintenance of the oral care program for the rest of the patient’s life along with 
regular dental exams and cleanings, every three to six months (Jansma et al, 1992). 
Following the recommended oral care program can significantly reduce the risk of 
developing oral complications or, at the very least, reduce their severity and duration. 
Failure to follow through with the recommended oral care program, on the other hand, 
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can lead to serious consequences such as rotting and loss of teeth, periodontal disease, 
inflammation and infection of facial bone structures, and bone loss (Dreizen, 1990).  An 
additional and very real concern with oral complications is that high oral toxicity may in 
some cases complicate treatment and require reducing treatment to a less toxic, but also 
less therapeutic dose, thus decreasing the curative properties of the cancer treatment and 
increasing the likelihood of metastasis, relapse, or secondary malignancies (Chambers, 
Toth, Martin, Fleming, & Lemon, 1995). 
 Appropriate oral hygiene is not the only recommendation for self-care made to patients 
with head and neck cancers.  One of the primary risk factor for developing cancer of the 
head and neck is tobacco use, in addition to alcohol abuse which is another contributing 
factor in head and neck cancers.  Both smoking and alcohol cessation is highly 
recommended to these patients and while most understand the reasons for quitting, many 
fail to quit after their diagnosis (Schnoll et al, 2003, Silverman, 1990).  Continued 
tobacco and alcohol use significantly increase the risk of relapse and secondary 
malignancies, and has been associated with lower response rates and shorter survival 
durations (Browman et al, 1993).  Further tobacco and alcohol use can also exacerbate the 
oral complications associated with radiotherapy.    
Adherence to components of the oral health regimen
Studies have examined adherence rates to both primary treatment and supportive 
health behaviors among head and neck cancer patients.  This section will review the 
literature on dependent variables proposed in this study: Adherence to oral care programs, 
tobacco cessation, and the discontinuation of alcohol use. 
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Adherence to Oral Hygiene Recommendations
As mentioned earlier an important part of initial consultations is an assessment of 
patients’ pretreatment dental status.  Good oral health is desirable to minimize 
complications and avoid extractions.  In a study of head and neck cancer patients 
scheduled for radiation therapy Lockhart and Clark (1994) found that among one hundred 
thirty-one patients the majority of dentulous patients could be classified as noncompliant 
with routine dental care (76%) and oral hygiene (65%).  No less than 97% of patients 
required some form of dental care prior to treatment, however, 81% of these patients 
failed to adhere to the recommended treatment.  These results suggest that non-adherence 
to the recommended dental care is a concern even before radiation therapy has been 
initiated. 
 Adherence to oral care programs continues to be a problem among head and neck 
cancer patients after treatment.  A retrospective study, assessing adherence to post-
radiation therapy dental follow-up in a population of head and neck cancer patients 
(Toljanic, Heshmati,  & Bedard, 2002), found that among 334 patients 170 (51%) failed 
to receive follow-up dental examinations within the first year post-treatment.  A similar 
study examined adherence to recommended fluoride use among 76 patients who had 
completed radiation therapy for head and neck cancer (Epstein, 1995).  Results of this 
study indicated that only 40% of patients were seen regularly in the dental clinic of the 
cancer agency, and overall only 43% reported using fluoride gel regularly (once a day). 
This number was higher among those who were seen in the dental clinic on a regular 
basis, 67%, versus 28% among the patients who were not seen on a regular basis.  The 
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study did not find any significant differences between the groups in frequency of tooth 
brushing and use of dental floss. 
 In a review of two different potency fluoride gels (Tavss, 1997) results indicated that 
both were equally effective in preventing caries, however, the stronger gel which could be 
applied once a day was associated with higher adherence among irradiated head and neck 
cancer patients compared to the low potency gel which had to be applied twice daily, 
suggesting that convenience may play an important role in adherence to oral hygiene 
programs among these patients. 
Smoking Cessation and Alcohol Use
Smoking is the primary risk factor for head and neck cancers.  However, a substantial 
number of patients continue to smoke after diagnosis and through treatment.  In a review 
by Cox et al (2002) results of studies examining smoking behavior after diagnosis in head 
and neck cancer patients indicated that the percentage of patients who continued to 
smoked range from 25 % to 55%.  Results from a prospective study (Silverman, 
Greenspan, & Gorsky, 1993), which followed head and neck cancer patients for up to 15 
years post treatment, found that 58 % of women and 52% of men continued to smoke. 
The study also found higher rates of recurrence among continued smokers than among 
quitters.  Two retrospective studies using patients’ charts to determine smoking status 
reported that 25 to 35% of head and neck cancer patients who smoked at the time of 
diagnosis continued to do so (Vander, DiNardo, & Oliver, 1997; Ostroff et al, 1995). 
 Other studies have attempted to identify predictors of smoking cessation among head 
and neck cancer.  One such study found that physical barriers associated with cancer 
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treatment that made it difficult or impossible to continue to smoke, and smoking cessation 
counseling at the time of diagnosis were both good predictors of discontinuation of 
smoking behavior, whereas heavy alcohol use was a negative predictor of smoking 
cessation (Vander, DiNardo, & Oliver, 1997).  Ostroff et al (1995) found that stage of 
disease and intensity of treatment predicted post-treatment tobacco use.  Specifically 
patients with less severe disease who underwent less extensive treatment were at 
increased risk for continued tobacco use.  Other factors that have been linked to poor 
smoking cessation are having relatives at home who smoke, a longer time between 
diagnosis and assessment, completion of medical treatment, greater nicotine dependence, 
lower self-efficacy, few quitting pros, low risk perceptions, a high number of quitting 
cons, fatalistic beliefs, and emotional distress (Schnoll, 2002). 
 Despite overwhelming evidence that alcohol use poses a threat in the development of 
head and neck cancers, few, if any, studies have examined the rates of alcohol use among 
head and neck cancer patients during and after treatment.  However, alcohol use has been 
linked to continued smoking, meaning the patients who drink regularly are less likely to 
quit smoking upon diagnosis of cancer (Vander, DiNardo, & Oliver, 1997).    
Summary
Head and neck cancers encompass cancers of the lips and oral cavity, paranasal 
sinuses and nasal cavity, salivary glands, oropharynx, nasopharynx, hypopharynx, larynx, 
and lymphnodes in the upper part of the neck.  Approximately 30,000 individuals in the 
US are diagnosed with head and neck cancer each year.  However, despite advances in 
surgery, radiation therapy, and chemotherapy five-year survival rates among head and 
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neck cancer patients remain low.  Primary risk factors for the development of head and 
neck cancers are tobacco and alcohol use.  Standard treatment of head and neck cancers 
typically consists of a combination of surgery and radiation therapy.  However, radiation 
therapy to the oral cavity and surrounding areas are associated with serious oral 
complications that necessitate a complex oral hygiene program for the rest of the patient’s 
life.  Discontinuation of tobacco and/or alcohol use is also highly recommended. 
Unfortunately, adherence rates to the oral care program and the cessation of smoking and 
alcohol consumption are far from optimal.   
Present Study 
 The present study examines the role of doctor-patient communication (the term 
“doctor” will hereafter refer to the dental oncologist), patients’ coping, and patients’ 
illness cognitions and knowledge about cancer on treatment adherence in the context of 
cancer.  Specifically, the study examines these relationships among patients being treated 
for head and neck cancer.   
 The focus on head and neck cancers was chosen for three reasons.  First, there is a 
paucity of research within the area of behavioral medicine mapping the predictors of 
treatment adherence among head and neck cancer patients. Second, treatment for head 
and neck cancer can be intense, requiring multimodal interventions, which have been 
associated with low adherence rates and a high number of unpleasant side effects. 
Finally, radiation to the oral cavity and surrounding areas has deleterious effects on 
patients’ oral health, and the demands for supportive health behaviors are high for head 
and neck cancer patients.  Considering these circumstances, this study focused 
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specifically on patient adherence to recommended oral care regimens, as well as patients’ 
abilities to refrain from tobacco and alcohol use, as these present additional risks for 
complications and relapse. 
Rationale
Given the scarcity of research on possible predictors of cancer treatment adherence 
and the overemphasis on breast and prostate cancers in the cancer adjustment literature, 
the study examines the predictive value of doctor-patient communication, coping, and 
illness related cognitions with respect to adherence to an oral health regimen.  This study 
will focus on patients with head and neck cancers as there is a lack of research examining 
the psychological impact of being diagnosed with cancers that to a certain extent may be 
self-inflicted primarily through alcohol and nicotine abuse. 
 Considering the finding that patients often report a lack of knowledge about cancer, 
their own diagnosis and prognosis as well as poor understanding of the suggested 
treatment (Chan & Woodruff, 1997) it is suggested that cognitions surrounding cancer, 
diagnosis, prognosis, and treatment may mediate the relationship between doctor-patient 
communication and adherence.   
 In a review of doctor-patient communication, Ong et al (1995) proposed a theoretical 
framework relating background, communication behaviors, and patient outcome 
variables.  Suggested background variables included culture, the doctor-patient 
relationship, types of patients and doctors, and disease characteristics.  Communicative 
behaviors encompassed three aspects; instrumental behavior (information sharing), 
affective behavior (expressing and tolerating affect), and socio-emotional behavior (non-
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verbal patient-centered behaviors).  Potential patient outcomes were cited as satisfaction 
with medical consultations, treatment compliance, recall and understanding of 
information, health status, and psychiatric co-morbidity.  Based on a review of the 
literature the authors suggested a link between background variables and communicative 
behaviors, which they proposed, might be related to patient outcomes.  Another model 
more specific to the relationship between the doctor-patient relationship and patient 
outcomes have been proposed by Lepper, Martin, and DiMatteo (1995).  This model 
pertains to the nonverbal exchange between patients and physicians and is based on the 
expectations for patient involvement on behalf of both patients and physicians.  Authors 
suggest that high patient treatment adherence is most likely in situations where both 
patient and physician expect patient involvement.  A third model, the health belief model, 
was originally formulated to explain the use of preventive services (Becker, 1974).  This 
model considers patients’ perceptions of the seriousness of their illness and the efficacy of 
the recommended treatment in explaining actual adherence to treatment.  The model 
encompasses the following: 1) the patient’s evaluation of his/her health status, i.e. 
seriousness of illness and perceived vulnerability to being ill and the prospect of a further 
declining status of health.  2) The patient’s perception of the risks and benefits associated 
with the recommended treatment, and 3) some form of either internal or external cue that 
prompts the patient to either comply or not comply, with the recommended treatment 
regiment (Becker & Rosenstock, 1984).  None of the three models has been tested so far. 
 The goal of this study was to closer examine some of the key relationships proposed 
within these frameworks. Specifically the study aimed to investigate the possible links 
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between physicians’ communicative behaviors, patients’ illness conceptions, and specific 
treatment adherence among head and neck cancer patients. 
Proposed Model
The study is a longitudinal investigation of several factors that may influence patients’ 
adherence to the oral health regimen.  Figure 1 graphically depicts the proposed model. 
Doctor-patient interaction encompasses two aspects: instrumental information, related to 
diagnosis, prognosis, and treatment, and affective quality which a measure of physician 
interpersonal skills.  Patients’ illness related conceptions incorporate two areas: beliefs 
about illness related factors such as diagnosis, prognosis, and vulnerability, and beliefs 
about treatment related factors such cost vs. benefit of treatment and treatment efficacy. 
Adherence was measured in three areas: adherence to the oral care program, smoking 
cessation, and abstinence from alcohol.  Adherence in each area will be assessed both 
subjectively, through self-report, and objectively, through dental exams.   Patients’ coping 
style is also examined in this model.  Coping style is determined by the ratio of adaptive 
to maladaptive coping strategies. 
Patient satisfaction  
with doctor-patient  
communication
Patient’s  
Adaptive coping Intent to adhere
Patient’s illness- 
related perceptions  
Adherence 
Figure 1.  Proposed model. 
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The variables in the proposed model are reviewed next. 
Doctor-Patient Communication 
 Despite the overwhelming finding that variables related directly to a patient’s 
relationship with their physician along with physician recommendations are among the 
foremost predictors of adherence to recommended cancer screening, very few studies 
have investigate the relationship between doctor-patient communication and treatment 
adherence. Most research examining the interaction between doctors and patients in the 
oncology setting has examined the relationship between communicative behaviors and 
patients’ satisfaction and psychosocial adjustment.  The results of this literature will be 
reviewed briefly below.  A discussion of the relatively few studies that has examined 
doctor-patient communication in the context of cancer treatment will follow.   
 Doctor-patient communication can be divided into three separate components.  The 
first component encompass what has been termed socio-emotional behaviors and taps 
physician behaviors such as verbal attentiveness, showing concerns, and negative talk. 
The second component has to do with the affective quality of the communication, i.e. is 
the doctor experienced as supportive, understanding, and caring by the patient.  The last 
component is concerned with the kinds and clarity of information that is exchanged 
during the consultation.  For example, is the information about the patient’s illness and 
treatment communicated in a way that is understandable to the patient and is the patient 
satisfied with the amount of information provided.  Each of these aspects of doctor-
patient communication is discussed below.  Because there is considerable overlap 
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between the socio-emotional and affective qualities in the research these will be discussed 
together. 
Affective and Socio-Emotional Qualities 
In a study examining patient perspectives on patient-health care provider 
communication among women undergoing chemotherapy for breast cancer Bakker, Fitch, 
Gray, Reed, and Bennett (2001) found that when rating their satisfaction with the doctor-
patient interaction, they placed the most importance on the nature of information 
exchange.  Patients cited positive communication styles as preferable along with feeling a 
connection with the provider.  Similarly, other studies have found that positive 
experiences resulted from consultations that were characterized by an affective 
communication style, a comprehensive patient-centered approach and the promotion of a 
working relationship (McWilliam, Brown, & Stewart, 2000; Ong, Visser, Lammes, & de 
Haes, 2000; Hebert, Jenckes, Ford, O'Connor, & Cooper, 2001).  These characteristics 
have been rated by patients as increasingly important when the prognosis is poor 
(Dowsett, Saul, Butow, Dunn, Boyer, Findlow, & Dunsmore, 2000).  Research into the 
specific physician behaviors related to patient satisfaction has suggested that using the 
patient’s first name, ensuring privacy during examinations and consultations, sitting down 
while talking with the patient, and listening without interrupting were all associated with 
higher satisfaction. 
 Satisfaction with the affective quality of doctor-patient communication has been linked 
with improved short-term psychological adjustment among patients.  In a study of the 
usefulness of a program designed to improve physicians’ communication with patients, 
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researchers found that when oncologists participated in a workshop prior to the pre-
treatment consultation, patients reported less depression compared to patients whose 
doctors did not receive the intervention (Rutter, Iconomou, & Quine, 1996).  These results 
are supported by a study of the relationships between breast cancer survivors' experiences 
during the diagnostic consultation and their subsequent long-term psychological 
adjustment which found that patients who perceived their physicians as displaying good 
interpersonal skills during the initial consultation reported better psychological 
adjustment (Mager, & Andrykowski, 2002).  Other studies have produced consistent 
results.  Investigations into the relationship between cancer patient’s perceptions of the 
quality of communication during the diagnostic consultation have suggested that patients 
who perceived interaction with their doctor as negative reported poorer psychological 
adjustment 3-4 months later (Omne-Ponten, Holmber, & Sjoden, 1994; Butow et al, 
1996).   
 Overall, results from these studies highlight the importance of the affective quality of 
the doctor-patient communication in relation to patient satisfaction and affective 
experience during the consultation.  Studies have also examined the relationship between 
doctor-patient communication and patients’ quality of life.  Results, however, suggest that 
the findings for adjustment do not extend to quality of life.  For example, in a study of 
cancer patients, who were followed for 12 months after diagnosis, findings revealed that 
doctors communication of information to the patients in a pre-treatment consultation, did 
not reliably predict patients quality of life 7 weeks after the consultation (Rutter, 
Iconomou, & Quine, 1996).  Similarly, another study examining the relationship between 
patients’ quality of life and the nature of the doctor-patient communication found that 
63
oncologists' behaviors were unrelated to patients' quality of life (Ong, Visser, Lammes, & 
de Haes, 2000).   
Next follows a discussion of the second component of doctor-patient communication. 
Instrumental Information
The second component of doctor-patient communication is clarity.  There are two 
aspects to clarity of communication between doctors and patients; patients’ understanding 
and recall of the information given, and patients’ desire for the kinds of information 
given.   
 The primary goal of medical consultations in the context of cancer, and in general, is 
to help the patient gain an understanding of their diagnosis, prognosis, and treatment 
options.  However, data suggests that a substantial number of cancer patients do not fully 
comprehend the provided medial information.  In a study of 100 cancer patients, 
Mackillip et al (1988) found that 33% of those with metastatic disease thought their 
illness was localized and that 34% of those being treated palliatively believed they would 
be cured.  These results have been supported in more recent studies.  For example, in a 
study of how patients perceive information conveyed by their physicians (Chan & 
Woodruff, 1997), results indicated that nearly 10% of patients were unaware that they had 
a diagnosis of cancer.  Upon further questioning, it became clear that one third of the 
patients, who had an incomplete understanding of their prognosis, overestimated their 
understanding of their actual prognosis.  Similar findings emerged from another study 
investigating communication differences between physicians and their patients in an 
oncology setting (Sher, Cella, Leslie, Bonomi, Taylor, & Serafian, 1997).  Here 
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researchers found that while physicians and patients disagreed on the valence of the 
information that was communicated, findings indicated that it were the patients who 
distorted the messages in a positive direction.  However, it should be considered that the 
psychological impact of being given a cancer diagnosis might interfere with patients’ 
ability to pay attention to other information provided during the consultation.  This factor 
may also be linked to patient recall of information. 
 In a study investigating the kinds of information patients wanted from their physicians 
Kaplowitz, Campo, and Chiu (2002) found, in a mail survey of cancer patients, that about 
80% of patients wanted a qualitative prognosis (i.e., will I die from the disease?), whereas 
only 50% wanted on a quantitative prognosis (i.e., how long will I survive?).  Results of 
this study also indicated that while 90% of those who wanted a qualitative prognosis were 
given one, only half of those who wanted a quantitative prognosis were given one. 
Further, among those who had wanted a qualitative prognosis only 15% failed to ask for 
it, whereas more than 30% of those who wanted a quantitative prognosis failed to ask for 
it.  Finally analyses also suggested that patients who had greater anxiety, a bad prognosis, 
and who needed to avoid thinking about death wanted, requested, and received 
significantly less information. Similarly, in an investigation of the doctor-patient 
interaction that compared patients’ information about their illness and their desire for 
information before and after consultations with their doctor, results suggested that a 
majority of patients did not feel they gained any significant additional information 
(Chaitchik et al, 1992). 
 Another important aspect of the doctor-patient communication is the experience of the 
doctors themselves.  Many doctors have reported their own difficulty and distress in 
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disclosing a cancer diagnoses to their patients leading them to present information in a 
hurried and uncaring manner due to their own discomfort, rather than a lack of respect 
and empathy for their patients (Ellis, & Tattersall, 1999). 
Communication and Adherence
Results from research on doctor-patient communication in the context of cancer have 
underlined the importance of the health care provider and patient communication on 
patients’ satisfaction with the information they have received.  If one assumes that 
satisfaction with information provided may be linked with a deeper understanding of 
one’s treatment, then these results implies that in-depth and repeated communication with 
health care providers about medical issues and treatment is integral to patients’ 
understanding of their illness and treatment options.  However, only few studies have 
sought to investigate the relationship between doctor-patient communication and 
treatment compliance despite the overwhelming finding that variables related directly to a 
patient’s relationship with their physician along with physician recommendations are 
among the foremost predictors of adherence to cancer screening procedures.  In a study 
examining the profile of patients who refused chemotherapy (Gilbar, 1989) results 
suggested that patients who had low confidence in their physicians exhibited higher rates 
of non-adherence as did those who had only little information about their illness.  In 
another study by Henman et al (2002) on factors influencing treatment decision making 
among women with breast cancer, findings suggested that while women cited the risk of 
recurrence, life expectancy, side-effects, and quality of life as influencing their decisions, 
they placed at least as much emphasis on their personal relationship with the specialist. 
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The specific physician characteristic that emerged as predictors of acceptance of primary 
treatment recommendations were; caring, understanding, respecting the patients and being 
perceived as trustworthy, open and honest. 
In summary, the patients’ perceptions of the affective quality of their interactions with 
doctors has been associated with patients’ satisfaction with the consultation and 
psychological adjustment.  With respect to instrumental information there appears to be a 
discrepancy between what doctors feel they have communicated and what patients report 
recalling with patients having a tendency to distort information in the positive direction. 
In addition, the desire for information varies widely among cancer patients.  Research on 
the relationship between doctor-patient communication and treatment adherence indicate 
that the physician’s behavior during the diagnostic consultation as well as patients’ 
confidence in their physician may predict subsequent treatment adherence.   
Coping 
 Receiving a diagnosis of cancer is a shocking and traumatic event; patients have to 
digest this new information along with a number of social, prognostic, and treatment 
related implications.  Research has suggested that cancer patients’ coping strategies are 
associated with their psychological adjustment to their illness.   
 Several studies have investigated the link between specific coping strategies and 
adjustment among cancer patients.   In studies of breast cancer patients results suggested 
that the use of emotion-focused coping, which included ventilation and avoidance 
strategies, was related to increased distress and poor adjustment (Ben-Zur, Gilbar, & Lev, 
2001; McCaul, Sandgren, King, O'Donnell, Branstetter, & Foreman, 1999).  Further, the 
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choice of coping strategy has been linked to subjective reports of physical and 
psychological side effects during treatment with adjuvant chemotherapy among women 
with breast cancer (Spairo, Boggs, Rodrigue, Urry et al, 1997).  Specifically, the authors 
found that women, who exhibited coping strategies characterized by engagement in 
understanding their illness and taking part in the medical decision progress, reported 
significantly fewer psychological and physical symptoms than those endorsing the use of 
avoidant coping strategies, suggesting that willingness to talk and think about the illness 
may be an important component in how side effects of treatment are experienced.  
 Other studies support the notion that a passive patient role is associated with poorer 
adaptation to illness than a more active role and emphasize the importance of promoting 
positive-focus coping strategies among patients (Cohen, 2002; Arraras, Wright, Jusue, 
Tejedor, & Calvo, 2002).  Further, women who take an active role, defined as the 
employment of coping strategies aimed at problem solving, the expression of emotion, 
and restructuring one's lifestyle, while undergoing diagnosis and treatment report better 
quality of life (Royak-Schaler, 1991).  In a study examining the effects of hope and 
coping strategies on adjustment to the diagnosis of cancer (Stanton, Danoff-Burg, & 
Huggins, 1991), results suggested that patients who accepted their diagnosis and who 
used a low rate of avoidant coping reported better psychological adjustment to their 
illness one year post diagnosis.   
 Another study of cancer patients' coping styles and doctor-patient communication 
(Ong, Visser, Van Zuuren, Rietbroek, Lammes, & de Haes, 1999) examined the 
relationship between coping style and patients' preferences for information and 
participation in decision-making, the relationship between monitoring and blunting 
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coping styles and prognosis, and the relationship between patients' coping styles and 
communicative behaviors and global affect during the initial oncological consultation. 
Results of the studies found that a monitoring coping style was linked to preference for 
more detailed information and increased participation in medical decision-making. 
Further, a monitoring coping style was also positively associated with patients' question 
asking and dominance during the consultation.  Similar results emerged from a study 
examining attitudes of cancer patients (Keltikangas-Jaervinen, 1986).  Findings revealed 
that patients who experienced their illness as a loss and who felt rational sorrow over lost 
health were more active in their own treatment and more likely to comply with treatment, 
whereas those who experienced their illness as a threat or challenge exhibited passive 
engagement in treatment decisions. 
 Overall, research suggests that patients, who employ coping styles that can be 
characterized by involvement in medical decision making and a desire to understand and 
gain information about their illness, tend to better adjusted than those who do not, and are 
more likely to be proactive in their interactions with physicians.   
Illness Perceptions 
 The cancer screening literature has suggested that major components in people’ 
decision to go through with cancer screening recommendations are knowledge about 
cancer and cancer screening as well as personal beliefs about the nature of the screening 
procedure and the usefulness of screening.  Research in the area of cancer treatment 
adherence has indicated that these factors may also play a role in patients’ decisions to 
adhere to treatment.  The specific components of patients’ illness perceptions that were 
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examined in this study pertains to beliefs about a) risks of complications and relapse, b) 
consequences of not adhering to recommended treatment, c) the benefits of adhering to 
recommendations, d) efficacy of treatment, and e) perceived barriers to adherence.   
 Patients’ illness perceptions have been suggested as essential in creating the cognitive 
and psychological framework within which patients make treatment decision (Buick, 
1997), and a series of studies have attempted to link patients’ illness-related cognitions to 
treatment adherence.  In a study exploring factors that influence medical information 
seeking and treatment engagement among cancer patients, results revealed that limited 
knowledge and misinformation about cancer were linked to poor adherence to health 
related behaviors among cancer patients (Matthews, Sellergren, Manfredi, & Williams, 
2002).   
 Patients’ beliefs about cancer treatment have also been associated with treatment 
adherence.  For example, patients who believed that side effects of treatment would be 
likely and severe were significantly more likely to be non-compliant (Siminoff & Fetting 
(1991) as were patients who reported low expectations of the treatment outcome (Gilbar, 
1989).  Another study examined adherence to oral medication regimens among adolescent 
and young adult cancer patients (Tamaroff, Festa, Adesman, & Walco, 1992). Results 
revealed no effects of treatment variables, such as treatment duration, continuity, or 
complexity. However, patients who adhered poorly to the therapeutic regimen had 
significantly less developed concepts of the illness (specifically, concepts of causality and 
prognosis), less perceived vulnerability, and higher levels of denial.  Horne & Weinman 
(1999) conducted a study of patients' personal beliefs about the necessity of their 
prescribed medication and their concerns about taking it among patients with chronic 
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illness.  The relationship between beliefs and reported adherence were examined and 
results indicated that beliefs about medicines were related to reported adherence. 
Specifically, high necessity scores with respect to the benefit of the medication were 
related to high adherence whereas a high number of concerns about the medication were 
correlated with lower reported adherence.  The lowest adherence was observed among 
patients whose concerns exceeded the perceived necessity of medication. 
 Other evidence for the link between patients’ illness perceptions and treatment 
adherence is circumstantial and has been derived indirectly by examining the influence of 
patients’ beliefs about cancer on psychological adjustment, which has been linked with 
treatment adherence.  Such studies have examined cognitions about cancer paying 
specific attention to patients’ emotional reaction to diagnosis and concerns about the 
treatment process, as well as the impact on patients’ sense of identity, interpersonal 
relationships, and beliefs about the future (Fife, 1995; Browne et al, 1988).  Results have 
suggested that having a positive attitude, characterized by optimism, having few irrational 
beliefs, and endorsement of internal goals, rather than external goals, predicts personal 
control and psychological adjustment to the illness (Fife, 1995; Arman, et al, 2001; 
Vickberg, et al, 2001; Thompson & Pitts, 1993).  
 Generally, research examining the effect of patients’ beliefs about their illness and 
treatment has suggested that there may be a link to treatment adherence.  Results from 
this research have suggested that the following components of illness perceptions may all 
be predictors of low treatment adherence: lack of knowledge about cancer and cancer 
treatment; beliefs about side effects; low expectations of treatment efficacy; poor 
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understanding of causality, prognosis, and vulnerability; and a high cost/benefit ratio of 
treatment. 
Hypotheses 
The following hypotheses were proposed:   
Hypotheses relating to doctor-patient communication
1. It was hypothesized that there would be a positive relationship between the patients’
perception of the affective quality of the doctor-patient communication, at baseline, and 
a. intent to adhere at baseline
b. adherence to the recommended oral care regimen (post-treatment and follow-up)
c. cessation of tobacco use (post-treatment and follow-up)
d. alcohol abstinence (post-treatment and follow-up)
e. patients’ illness perceptions (baseline, post-treatment, and follow-up)
2. It was hypothesized that there would be a positive relationship between patients’
perception of the instrumental/informative quality of the doctor-patient communication, at 
baseline, and 
a. intent to adhere at baseline
b. adherence to the recommended oral care regimen (post-treatment and follow-up)
c. cessation of tobacco use (post-treatment and follow-up)
d. alcohol abstinence (post-treatment and follow-up)
e. patients’ illness perceptions (baseline, post-treatment, and follow-up)
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Hypotheses pertaining to patient coping
3. It was hypothesized that there would be a positive relationship between patients’
adaptive coping and  
a. intent to adhere at baseline
b. adherence to the recommended oral care regimen (post-treatment and follow-up)
c. cessation of tobacco use (post-treatment and follow-up)
d. alcohol abstinence (post-treatment and follow-up)
e. patients’ illness perceptions (baseline, post-treatment, and follow-up)
4. It was hypothesized that there would be a negative relationship between patients’
maladaptive coping and 
a. intent to adhere at baseline
b. adherence to the recommended oral care regimen (post-treatment and follow-up)
c. cessation of tobacco use (post-treatment and follow-up)
d. alcohol abstinence (post-treatment and follow-up)
e. patients’ illness perceptions (baseline, post-treatment, and follow-up)
Hypotheses related to illness perceptions
5. It was hypothesized that patient’s illness related perceptions would be positively
related to    
a. intent to adhere at baseline
b. adherence to the recommended oral care regimen (post-treatment and follow-up)
c. cessation of tobacco use (post-treatment and follow-up)
d. alcohol abstinence (post-treatment and follow-up)
73
Hypotheses related to intent to adhere
6. With regard to the predictive value of baseline intent to adhere on actual adherence at
follow-up, it was hypothesized that baseline intent to adhere with doctors 
recommendations would be positively related to actual adherence to  
a. the recommended oral care regimen (post-treatment and follow-up)
b. cessation of tobacco use (post-treatment and follow-up)
c. alcohol abstinence (post-treatment and follow-up)
Mediation hypotheses 
7. It was hypothesized that patients’ illness perceptions would emerge as a partial
mediator of the relationship between patients’ perceptions of the affective quality of the 
doctor-patient communication, at baseline, and  
a. adherence to the recommended oral care regimen (post-treatment and follow-up)
b. cessation of tobacco use (post-treatment and follow-up)
c. alcohol abstinence (post-treatment and follow-up)
8. Similarly, it was hypothesized that patients’ illness perceptions would emerge as a
partial mediator of the relationship between patients’ perceptions of the 
instrumental/informative quality of the doctor-patient communication and 
a. adherence to the recommended oral care regimen (post-treatment and follow-up)
b. cessation of tobacco use (post-treatment and follow-up)
c. alcohol abstinence (post-treatment and follow-up)
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Moderation hypotheses 
9. It was hypothesized that patients’ coping would moderate the relationship between
patients’ perceptions of the affective quality of the doctor-patient communication, at 
baseline, and  
a. adherence to the recommended oral care regimen (post-treatment and follow-up)
b. cessation of tobacco use (post-treatment and follow-up)
c. alcohol abstinence (post-treatment and follow-up)
10. Similarly, it was hypothesized that patients’ coping would moderate the relationship
between patients’ perceptions of the instrumental/informative quality of the doctor-patient 
communication, at baseline, and 
a. adherence to the recommended oral care regimen (post-treatment and follow-up)
b. cessation of tobacco use (post-treatment and follow-up)
c. alcohol abstinence (post-treatment and follow-up)
Exploratory questions
Exploratory analyses examined the moderating effects of depression, cancer site, stage 
of illness, treatment modality, and oral functioning on the relationships between  
a. patients’ perceptions of doctor-patient communication and patient adherence
b. patients’ illness perceptions and patient adherence
c. patients’ coping and patient adherence
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CHAPTER 4: RESEARCH DESIGN AND METHODS 
Design 
 This is a longitudinal study examining adherence to an oral hygiene regimen, tobacco 
cessation, and alcohol abstinence among patients with oral or oralpharyngeal cancer.  One 
hundred and ten patients scheduled for radiation therapy at the University of Texas MD 
Anderson Cancer Center (UTMDACC) were enrolled in the study.   Utilizing self-
administered questionnaires, baseline assessments of all independent variables in the 
proposed model were made after the initial consultation with the dental oncologist.  All 
patients were contacted for a follow up evaluation of baseline measures in addition to 
subjective measures of adherence to the recommended treatment regimen immediately 
after the end of treatment and again 3 months later. 
Eligibility 
 Participants were solicited through the UTMDACC head and neck cancer radiation 
clinic. Patients with oral cavity or oralpharyngeal cancers who were scheduled to receive 
radiation therapy to the oral cavity or the lower part of the face were eligible for the 
study.  Two restrictions applied: only patients who were oriented to person, place, and 
time were included in the study as previous research has indicated that severe psychiatric 
illness often hinders a patient’s ability respond to questionnaires as well as negatively 
impact their ability to adhere to medical recommendations (Kunkel, Woods, Rodgers, & 
Myers, 1997).  Secondly, due to the specific aim of this study, to investigate adherence to 
a strict oral care regimen, only dentulous patients were selected for participation in the 
study.      
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Procedures 
 One hundred and twenty six patients were approached for participation in the study. 
Eight declined participation due to feeling too ill, already being part of other studies and 
feeling one more study would be too much, or stated they were not interested with no 
further explanation.  Attrition equaled 9.3% with 4 patients dying before completing the 
study and 7 patients dropping out due to feeling ill or too overwhelmed. 
 Patients were enrolled in the study post diagnosis but prior to radiation treatment.  All 
patients underwent an extensive dental exam and evaluation performed by a dental 
oncologist to assess baseline oral health status.  Upon conclusion of the dental 
consultation, but prior to radiation therapy, all patients were offered the opportunity to 
participate in the study.  If a patient expressed interest in participating, a brief interview 
followed during which eligibility was determined.  If the patient was eligible, the consent 
form and the purpose of the study were discussed.  Patients who chose to participate were 
asked to fill out a series of questionnaire at baseline assessing:  Demographic variables, 
medical history including baseline oral care practices, perceptions of the quality of 
doctor-patient communication, illness perceptions, intentions of adhering, baseline oral 
functioning, coping, and depression. 
 The treatment phase with radiation for head and neck cancer typically lasts from 5 to 8 
weeks depending on stage and location of the cancer.  Within one week of the end of 
treatment all patients were contacted for a follow up evaluation of: self-reported 
adherence to oral care regimen, smoking cessation and alcohol abstinence; illness 
perceptions; oral functioning; and depression.  This evaluation was repeated at a second 





Demographic information was collected including: date of birth, current age, ethnic 
background, marital status, employment status, level of education, and annual household 
income. 
Variables Pertaining to Medical History
Medical history was collected by chart review. This information included general 
medical history such as 1) the presence and treatment of non-cancer medical conditions, 
2) family history of cancer, 3) previous history of cancer and medical information
pertaining to the current cancer diagnosis: 1) the site of the cancer, 2) the stage of the 
cancer, and 3) the recommended treatment plan (surgery and radiation vs. radiation 
alone).   
 Other medical information was obtained through questionnaire: 1) smoking status, 2) 
alcohol use, and frequency of 3) brushing, 4) flossing, and 5) dental exams. 
Control Variables
Oral Functioning
Oral functioning was assessed to measure the extent to which cancer and cancer 
treatment has impacted patients’ ability to perform normal activities involving the 
physical structures of the neck and oral cavity.  Head and neck cancer patients often 
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experience impairments in their ability to chew, swallow, breathe normally, and 
communicate verbally.  
 Oral functioning was assessed using the Head and Neck Cancer Subscale of the 
Functional Assessment of Cancer Therapy-Head and Neck Scale, FACT-H&N (List et al, 
1996).   The FACT-H&N consists of a core scale FACT-General (FACT-G) in addition to 
a Head and Neck Cancer Subscale (NHCS).  The FACT-G is a multidimensional Quality 
of Life instrument developed by Cella et al (1993).  This instrument has been specifically 
designed to be used among cancer patients.  Only the HNCS will be used in this study. 
The HNCS assesses the specific functional impact of head and neck cancer.  The scale 
consists of 9 items tapping oral functioning, which are scored on a 5-point Likert scale 
and summed for a total score.  The measure has an internal consistency of α = .63 (List et 
al, 1996). 
Mental Status
Mental status was assessed at baseline using a checklist of the Mental Status 
Examination (MSE).  The MSE has a long history of use for obtaining information about 
a patient’s level of functioning and self-presentation ( ). The MSE assesses functioning in 
four categories: appearance and general behavior, interview behavior, thought, and 
cognitive functioning.       
Depression
Given the high prevalence of depression among medical patients, including cancer 
patients, depression will be assessed at each time point using the Center for 
Epidemiologic Studies – Depression Scale (CES-D) (Radloff, 1977).  The CES-D Scale is 
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a short, and widely used, self-report scale designed to measure depressive symptoms in 
the general population and has been examined for use specifically in the head and neck 
cancer population (Katz et al, 2004).  The measure has good internal consistency, alpha = 
.80, and has been well validated.  It was chosen over other measures of depression due to 
is relative low number of items tapping physical signs of depression, such as fatigue, that 
might be confused with the physiological correlates of cancer and cancer treatment.  The 
measure consists of 20 items scored on a 4-point scale, with higher scores reflecting more 
severe depressive pathology.  Items are summed to arrive at a conclusive score. 
Independent Measures
Doctor-Patient Communication
In this study doctor-patient communication refers to the interaction the patient has with 
his or her dental oncologist.  Patient perceptions of doctor-patient communication include 
two aspects.  The first aspect concerns the patient’s perception of the quality of the 
information received during the consultation, i.e. is the information communicated in a 
manner that the patient can understand, does the doctor answer questions, does the patient 
feel that enough information has been given, and is the information appropriate to the 
patients specific circumstance.  The second aspect of communication that was examined 
is concerned with the patients’ experience of affective nature of the consultation, does the 
doctor express appropriate affect, is he/she experienced as supportive and caring, and is 
the doctor able to tolerate patient affect.  Finally, there is the socio-emotional aspect of 
the consultation, which is concerned with non-verbal behaviors that express caring and a 
focus on the patient, i.e. does the doctor take time to talk with the patient or is he/she 
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experienced as being in a rush, and does the doctor sit down while talking to the patient. 
Patients’ perceptions of the instrumental, affective, and socio-emotional qualities of the 
consultation was assessed using the Cancer Diagnostic Interview Scale, CDIS (Roberts, 
Cox, Reintgen, Baile, & Gibertine, 1994).  The CDIS assesses patients’ perceptions of 
their doctor’s communication in the three areas described above.  The CDIS consists of 
20 items scored on a 5-point Likert scale.  The CDIS has an internal consistency of .92. 
Coping
Patient’s coping strategies was assessed using the dispositional version of the brief 
COPE (Carver, 1997; Carver, & Scheier, 1994). The COPE is a multidimensional coping 
inventory which assesses response to stress in several different areas (Carver, Scheier, & 
Weintraub, 989).  The Brief COPE is an abbreviated version of the COPE, consisting of 
two items from each of the 12 original subscales resulting in 24, items, which are scored 
on a 4-point Likert scale.  Each scale can be categorized as depicting either adaptive or 
maladaptive coping.  The scales have good internal consistency ranging from .45 to .92. 
Illness Perceptions
Patients’ illness perceptions were assessed using the Adherence Determination 
Questionnaire (ADQ) (DiMatteo, et al, 1993).  The ADQ is a measure designed to 
identify predictors of treatment adherence.  The ADQ consist of 7 subscales assessing: 
perceived utility of treatment, perceived severity of illness, perceived susceptibility to 
illness, future intentions of adhering, perception of barriers to adhering, interpersonal 
aspects of care and subjective norms.  The latter two subscales were not included in this 
study.  Internal consistencies for the five subscales included in the study are as follows: 
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perceived utility of treatment (α = .76), perceived severity of illness (α = .65), perceived 
susceptibility to illness (α = .69), future intentions of adhering (α = .84), and perception of 
barriers to adhering (α = .65). 
 Another aspect of patients’ illness perceptions that was assessed is concerned with 
patients’ beliefs about the causes of their illness.  The Illness Perceptions Questionnaire 
(IPQ) (Weinman, Petrie, Moss-Morris, & Horne, 1996) is a valid instrument, consisting 
of five scales, which assesses patients’ cognitive representations of illness.  Each scale 
can be measured and scored independently.  The causal component scale, which will be 
used in this study, comprises patients’ personal ideas about etiology.  The scale consists 
of 12 items.  The authors have deemed it inappropriate to sum all of the items as each 
represent a specific causal beliefs.  For the purposes of this study, however, items will be 
combined into two categories assessing internal versus external causes. 
Dependent Measures - Adherence
Adherence will be measured in three different areas: adherence to an oral care 
regimen, tobacco use, and alcohol consumption.  Tobacco and alcohol use were assessed 
using items from the Behavioral Risk Factor Surveillance System (BRFSS) developed by 
the Centers for Disease Control and Prevention (Centers for Disease Control and 
Prevention, 1999).  In the analyses tobacco use was operationalized as the average 
number of cigarettes smoked a day over the past 2 weeks.  Alcohol use was 
operationalized at the number of alcoholic drinks at patient had had over the past month. 
Eight self-report items asking patients about frequency of tooth brushing, flossing, dental 
visits and other dental care at baseline.  There was no existing measure for adherence to 
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oral care.  A measure consisting of 12 face valid items was created assessing tooth 
brushing, flossing, fluoride application, and use of mouth rinse at each follow-up data 
point.  Each item was scored so that a higher score reflected behavior that was closer to 
the recommendations made by the dental oncologist.  Items were then summed to produce 
a single score for oral care at each time point. Internal consistent was moderate.  Alpha = 
.50 at post-treatment and .51 at follow-up.  Though assessment of the patient's oral health 
was also to be done objectively at the end of treatment by a dental oncologist, the logistics 
of getting patients back to the dentist at the time of each assessment and getting each 
dentist to gather the required information was beyond the scope of this study.     
 A broad assessment of patients’ adherence to their doctor’s recommendations were 
also obtained through the General Adherence Scale (GAS) (DiMatteo, Hays, & 
Sherbourne, 1992).  The GAS is a five-item scale assessing patients’ consistency in 
following through with medical recommendations.  The GAS has been validated in 
several illness populations, including the head and neck cancer population, and internal 
consistency has been reported to be .66 or higher (DiMatteo, Hays, & Sherbourne, 1992).     
Analyses 
Descriptive Statistics
Descriptive analyses compiling means and standard deviations for the major study 
variables were computed.  Zero-order correlations were also calculated among study 
variables.   
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Predictive Analyses
The shared and unique predictive variance of each independent variable (patients’ 
perceptions of doctor-patient communication, patients’ illness perceptions, and patients’ 
dispositional coping) with the dependent variable, patient adherence (measured as 1. 
adherence to the recommended oral care regimen, 2. cessation of tobacco use, and 3. 
alcohol abstinence) was examined using linear regression analyses at each time point.     
Mediation Analyses
It was hypothesized that patients’ illness perceptions would operate as a partial 
mediator of the relationship between patients’ perceptions of both aspects of the doctor-
patient communication at baseline and adherence.   
 Linear regression analyses were conducted between the independent variable and 
dependent variable, and between the independent variable and the proposed mediator to 
determine whether the relationships were appropriate (i.e. were significant) for 
mediational analysis.   If these paths were significant, the mediational model was 
examined with path analysis applying Baron and Kenny’s (1986) criteria for mediation, 
which states that mediation can be inferred when the regression of the dependent variable 
on the independent variable becomes non-significant (indicating full mediation) when the 




Patients’ adaptive coping was hypothesized to strengthen the relationship between 
both aspects of the doctor-patient communication (affective quality and instrumental 
information) and patient adherence.   
 Linear regression analyses were conducted to ensure that moderational analysis is 
appropriate.  According to Baron and Kenny (1986) it is preferable that the moderator be 
uncorrelated with the independent variable and the dependent variable or, at the very 
least, that these relationships are weak.  Using the criteria set forth by Baron and Kenny, 
the independent variable and the moderator will both entered in block 1 of a regression 
model and the interaction term will be entered in block 2.  According to Baron and Kenny 
(1986) moderation by the proposed moderator may be inferred if the interaction term 
produces a significant result.  If the interaction term was significant, the hypothesized 
model was examined separately at low and high (median split) levels of adaptive coping.   
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CHAPTER 5: RESULTS 
Demographics 
 The sample consisted of 107 patients diagnosed with head and neck cancer.  All 
patients were treated at MDACC.  The sample was primarily male: 73.2% versus 26.8% 
female.  Age ranged from 32 to 76 years old.  The mean age was 55.   The sample was 
overwhelmingly Caucasian, 90.7%, with 3.1% African Americans, 3.1% Asian, 1% 
Native American, and 2.1% Hispanic patients.  Most patients were married, 80.4%, with 
6.2% indicating that they had never married, 9.3% indicating divorce or separation, 2.1% 
indicating that they were widowed, and 2.1% indicating “other” marital status.  Sixty 
percent of the sample was employed full time, 4.2% were unemployed, 6.3% worked 
within the home, 22.1% were retired, and 6.3% were disabled.  The sample was well 
educated with 27.1% have completed some college, 30.2% having graduated college, and 
20.8% having postgraduate education or degrees.   Seventeen percent had a high school 
diploma, and only 4.2% did not graduate high school.  Income was above average as well 
with 68% reporting an income of $50.000 or more a year. 
Illness Characteristics 
 Among patients in the current sample 26.4% had a previous diagnosis of cancer.  Head 
and neck cancer had been present in 52% of these cases.  Sixty seven percent of patients 
had a family history of cancer.  The sites of current cancer were distributed as follows: 
27.9% had oral cancer, 67.6% had oralpharyngeal cancer, and 4.4% had cancers at other 
head and neck sites.  Treatment varied from radiation only, 22%, to concurrent chemo-
radiation, 16.7%, and surgery followed by radiation, 38.9%.  Of those receiving 
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chemotherapy most received 3 cycles.  The mode for radiation treatment was 30 
treatments spaced over a 6-week period. 
Adherence Rates 
 At baseline 80.9% of the sample reported brushing their teeth daily, and of those 60% 
reported brushing twice a day or more often.  Thirty-one percent reported that they 
flossed daily and among those who did, 54% reported that they flossed at least once a 
day.  However, 80% of the sample had not been to see a dentist or have their teeth 
cleaned for more than 5 years.  With respect to tobacco and alcohol use, data revealed that 
at baseline only 6% smoked on a daily basis, 1.8% used smokeless tobacco, and 38% 
revealed some use of alcohol over the past month.  It should be noted though that between 
40 – 70% of the sample had missing data for these three variables. 
 At post-treatment 46% reported brushing their teeth daily.  Approximately 50% of the 
sample had no data for oral care at post-treatment.  Of those who did brush daily, 95% 
reported brushing at least twice a day.  This is up by almost 40% from baseline.  The rate 
of flossing went down to 23% reporting daily flossing, and among those 28% flossed 
more than once a day.   At the end of radiation treatment, when oral discomfort is likely 
the worst, 30 % of the sample reported using fluoride daily as instructed.  A higher 
number, 45 %, reported using the baking soda rinsing solution.  Interestingly, data 
revealed a higher rate of cigarette use at post-treatment, with 25 % of the sample 
indicating that they smoked 1 cigarette a day.  Only one patient reported using smokeless 
tobacco at post-treatment.  Alcohol use was down significantly from baseline with only 
4% of the sample reporting any use of alcohol over the past month.  As was the case at 
87
baseline, a high number of patients had some missing data with respect to the three 
outcome variables: Oral care, tobacco use, and alcohol use. 
 Among the data that was collected at follow-up 39 % of patients reported daily 
brushing, and among those 75 % brushed at least twice a day.  However, only 17 % of the 
sample reported flossing their teeth daily at follow-up, and among those who did 30% 
flossed more than once a day.  Use of fluoride was a disappointing 18 %, and use of 
baking soda rinse had dropped to 20%.  Approximately 13% of those who had data 
available at follow-up reported daily use of cigarettes, no one reported using smokeless 
tobacco, and 12% reported alcohol use within the past month.  However, many patients 
had at least some data missing from the three outcome measures.   
Descriptive Statistics and Predictive Analyses 
 Descriptive analyses compiling means and standard deviations for the major study 
variables were computed (tables 1 - 4).  Zero-order correlations were also computed 
between all major variables in the model.  They are reported below for each hypothesis. 
See also tables 5- 54.   The shared and unique predictive variance of each independent 
variable (patients’ perceptions of doctor-patient communication, patients’ illness 
perceptions, and patients’ dispositional coping) with the dependent variable, patient 
adherence, measured as 1) adherence to the recommended oral care regimen, 2) cessation 
of tobacco use, 3) alcohol abstinence, and 4) overall self-reported adherence, was 
examined using linear regression analyses, controlling for the baseline value of each 
dependent variable, at each time point.   Results are reported below for each hypothesis.   
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N Missing Minimum Maximum Mean Std. Deviation
Instrumental 
information 
86 21 10.00 40.00 25.337 5.005 
Socio-emotional 
behavior 
88 19 13.00 30.00 25.034 4.066 
Affective quality 83 8.00 30.00 13.373 4.053 
Baseline 
avoidant coping 
90 17 13.00 33.00 21.050 4.217 
Baseline 
approach coping
90 17 23.00 47.00 36.977 5.662 
External causes 92 15 11.00 31.00 19.619 4.989 
Internal causes 94 13 9.00 33.00 18.010 6.181 
Baseline utility 
subscale  
92 15 12.00 40.00 24.597 4.552 
Baseline severity 
subscale  




91 16 4.00 16.00 10.472 2.895 
Baseline barriers 
subscale 




91 16 10.00 20.00 12.505 2.213 
oral care at 
baseline  
97 10 7.00 30.00 21.154 4.826 
Cigarettes per 
day 
70 37 .00 30.00 1.428 5.417 
Smokeless 
tobacco use 
2 105 1.00 1.00 1.000 .000 
Monthly alcohol 
use 
42 65 .00 70.00 17.702 20.332 
Table 1:  Baseline table with means and standard deviations for each major variable in the 
model. 
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N Missing Min Max Mean Std. Deviation
T2 utility 
subscale  
60 47 24.00 40.00 37.300 3.907 
T2 severity 
subscale  
55 52 10.00 18.00 13.509 2.053 
T2 susceptability 
subscale  
59 48 6.00 18.00 12.016 2.603 
T2 barriers 
subscale  
60 47 11.00 20.00 16.900 2.588 
T2 intentions to 
adhere 
60 47 13.00 20.00 19.133 1.630 
Oral care 40 67 27.00 45.00 36.550 4.030 
No of Cigarettes 
a day 
32 75 .00 30.00 1.750 5.168 
Smokeless 
tobacco  
1 106 1.00 1.00 1.000 a
Monthly alcohol 
use  
10 97 .00 62.50 15.050 24.210 
Self-reported 
Adherence 
56 51 5.00 28.00 17.419 4.415 
Table 2:  Post-treatment table with means and standard deviations for each major variable 
in the model. 
a. Cannot be computed because at least one of the variables is a constant.
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N Missing Min Max Mean Std. Deviation
T3 utility 
subscale  
44 63 16.00 26.00 23.568 1.809 
T3 severity 
subscale  
45 62 4.00 12.00 9.200 1.914 
T3 susceptability 
subscale  
45 62 4.00 14.00 10.088 2.618 
T3 barriers 
subscale  
45 62 10.00 16.00 12.733 1.543 
T3 intentions to 
adhere 
45 62 8.00 14.00 11.711 .869 
Oral care 17 90 22.33 44.00 34.705 4.851 
Cigarettes per 
day 
15 92 1.00 1.00 1.000 0.000 
Smokeless 
tobacco 
0 107 a a a a
Monthly use of 
alcohol 
18 89 .00 24.00 7.000 7.259 
Self-reported 
Adherence 
44 63 4.00 17.00 12.568 2.084 
Table 3:  Follow-up table with means and standard deviations for each major variable in 
the model.  
a. Cannot be computed because at least one of the variables is a constant.
N Missing Min Max Mean Std. 
Deviation
Baseline CESD 88 19 .00 45.00 8.670 9.468 
Post-Treatment CESD 53 54 1.00 47.00 13.000 9.575 
Follow-Up CESD  45 62 .00 52.00 9.644 12.227 
Baseline FACTHN 86 21 24.00 36.00 30.983 3.609 
Post-Treatment FACTHN 51 56 19.00 36.00 29.941 3.036 
Follow-Up FACTHN 45 62 25.00 35.00 30.578 2.554 
Table 4: Means and Standard deviations of Depression at each time point and functional 
status at each time point. 
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Hypotheses Relating to Doctor-Patient Communication
It was expected that there would be a positive relationship between the three aspects 
patients’ perception of the doctor-patient communication at baseline (instrumental 
information, socio-emotional, and affective quality), and intent to adhere (baseline, post-
treatment, and follow-up) as well as adherence to the recommended oral care regimen 
(post-treatment and follow-up).  A negative correlation was predicted between doctor-
patient communication and cessation of tobacco use (post-treatment and follow-up) as 
well as between doctor-patient communication and alcohol abstinence (post-treatment and 
follow-up).  A positive correlation was predicted for doctor-patient communication and 
oral care as well as self-reported adherence (post-treatment and follow-up).   It was 
hypothesized that patients’ illness perceptions (baseline, post-treatment, and follow-up), 
would relate to doctor-patient communication as follows:  it was predicted that there 
would be a positive relationship between beliefs about the utility of treatment, but a 
negative relationship between doctor-patient communication and beliefs about severity, 
susceptibility, and barriers to adherence. 
Socio-Emotional Behavior
It had been predicted that there would be a positive relationship between the patients’ 
perception of the socio-emotional behavior displayed by the doctor, at baseline, and intent 
to adhere (post-treatment and follow-up) and oral care (post-treatment and follow-up).  It 
was expected that there would be a negative relationship between the socio-emotional 
behavior displayed by the doctor and tobacco use (post-treatment and follow-up) and 
alcohol use (post-treatment and follow-up).  Analyses were also performed to examine the 
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relationship between patients’ perception of the socio-emotional behavior displayed by 
the doctor and patients’ illness perceptions at each time point.  See tables 5-13, page 100. 
Analyses produced the following results. 
a. As expected intent to adhere at baseline was positively related to the socio-
emotional behavior of the doctor.  There was a significant correlation between the
socio-emotional quality of doctor-patient communication at baseline and intent to
adhere at baseline (r = .225, p < 0.05).  However, this finding did not extend to
other time points.
b. It was hypothesized that there would be a positive relationship between the
patients’ perception of the socio-emotional behavior displayed by the doctor and
the patient’s later adherence to the recommended oral care regimen (post-
treatment and follow-up).  There were no significant correlations or regressions
found at any time point for oral care and the socio-emotional behavior of the
doctor.
c. It was predicted that there would be a negative relationship between the patients’
perceptions of the socio-emotional behavior displayed by the doctor and tobacco
use (post-treatment and follow-up).  There were no significant correlations or
regressions found for tobacco use and socio-emotional behavior of the doctor at
any time point.
d. It had been expected that there would be a negative relationship between the
patients’ perception of the socio-emotional behavior displayed by the doctor and
alcohol use (post-treatment and follow-up).  There were no significant correlations
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or regressions found for alcohol use care and socio-emotional behavior of the 
doctor.  
e. Correlation analyses between the patients’ perception of the socio-emotional
behavior displayed by the doctor and illness perceptions produced the following
results:  There was a negative correlation between socio-emotional behavior and
baseline beliefs about the severity of illness (r = -.263, p < 0.05) and baseline
beliefs about barriers to adherence (r = -.240, p < 0.05).  That is, the more satisfied
patients were with physician behavior, the less severe the believed the oral
complications were and the fewer barriers they perceived at baseline.  Socio-
emotional behavior was also negatively correlated with beliefs about barriers at
post-treatment (r = -.457, p < 0.01) and beliefs about susceptibility to future
complications at follow-up (r = -.394, p < 0.05).  Linear regressions found that
physician’s socio-emotional behavior was a good predictor of perceived barriers at
post-treatment (β = -.403, p < 0.01) and beliefs about susceptibility at follow-up
(β = -.376, p < 0.01).  That is, the more satisfied patients were with physician
behavior, the fewer barriers they perceived and the less susceptible they believed
themselves to be to future complications.
Affective Quality
It was hypothesized that there would be a positive relationship between the patients’ 
perception of the affective quality of the doctor-patient communication, at baseline, and 
intent to adhere (post-treatment and follow-up) and oral care (post-treatment and follow-
up).  It was expected that there would be a negative relationship between the affective 
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quality of the doctor-patient communication and tobacco use (post-treatment and follow-
up) and alcohol use (post-treatment and follow-up).  Analyses were also performed to 
examine the relationship between patients’ perceptions of the affective quality of the 
doctor-patient communication and patients’ illness perceptions at each time point.  See 
tables 5-13, page 100. 
a. Intent to adhere at baseline was hypothesized to be positively related to the
affective quality of the doctor-patient communication.  Consistent with
hypotheses, there was a significant correlation between the affective quality and
intent to adhere at baseline (r = .798, p < 0.01).  However, no other significant
correlations or regressions were found at any time point.
b. It was predicted that there would be a positive relationship between the patients’
perception of the affective quality of the doctor-patient communication and
adherence to the recommended oral care regimen (post-treatment and follow-up).
Contrary to predictions, there were no significant correlations or regressions found
for oral care and affective quality.
c. It had been expected that there would be a negative relationship between the
patients’ perception of the affective quality of the doctor-patient communication
and tobacco use (post-treatment and follow-up).  While there was a correlation
between the affective quality and baseline use of cigarettes (r = .281, p < 0.05),
there were no other significant correlations, nor regressions, found for either of the
two downstream time points.
d. It was hypothesized that there would be a negative relationship between the
affective quality of the doctor-patient communication and alcohol use (post-
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treatment and follow-up).  However, there were no significant correlations or 
regressions found for alcohol use and affective quality. 
e. Correlation analyses between the patients’ perception of the affective quality of
the doctor-patient communication and illness perceptions produced the following
results:  Affective quality of the doctor-patient communication was correlated
with baseline beliefs about the utility of treatment (r = .785, p < 0.01) and baseline
beliefs about barriers to adherence (r = -.604, p < 0.01).  That is the more satisfied
patients were with the affective quality of the communication the higher their
belief in the utility of treatment and the less barriers they perceived at baseline.
There were no significant predictive relationships between these variables at any
time point.
Instrumental Quality
It was hypothesized that there would be a positive relationship between the patients’ 
perception of the instrumental quality of the doctor-patient communication, at baseline, 
and intent to adhere (post-treatment and follow-up) as well as between instrumental 
quality and oral care (post-treatment and follow-up).  It was expected that there would be 
a negative relationship between the affective quality of the doctor-patient communication 
and tobacco use (post-treatment and follow-up) and alcohol use (post-treatment and 
follow-up).  Analyses were also performed to examine the relationship between patients’ 
perceptions of the instrumental quality of the doctor-patient communication and patients’ 
illness perceptions at each time point.  See tables 5-13, page 100. 
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a. Intent to adhere at baseline was hypothesized to be positively related to the
instrumental quality of the doctor-patient communication.  Consistent with
hypotheses, there was a significant correlation between the instrumental quality of
the doctor-patient communication and intent to adhere at baseline (r = .602, p <
0.01) and intent to adhere at follow-up (r = .331, p < 0.05).  That is the more
satisfied the patient was with the instrumental quality, the better the intent to
adhere was at baseline and post-treatment.  The relationship between instrumental
quality and intent to adhere at follow-up remained significant with regression
analysis controlling for baseline intent to adhere (β = .352, p < 0.05).
b. It was predicted that there would be a positive relationship between the patients’
perception of the instrumental quality of the doctor-patient communication and
adherence to the recommended oral care regimen (post-treatment and follow-up).
However, there were no significant correlations or regressions found for oral care
and instrumental quality.
c. It was expected that there would be a negative relationship between the
instrumental quality of the doctor-patient communication and tobacco use (post-
treatment and follow-up).  Contrary to expectations, there were no significant
correlations or regressions found for tobacco use and instrumental quality.
d. It was hypothesized that there would be a negative relationship between the
instrumental quality of the doctor-patient communication and alcohol use (post-
treatment and follow-up).  However, there were no significant correlations or
regressions found for alcohol use care and instrumental quality.
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e. It was predicted that patients’ illness perceptions (baseline, post-treatment, and
follow-up), would relate to the instrumental quality of the doctor-patient
communication as follows.  There would be a positive relationship between
instrumental quality and beliefs about the utility of treatment, but a negative
relationship between instrumental quality and beliefs about severity,
susceptibility, and barriers to adherence.   As hypothesized instrumental quality
was positively correlated with beliefs about the utility of treatment at baseline (r =
.526, p < 0.01) and at follow-up (r = .454, p < 0.01).  Consistent with hypotheses
instrumental quality was negatively correlated with beliefs about barriers to
adherence at baseline (r = -.472, p < 0.01) and also a post-treatment (r = -.281, p <
0.05).   Regression analyses revealed that instrumental quality of the doctor-
patient communication was a good predictor of beliefs about the utility of
treatment at follow-up (β = .453, p < 0.01).  That is, the more satisfied patients























N 79 50 37
Table 5.  Correlations between doctor-patient communication and intentions to adhere at 
baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed).  
* Correlation is significant at the 0.05 level (2-tailed).
oral care at 
baseline 












N 88 35 15
CDIS affective Pearson 
Correlation 
-.106 -.081 .031
N 83 34 14
Table 6.  Correlations between doctor-patient communication and oral care at baseline, 
post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 





T2 Cigarettes a 
day 












N 62 29 13
CDIS affective Pearson 
Correlation 
.281* .350 a
N 61 28 13
Table 7.  Correlations between doctor-patient communication and tobacco use as baseline, 
post-treatment, and follow-up.   
a. Cannot be computed because at least one of the variables is a constant
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Baseline 
alcohol use 












N 38 10 15
CDIS affective Pearson 
Correlation 
-.118 -.083 -.025
N 36 10 14
Table 8.  Correlations between doctor-patient communication and alcohol use as baseline, 
post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
.
External causes Internal causes 
CDIS 
instrumental 




Pearson Correlation -.205 -.178 
N 83 85
CDIS affective Pearson Correlation .110 .046 
N 78 80
Table 9.  Correlations between doctor-patient communication and beliefs about causes of 
current illness at baseline.   
**Correlation is significant at the 0.01 level (2-tailed). 














.526** .048 -.062 -.472** 





.083 -.263* -.180 -.240* 
N 85 82 84 86
CDIS affective Pearson 
Correlation
.785** .152 .212 -.604** 
N 80 77 79 81
Table 10.  Correlations between doctor-patient communication and beliefs utility of 
treatment, severity of illness, susceptibility to future complications, and barriers to 
adherence at baseline.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).





.101 -.048 .090 -.281* 





.185 .133 -.081 .183 
N 52 49 52 53
CDIS affective Pearson 
Correlation
.045 -.066 .094 -.457** 
N 50 47 50 51
Table 11.  Correlations between doctor-patient communication and beliefs utility of 
treatment, severity of illness, susceptibility to future complications, and barriers to 
adherence at post-treatment.   
**Correlation is significant at the 0.01 level (2-tailed). 











.454 -.042 -.253 -.170 





-.111 -.281 -.394 -.285 
N 40 41 41 41
CDIS affective Pearson 
Correlation
-.017 -.007 .272 .315 
N 36 37 37 37
Table 12.  Correlations between doctor-patient communication and beliefs utility of 
treatment, severity of illness, susceptibility to future complications, and barriers to 
adherence at follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).



















Table 13. Correlations between doctor-patient communication and self-reported 
adherence at post-treatment and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Hypotheses Pertaining to Patient Coping
Adaptive Coping
It was hypothesized that there would be a positive relationship between patients’ 
adaptive coping and the variables in the model.  That is, the more adaptive coping the 
better the intent to adhere, the better the adherence to oral care recommendations, the less 
tobacco and alcohol use, and the more optimistic the illness perceptions. 
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a. No correlations were found at baseline between adaptive coping and intent to
adhere at baseline, post-treatment, and follow-up.  There was a positive
correlation (r = .310, p < 0.05) between adaptive coping and intent to adhere at
post-treatment.  The more adaptive coping at baseline, the better the intent to
adhere at post-treatment.  No correlation was found between adaptive coping and
intent to adhere at follow-up.  See table 14.  Linear regression analyses revealed













1.000 .208 .310* .036





.208 1.000 .175 -.031





.310* .175 1.000 .035





.036 -.031 .035 1.000
N 41 43 37 45
Table 14.  Correlations between adaptive coping and intentions to adhere at baseline, post-
treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
b. It was hypothesized that there would be a positive relationship between oral care
at baseline, post treatment, and follow-up and patients’ adaptive coping.  No
significant relationships emerged between oral care and adaptive coping.  See
table 15.  Linear regression analyses found no predictive relationships between













1.000 .166 .294 .451
N 90 90 35 15




.166 1.000 .336 .160
N 90 97 38 17
T2 ORAL CARE Pearson 
Correlation
.294 .336 1.000 .612





.451 .160 .612 1.000
N 15 17 14 17
Table 15.  Correlations between adaptive coping and oral care at baseline, post-treatment, 
and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
c. It was predicted that tobacco use at baseline, post-treatment, and follow-up would
be negatively correlated with adaptive coping.  There were no significant
relationships found between adaptive coping and tobacco use at any time point.
See table 16.  Linear regression analyses revealed no predictive value of adaptive
coping on tobacco use.  (Note that N was too small for analyses at follow-up for
cigarettes and at both post-treatment and follow-up for smokeless tobacco).
Baseline No  
Cigarettes a day 
T2 Cigarettes a day 
Baseline approach 
coping  
Pearson Correlation .041 .247 
N 66 28
Table 16.  Correlations between adaptive coping and tobacco use at baseline, post-
treatment, and follow-up.  Correlations for smokeless tobacco use at each time point, and 
cigarette use at follow-up could not be computed because at least one of the variables was 
a constant. 
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
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d. It was hypothesized that there would be a negative correlation between alcohol
use at baseline, post-treatment, and follow-up and adaptive coping.  Again no
significant relationships emerged.  See table 17.  Neither did linear regression
analyses produce any significant predictive relationships between adaptive coping

















1.000 -.259 -.085 .161 
N 90 40 10 15
Baseline 




-.259 1.000 .550 .708 





-.085 .550 1.000 .
N 10 7 10 1
T3 monthly 
 use of alcohol
Pearson 
Correlation
.161 .708 . 1.000
N 15 11 1 18
Table 17.  Correlations between adaptive coping and alcohol use at baseline, post-
treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
e. There were a number of significant correlations between adaptive coping at
baseline and patients’ illness perceptions at baseline, post-treatment, and follow-
up.  At baseline adaptive coping was positively correlated with beliefs about the
causes of illness as follows: internal causes (r = .222, p < 0.05); external causes (r
= .304, p < 0.01).  This indicates that the more adaptive coping a patient engaged
in the more possible causes he/she endorsed and the stronger the belief was in
these cause regardless of whether these causes were internal or external.  See table
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18. Adaptive coping was negatively correlated with baseline beliefs about
severity of one’s illness (r = -.455, p < 0.01) and beliefs about barriers to 
successful adherence (r = -.244, r < 0.05).  That is, the more adaptive coping, the 
less severe one’s illness was perceived to be and the fewer barriers to adherences 
were expected.  See table 19.  There were no significant relationships between 
illness perceptions and adaptive coping at post-treatment (Table 20).  However, 
adaptive coping was negatively correlated with follow-up beliefs about severity of 
one’s illness (r = -.426, p < 0.01) and beliefs about susceptibility to future 
complications (r = -.361, p < 0.05).   See tables 19-21.  That is, the more adaptive 
coping at baseline, the less severe the illness is perceived to be at follow-up and 



























N 88 92 94
Table 18.  Correlations between approach coping and causes of illness at baseline.  
** Correlation is significant at the 0.01 level (2-tailed). 





















1.000 .147 -.455** -.164 -.244* 






.147 1.000 .103 .064 -.659** 







-.455** .103 1.000 .326** -.085 








-.164 .064 .326** 1.000 -.042 






-.244* -.659** -.085 -.042 1.000 
N 86 92 89 91 93
Table 19.  Correlations between adaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
baseline.   
**Correlation is significant at the 0.01 level (2-tailed). 


















1.000 .173 .029 -.167 .098 





.173 1.000 .248 .011 .140 






.029 .248 1.000 .165 .164 







-.167 .011 .165 1.000 -.216 






.098 .140 .164 -.216 1.000 
N 52 59 55 58 60
Table 20.  Correlations between adaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
post-treatment.   
**Correlation is significant at the 0.01 level (2-tailed). 













1.000 -.045 -.426** -.361* -.249 
N 90 41 41 41 41
T3 utility Pearson 
Correlation
-.045 1.000 .148 .000 -.072 





-.426** .148 1.000 .364* .303* 






-.361* .000 .364* 1.000 .214 





-.249 -.072 .303* .214 1.000 
N 41 44 45 45 45
Table 21.  Correlations between adaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
post-treatment.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Linear regression analyses produced the following results:  No predictive value 
of adaptive coping on beliefs about utility of treatment at either downstream time 
point.  This was also true for beliefs about severity of illness.  However, adaptive 
coping does predict beliefs about susceptibility of future complications at follow-
up (β = -.334, p < 0.01).  That is, the more adaptive coping, the less susceptible a 
patient believes he/she is to future oral complications.  There was also a 
significant predictive relationship between adaptive coping and beliefs about 
barriers to treatment at post-treatment (β = .291, p < 0.05).  That is the more 
adaptive coping at baseline, the more barriers were perceived at post-treatment 
(this might reflect a realistic view of what one will have to do to be able to 
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successfully adhere to oral care recommendations).  This relationship was not 
significant at follow-up.  No other significant results were found. 
Maladaptive Coping
It was hypothesized that there would be a negative relationship between patients’ 
maladaptive coping and the variables in the model.  That is, the more maladaptive coping 
the poorer the intent to adhere, the worse the adherence to oral care recommendations, the 
more tobacco and alcohol use, and the less optimistic the illness perceptions. 
a. It was predicted that there would be a negative relationship between maladaptive
coping and intent to adhere at baseline, post-treatment, or follow-up.  No
significant correlations emerged between the two variables at any time point.  See
table 22.  Similarly, linear regression analyses found no predictive relationships













1.000 -.062 -.034 .197





-.062 1.000 .175 -.031
N 84 91 54 43
T2 intentions  Pearson 
Correlation
-.034 .175 1.000 .035
N 52 54 60 37
T3 intentions Pearson 
Correlation
.197 -.031 .035 1.000
N 42 43 37 45
Table 22.  Correlations between maladaptive coping and intentions to adhere at baseline, 
post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
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b. It was hypothesized that maladaptive coping and adherence to the recommended
oral care regimen, at post-treatment and follow-up, would correlate negatively.
There were no correlations between maladaptive coping and adherence to the oral
care regimen at any time point.  See table 23.  Neither did linear regression
analyses produce any significant predictive relationship between maladaptive
coping and oral care at either post-treatment or follow-up.
Baseline avoidant 
coping 










1.000 .094 -.139 -.181
N 90 90 34 15




.094 1.000 .336 .160
N 90 97 38 17
T2 ORAL CARE Pearson 
Correlation 
-.139 .336 1.000 .612





-.181 .160 .612 1.000
N 15 17 14 17
Table 23.  Correlations between maladaptive coping and oral care at baseline, post-
treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
c. Hypotheses predicted a positive relationship between tobacco use and maladaptive
coping for those patients who smoked at baseline.  There were no correlations
between maladaptive coping and tobacco use at any time point.  See table 24.
Linear regression analyses revealed no significant predictive relationships
between maladaptive coping and tobacco use at any of the downstream time
points (note that N was too small for analyses for cigarette use at post-treatment
and smokeless tobacco use at both post-treatment and follow-up.
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Baseline Cigarettes a 
day 




Pearson Correlation .102 .031 
N 67 29
Table 24.  Correlations between maladaptive coping and tobacco use at baseline, post-
treatment, and follow-up.  Correlations for smokeless tobacco use at each time point, and 
cigarette use at follow-up could not be computed because at least one of the variables was 
a constant. 
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
d. Likewise, a negative relationship was expected to emerge between maladaptive
coping and alcohol use at post-treatment and follow-up.  There were no
correlations between maladaptive coping and alcohol use at any time point.  See
table 25.  No significant predictive analyses emerged by linear regression analyses

















1.000 .214 -.307 -.356
N 90 38 10 17
Baseline 




.214 1.000 .550 .708
N 38 42 7 11




-.307 .550 1.000 a.
N 10 7 10 1
T3 monthly 
 use of alcohol 
Pearson 
Correlation 
-.356 .708 . 1.000
N 17 11 1 18
Table 25.  Correlations between maladaptive coping and alcohol use at baseline, post-
treatment, and follow-up.   
a. Cannot be computed because at least one of the variables is a constant.
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
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e. It was also hypothesized that maladaptive coping would be negatively related to
patients’ illness perceptions (baseline, post-treatment, and follow-up).  There were
no correlations between maladaptive coping and illness perceptions at any time
point.  See tables 26-29.  Nor, did linear regression analyses produce any
significant predictive relationships between maladaptive coping and beliefs about
utility of treatment, severity of illness, susceptibility to future complications, and
























N 87 92 94
Table 26.  Correlations between maladaptive coping and causes of illness at baseline.  
** Correlation is significant at the 0.01 level (2-tailed). 






















1.000 -.142 -.004 .021 .165 






-.142 1.000 .103 .064 -.659** 







-.004 .103 1.000 .326** -.085







.021 .064 .326** 1.000 -.042






.165 -.659** -.085 -.042 1.000 
N 86 92 89 91 93
Table 27.  Correlations between maldadaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
baseline.   
**Correlation is significant at the 0.01 level (2-tailed). 



















1.000 .038 .058 -.136 .155 





.038 1.000 .248 .011 .140 
N 52 60 55 58 59 




.058 .248 1.000 .165 .164 






-.136 .011 .165 1.000 -.216 
N 51 58 55 59 58 




.155 .140 .164 -.216 1.000 
N 52 59 55 58 60 
Table 28.  Correlations between maladaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
post-treatment.   
**Correlation is significant at the 0.01 level (2-tailed). 













1.000 .272 -.182 -.202 .124 
N 90 42 42 42 42
T3 utility Pearson 
Correlation 
.272 1.000 .148 .000 -.072 
N 42 44 44 44 44
T3 severity Pearson 
Correlation 
-.182 .148 1.000 .364* .303* 





-.202 .000 .364* 1.000 .214 
N 42 44 45 45 45
T3 barriers Pearson 
Correlation 
.124 -.072 .303* .214 1.000 
N 42 44 45 45 45
Table29.  Correlations between maladaptive coping and beliefs about utility of treatment, 
severity of illness, susceptibility to future complications, and barriers to adherence at 
follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Hypotheses Related to Illness Perceptions
Illness perceptions encompass 4 different subscales: beliefs about utility of treatment, 
severity of illness, susceptibility to future complications or illness, and barriers to 
adherence.   
a. It was hypothesized that utility of treatment, severity of illness, and susceptibility
to future complications would all be positively related to intent to adhere, but that
barriers to illness would be negatively related to intent to adhere.  There were a
number of correlations between intent to adhere and illness perceptions.  As
predicted a positive correlation was found between beliefs about the utility of
treatment (r = .829, p < 0.01) and intent to adhere at baseline.  That is, the higher
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the belief in the utility of the oral care regiment, the better the intents to adhere. 
This same relationship was also present at post-treatment (r = .663, p < 0.01). 
There was also a negative correlation between beliefs about barriers to adherence 
and intent to adhere at baseline (r = - .788, p < 0.01).   There more barriers that are 
perceived, the less likely the intent to adhere.  Post-treatment barriers were 
negatively correlated with intentions at baseline (r = -.428, p < 0.01).   That is, the 
less intent to adhere at baseline, the more barriers were perceived at post-treatment 
with respect to future adherence.  There were also significant negative correlations 
between baseline intent to adhere and follow-up beliefs about severity of illness  
(r = -.341, p < 0.05) and barriers to adherence (r = - .382, p < 0.05).  In other 
words, the less intent to adhere at baseline the more severe the illness was 
perceived to be and the more barriers to adherence were perceived at follow-up. 
See tables 30-32.   
Baseline 
intentions 
T2 intentions T3 intentions 
Baseline utility  Pearson 
Correlation 
.829** .106 -.001
N 91 54 43
Baseline  severity Pearson 
Correlation 
.151 -.148 .072






N 91 54 43
Baseline barriers Pearson 
Correlation 
-.788** -.206 -.030
N 91 54 43
Table 30.  Correlations between baseline beliefs about utility of treatment, severity of 
illness, susceptibility to future complications, barriers to adherence and intent to adhere at 
baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 




T2 intentions T3 intentions 
T2 utility  Pearson 
Correlation 
.170 .663** -.031 
N 54 59 37 
T2 severity  Pearson 
Correlation 
-.072 .085 .215 
N 49 55 34 
T2 susceptibility Pearson 
Correlation 
.058 .072 -.119 
N 53 59 36 
T2 barriers Pearson 
Correlation 
-.428** .107 .282 
N 54 59 38 
Table 31.  Correlations between post-treatment beliefs about utility of treatment, severity 
of illness, susceptibility to future complications, barriers to adherence and intent to adhere 
at baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
Baseline 
intentions 
T2  intentions T3 intentions 
T3 utility Pearson 
Correlation 
-.270 -.306 .269 
N 42 36 44 
T3 severity Pearson 
Correlation 
-.341* .006 -.224 
N 43 37 45 
T3 susceptibility Pearson 
Correlation 
-.242 -.063 -.118 
N 43 37 45 
T3 barriers Pearson 
Correlation 
-.382* -.166 .077 
N 43 37 45 
Table 32.  Correlations between follow-up beliefs about utility of treatment, severity of 
illness, susceptibility to future complications, barriers to adherence and intent to adhere at 
baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
Regression analyses were conducted to test the predictive value of beliefs 
about utility of treatment, severity of illness, susceptibility to future complications, 
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and barriers to adherence on intent to adhere.  Illness perceptions did not emerge 
as significant predictors of intent to adhere at either post-treatment or follow-up.     
b. It was hypothesized that utility of treatment, severity of illness, and susceptibility
to future complications would all be positively related to oral care, whereas
barriers to adhere would be negatively related to oral care.  A significant negative
relationship emerged between baseline beliefs about the severity of illness and
follow-up oral care.  That is the more severe the illness is perceived to be, the less
likely a patient was to practice good oral care at follow-up (r = -.540, p < 0.05).
See table 33.  Regression analyses with illness perceptions as the independent
variable produced the following results:  Beliefs about utility of treatment,
susceptibility to future complications, and barriers to adherence did not emerge as
a significant predictor of oral care at either post-treatment or follow-up.  Severity
of illness was a significant predictor of oral care at follow-up (β = -.549, p < 0.05).
That is, the more severe the illness was perceived to be, the less likely a patient
was to follow the oral care recommendations (does patient give up in the face of
what is perceived to be a severe illness or do patients who correctly identify their
illness as severe suffer more treatment side effects, as a consequence of more
prolonged treatment, that in turn prevents adherence?).
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oral care at 
baseline 
T2 Oral care T3 oral care 
Baseline utility  Pearson 
Correlation 
.003 -.019 -.394
N 92 36 15
Baseline severity Pearson 
Correlation 
-.022 -.326 -.540*
N 89 35 14
Baseline barriers Pearson 
Correlation 
.091 .081 -.083






N 91 36 15
T2 utility Pearson 
Correlation 
-.086 .192 .240
N 57 38 15
T2 severity  Pearson 
Correlation 
-.013 .011 -.248
N 52 35 15
T2  Pearson 
Correlation 
-.064 -.015 -.295
N 56 38 16
T2 barriers Pearson 
Correlation 
-.019 .189 .288
N 57 38 16
T3 utilityI Pearson 
Correlation 
.227 -.250 -.058
N 44 24 14
T3 severity Pearson 
Correlation 
-.115 -.080 -.072
N 45 25 15
T3 susceptibility Pearson 
Correlation 
-.204 -.138 -.477
N 45 25 15
T3 barriers Pearson 
Correlation 
-.207 .107 .090
N 45 25 15
Table 33.  Correlations between baseline, post-treatment, and follow-up beliefs about 
utility of treatment, severity of illness, susceptibility to future complications, barriers to 
adherence and oral care at baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
c. It was hypothesized that utility of treatment, severity of illness, and susceptibility
to future complications would all be negatively related to tobacco use, but that 
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barriers to illness would be positively related to cessation of tobacco use (post-
treatment and follow-up).  Baseline illness perceptions were significantly 
correlated with tobacco use at post-treatment as follows:  The higher the belief in 
the utility of treatment, the more reported tobacco use (does pt believe that 
treatment can counter effects of smoking?) (r = .381, p < 0.05).  The more severe 
the illness is believed to be, the more reported tobacco use (does pt believe that 
smoking doesn’t matter since illness is so severe?) (r = .431, p < 0.05).  The more 
barriers to adherence; the less reported tobacco use (the more difficult the oral 
care regimen is perceived to be, the better patients are at refraining from 
smoking?) (r = -.411, p < 0.05).   There were no significant correlations for 
follow-up tobacco use.  See table 34.  
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Baseline  Cigarettes T2 Cigarettes 
Baseline utility Pearson Correlation .151 .381* 
N 65 29
Baseline severity Pearson Correlation .035 .431* 
N 63 29
Baseline susceptability Pearson Correlation .022 .226 
N 65 29
Baseline barriers Pearson Correlation -.008 -.411* 
N 66 29
T2 utility Pearson Correlation .119 .018 
N 41 31
T2 severity  Pearson Correlation .083 -.048 
N 36 27
T2 susceptibility Pearson Correlation -.058 -.014 
N 40 30
T2 support  Pearson Correlation .016 -.179 
N 41 32
T3 utility Pearson Correlation .008 a. 
N 33 18
T3 severity Pearson Correlation .013 a. 
N 34 19
T3 susceptibility Pearson Correlation .039 a. 
N 34 19
T3 barriers Pearson Correlation .106 a. 
N 34 19
Table 34. Correlations between baseline, post-treatment, and follow-up beliefs about 
utility of treatment, severity of illness, susceptibility to future complications, barriers to 
adherence and cigarette use at baseline and post-treatment.  Correlations for smokeless 
tobacco use at each time point, and cigarette use at follow-up could not be computed 
because at least one of the variables was a constant. 
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Regression analyses were conducted to test the predictive value of illness 
perceptions and tobacco use.  Beliefs about the utility of treatment did predict 
cigarette use at post-treatment (β = .407, p < 0.05).  That is, the higher the belief 
that treatment is useful, the more reported cigarette use (does pt believe that 
treatment is so powerful that it will cancel out bad effects of smoking?).  This 
relationship was not significant at follow-up, or for smokeless tobacco at any time 
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point (because the sample size was too small and the variable ended up 
representing a constant).  Beliefs about the severity of illness also emerged as a 
significant predictor cigarette/cigar use at post-treatment (β = .431, p < 0.05).   
That is, the more severe the illness is perceived to be, the more the reported use of 
cigarettes (again, does patient give up in the face of what is perceived to be a very 
severe illness?).  This relationship was not reproduced for cigarettes at follow-up 
or for smokeless tobacco use (again due to a small sample size the variable ended 
up representing a constant).  Beliefs about susceptibility to future complications 
did not predict tobacco use at either post-treatment or follow-up.  Beliefs about 
barriers to adherence did emerge as a significant predictor of post-treatment 
cigarette use (β = -.505, p < 0.05).  The more barriers are perceived at baseline, 
the less the reported use of cigarettes at post-treatment.  There were no other 
significant relationships between beliefs about barriers to adherence and tobacco 
use at post-treatment or follow-up. 
d. It was hypothesized that utility of treatment, severity of illness, and susceptibility
to future complications would all be negatively related to alcohol use, but that
barriers to illness would be positively related to cessation of alcohol use (post-
treatment and follow-up).  There was a significant negative correlation between
baseline beliefs about barriers to adherence and follow-up alcohol use(r = -.566, p
< 0.05).  That is, the more barriers are perceived at baseline, the less reported
alcohol use at follow-up.  There was also a significant correlation between
baseline alcohol use and beliefs about the utility of treatment at post-treatment (r =
-.520, p < 0.01).  That is the more reported alcohol use at baseline, the lower the
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belief in the utility of treatment at post-treatment.  See table 35.  Regression 
analyses tested the predictive value of illness perceptions on alcohol use.  Beliefs 
about utility of treatment, severity of illness, and susceptibility to future 
complications did not emerge as significant predictors of alcohol use at either 
post-treatment or follow-up.  However, there was a significant predictive 
relationship between beliefs about barriers to adherence and alcohol use at follow-
up (β = -.520, p < 0.05).  That is, the more barriers were perceived at baseline, the 





























N 42 9 17
T2  utility  Pearson 
Correlation 
-.520** -.420 -.368
N 29 10 15
T2 severity  Pearson 
Correlation 
.141 -.154 .040






N 27 10 13
T2  barriers Pearson 
Correlation 
-.306 -.394 -.411
N 28 10 15
T3 utility Pearson 
Correlation 
.347 .296 -.416
N 22 5 17
T3 severity Pearson 
Correlation 
.170 .282 -.284






N 22 5 17
T3 barriers Pearson 
Correlation 
.150 -.524 -.239
N 22 5 17
Table 35.  Correlations between baseline, post-treatment, and follow-up beliefs about 
utility of treatment, severity of illness, susceptibility to future complications, barriers to 
adherence and alcohol use at baseline, post-treatment, and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
e. Finally, it was hypothesized that a positive relationship would emerge between
beliefs about the utility of treatment, the severity of illness, and susceptibility to 
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future complications and overall self-reported adherence, whereas there would be 
a negative correlation between barriers to adherence and overall self-reported 
adherence.  Correlation analyses revealed several significant relationships between 
illness perceptions and overall self-reported adherence.  There was a significant 
positive correlation between belief in utility of treatment at baseline, and overall 
adherence reported at post-treatment (r = .362, p < 0.01).  A negative correlation 
also emerged between barriers perceived at baseline, and overall adherence is 
reported at post treatment (r = -.587, p < 0.01).  The more overall adherence at 
post-treatment was correlated with fewer barriers perceived at follow-up (r =  
-.396, p < 0.05), and finally, post-treatment beliefs about severity were positively 
correlated with follow-up overall adherence (r = .369, p < 0.05).  See table 36. 
However, regression analyses failed to produce any significant findings with 
respect to the predictive value of illness perceptions on overall self-reported 
adherence at either post-treatment or follow-up.   
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T2 overall adherence T3 overall 
adherence 
















































Table 36.  Correlations between baseline, post-treatment, and follow-up beliefs about 
utility of treatment, severity of illness, susceptibility to future complications, barriers to 
adherence and overall adherence at post-treatment and follow-up.   
**Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
127
Hypotheses Related to Intent to Adhere
With regard to the intent to adhere is was hypothesized that baseline intent to adhere with 
doctors’ recommendations would be positively related to actual adherence to each of the 
outcome variables (oral care, tobacco, use, and alcohol use) as well as self-reported 
overall adherence. 
a. It was predicted that there would be a positive relationship between intent to
adhere and oral care at each time point.  There was a significant correlation
between oral care at post-treatment and intentions to adhere at follow-up (r = .460,
p < 0.05).  That is, the better the oral care was at post-treatment, the better the
intentions to continue good oral care at follow-up.  Oral care at follow-up was also
significantly correlated with intentions to adhere at follow-up (r = .718, p < 0.01).
See table 37.   However, regression analyses did not reveal any significant
findings with respect to the predictive value of intentions to adhere on oral care at
either post-treatment or follow-up, nor did intentions at post-treatment predict oral
care at follow-up.
Baseline intentions T2 intentions T3 intentions 





Sig. (2-tailed) .217 .193 .599






Sig. (2-tailed) .471 .799 .021
N 36 39 25
T3 




Sig. (2-tailed) .236 .659 .003
N 15 16 15
Table 37.  Correlations between intent to adhere at baseline, post-treatment, and follow-
up and oral care at baseline, post-treatment, and follow-up. 
* Correlation is significant at the 0.05 level (2-tailed).
**  Correlation is significant at the 0.01 level (2-tailed). 
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b. It was expected that there would be a negative relationship between intentions to
adhere and tobacco use, so that the better the intentions, the less a patient would
smoke.  What was found was the opposite; a positive correlation between baseline
intent to adhere and post-treatment tobacco use (r = .431, p < 0.05).  That is, the
better the intentions to adhere at baseline, the more reported cigarette use at post-
treatment.  See table 38.   Linear regression analyses revealed that intentions to
adhere at baseline significantly predict cigarette use at post-treatment (β = .464, p
< 0.01).  There were no other significant relationships between intentions to
adhere at baseline, or post-treatment, and tobacco use.
Baseline Cigarettes T2 Cigarettes 
Baseline intentions  Pearson Correlation .116 .413* 
N 65 29
T2  intentions  Pearson Correlation .023 -.018 
N 41 31
T3 intentions Pearson Correlation .071 a. 
N 34 19
Table 38.  Correlations between intent to adhere at baseline, post-treatment, and follow-
up and tobacco use at baseline, post-treatment, and follow-up. Correlations for smokeless 
tobacco use at each time point, and cigarette use at follow-up could not be computed 
because at least one of the variables was a constant. 
a. Cannot be computed because at least one of the variables is a constant.
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed). 
c. A negative correlation emerged between post-treatment intent to adhere and
follow-up alcohol use (r = -.585, p < 0.05).  That is, the better the intent to adhere
at post-treatment, the less alcohol use was reported at follow-up.  There was also a
negative correlation between baseline alcohol use and post-treatment intentions to
adhere (r = -.510, p < 0.01). That is, the more alcohol use reported by the patient
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at baseline, the less the intent to adhere at post-treatment.  See table 39. 
Regression analyses found no significant predictive relationships between 
intentions to adhere and alcohol use at any time point. 






N 41 9 17
T2 intentions  Pearson 
Correlation 
-.510** .032 -.585*
N 28 10 14
T3 intentions Pearson 
Correlation 
-.259 -.818 -.425
N 22 5 17
Table 39.  Correlations between intent to adhere at baseline, post-treatment, and follow-
up and alcohol use at baseline, post-treatment, and follow-up. 
a. Could not be computed because at least one of the variables was a constant.
* Correlation is significant at the 0.05 level (2-tailed).
**  Correlation is significant at the 0.01 level (2-tailed). 
d. A positive relationship was hypothesized between intent to adhere and overall
self-reported adherence.  There was a positive correlation between intent to adhere
at baseline (r = .602, p < 0.01), post-treatment (r = .332, 0.05), and follow-up (r =
.348, p < 0.05) and post-treatment overall self-reported adherence.  There was also
a significant correlation between post-treatment intentions to adhere and overall
self-reported adherence at follow-up (r = .602, 0.05).  See table 40.
Baseline 
intentions 
T2  intentions T3 intentions 











N 42 37 42
Table 40.  Correlations between intent to adhere at baseline, post-treatment, and follow-
up and overall self-reported adherence at baseline, post-treatment, and follow-up. 
* Correlation is significant at the 0.05 level (2-tailed).
**  Correlation is significant at the 0.01 level (2-tailed). 
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Linear regressing analyses produced the following results.  There was a 
significant predictive relationship between post-treatment intentions to adhere and 
follow-up self-reported adherence (β = .366, p < 0.05).   The better the intentions 
to adhere at post-treatment, the better the self-reported adherence at follow-up 
(this might be a reflection of improved oral functional status, though technically 
you would expect oral complications from XRT to be the worst right at the end of 
treatment). 
Summary of proposed Model 
 The illustration below presents a summary of findings as they pertain to the predictive 






















While the model itself did not explain factors that may lead to adherence, it is 
important to note that several of the paths in the model were found to be significant.  Such 
findings ought to help guide future research in the area of oral care among head and neck 
cancer patients.  The rest of this chapter will discuss findings of exploratory analyses. 
Exploratory Questions 
 Exploratory analyses examined the relationships of depression, cancer site, treatment 
modality, and functional status on other variables in the model.  Zero-order correlations 
and predictive statistics are reported for depressions and oral functional status below. 
GLM repeated measures and univariate analyses examined the effect of cancer site and 
treatment modality on major variables of the model. 
Depression
Correlation analyses between depression and variables in the model produced the 
following correlations.  Baseline depression was positively correlated with both post-
treatment (r = .320, p < 0.05) and follow-up depression (r = .325, p < 0.05).  A correlation 
was found between socio-emotional behavior of the doctor and reported depression at 
baseline (r = -.269, p < 0.05), but not at post-treatment or follow-up.  That is, the better 
the doctor’s behavior was perceived to be, the less depression was reported.  A significant 
correlation emerged between baseline depression and baseline avoidant coping (r = .569, 
p < 0.01), baseline maladaptive coping and follow-up depression (r = .314, p < 0.05), and 
between baseline depression and baseline adaptive coping (r = -.343, p < 0.01).  Baseline 
depression is also correlated (r = -.314, p < 0.05) with post-treatment beliefs about the 
utility of treatment.   No other significant correlations were found between illness 
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perceptions and depression at any time point.  There is a significant correlation between 
baseline oral care and follow-up depression (r = .343, p < 0.05), but no other correlations 
between depression and oral care at any time point.  There are no significant relationships 
between depression and tobacco use at any time point.  Depression and alcohol use is 
positively correlation at baseline (r = .343, p < 0.05), but negatively correlated at follow-
up (r = -.597, p < 0.05).  There is a significant correlation between depression at post-
treatment and overall self-reported adherence at follow-up (r = -.407, p < 0.05).  There 
were no significant correlations between intentions to adhere and depression at any time 
point.  Finally, baseline depression is correlated with baseline oral functional status (r = 
.262, p < 0.05).  This same relationship is also significant at post-treatment (r = .469, p < 
0.01) and at follow-up (r = .594, p < 0.01).  See tables 41- 45. 
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Baseline CESD T2 CESD T3 CESD 
Baseline utility  Pearson Correlation -.173 .125 .113 
N 84 50 43
Baseline  
severity  
Pearson Correlation .060 .010 .040 
N 82 49 42
Baseline 
susceptibility  
Pearson Correlation .182 .153 -.105 
N 83 50 43
Baseline barriers Pearson Correlation .185 -.220 .090 
N 85 50 43
T2 utility Pearson Correlation -.314* .006 -.044 
N 51 51 37
T2 severity  Pearson Correlation -.001 -.205 .115 
N 47 47 35
T2 susceptibility Pearson Correlation -.166 .005 -.177 
N 50 50 37
T2 barriers Pearson Correlation .066 -.210 -.004 
N 50 52 38
T3 utility Pearson Correlation .210 .221 -.188 
N 40 35 42
T3 severity Pearson Correlation .179 -.083 -.157 
N 40 36 43
T3 susceptibility Pearson Correlation .071 -.039 .079 
N 40 36 43
T3 barriers Pearson Correlation .031 -.002 .214 
N 40 36 43
Table 41.  Correlations between depression at baseline, post-treatment, and follow-up and 
illness perceptions baseline, post-treatment, and follow-up. 
* Correlation is significant at the 0.05 level (2-tailed).















.569** -.343** .137 .037
N 86 86 83 85
T2 CESD Pearson 
Correlation 
.269 -.026 .183 .048
N 47 47 49 50
T3 CESD  Pearson 
Correlation 
.314* -.127 .179 .079
N 43 41 43 43
Table 42.  Correlation matrix for depression at baseline, post-treatment, and follow-up 
with coping and beliefs about causes of illness. 
* Correlation is significant at the 0.05 level (2-tailed).


















.089 -.164 -.169 .343* -.119 -.115 
N 88 34 13 38 9 16 
T2 CESD Pearson 
Correlation
.215 -.310 -.127 .360 -.072 .103 
N 52 34 14 25 9 16 
T3 CESD  Pearson 
Correlation
.343* -.024 -.199 .350 -.075 -.597* 
N 45 25 15 22 6 17 
Table 43.  Correlation matrix for depression at baseline, post-treatment, and follow-up 
with oral care and alcohol use at each time point. 
* Correlation is significant at the 0.05 level (2-tailed). 


















.105 -.026 .262* .135 .074 
N 49 40 87 51 40 
T2 CESD Pearson 
Correlation 
-.059 -.407* .162 .469** .103 
N 48 35 50 51 35 
T3 CESD  Pearson 
Correlation 
-.029 -.277 -.176 .357* .594** 
N 36 43 43 37 43 
Table 44.  Correlation matrix for depression at baseline, post-treatment, and follow-up 
with self-reported adherence and oral complications (FACTHN). 
* Correlation is significant at the 0.05 level (2-tailed). 




T2 intentions T3 intentions 
Baseline CESD Pearson 
Correlation 
-.143 -.269 .051 
N 83 51 40 
T2 CESD Pearson 
Correlation 
.081 -.156 -.236 
N 50 51 36 
T3 CESD  Pearson 
Correlation 
.043 -.218 .054 
N 43 38 43 
Table 45.  Correlation matrix for depression at baseline, post-treatment, and follow-up 
with intentions to adhere at each timepoint. 
* Correlation is significant at the 0.05 level (2-tailed). 
**  Correlation is significant at the 0.01 level (2-tailed). 
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In regression analyses, depression at baseline did not predict beliefs about utility of 
treatment, severity of illness, or barriers to adherence at either post-treatment or at follow-
up.  Neither did post-treatment depression predict follow-up beliefs about utility of 
treatment, severity of illness, susceptibility to future complications, or barriers to 
adherence.  Baseline depression did emerge as a significant predictor of post-treatment 
beliefs about susceptibility (β = -.259, p < 0.05).   That is, the less depression at baseline, 
the more susceptible patient believes he/she is to future complications at post-treatment. 
This relationship did not replicate at follow-up.  No significant regressions were found for 
baseline depression and intent to adhere at either post-treatment or follow-up.  However, 
post-treatment depression did predict follow-up intentions to adhere (β = -.373, p < 0.05).  
That is, the more depressed at post-treatment, the lower the intent to adhere at follow-up. 
Regression analyses between depression and oral care, tobacco use, and alcohol use did 
not produce any significant relationships.   
Oral Functional Status
Functional status relates to variables in the model as follows:  There was a significant 
correlation between oral functional status and the affective quality of doctor-patient 
communication at baseline (r = -.242, p < 0.05).  No relationships were found between 
coping and oral functional status or between patients’ beliefs about the causes of illness 
and oral functional status.  With respect to illness perceptions the following relationships 
emerged.  Baseline oral functional status was correlated with baseline beliefs about 
susceptibility to future oral complications (r = -.248, p < 0.05), post-treatment beliefs 
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about susceptibility to future oral complications (r = -.373, p < 0.01), and follow-up 
beliefs about susceptibility (r = -352, p < 0.05).  Post-treatment oral functional status was 
correlated with baseline beliefs about barriers to adherence (r = .293, p < 0.05), and 
follow-up oral functional status was correlated with follow-up beliefs about susceptibility 
(r = -.480, p < 0.05).  There were no other significant relationships between functional 
status and illness perceptions at any other time point.  Functional status was also related 
to intentions to adhere.  Specifically, baseline functional status was positively correlated 
with baseline intentions to adhere (r = .255, p < 0.05).  Post-treatment intents to adhere 
were correlated with follow-up intentions to adhere (r = -.350, p < 0.05).  Follow-up 
functional status was not related to intentions to adhere.  Only one correlation was found 
between functional status and oral care.  Baseline oral care was significantly correlated 
with baseline functional status (r = .256, p < 0.05).   There were no significant 
correlations between functional status and tobacco use or alcohol use at any time points, 
nor were there any significant relationships between oral functional status and self-






Baseline FACTHN Pearson 
Correlation 
.079 .117 -.242*
N 78 79 75
T2 FACTHN  Pearson 
Correlation 
.145 .173 -.238
N 46 47 45
T3 FACTHN Pearson 
Correlation 
.256 .224 -.094
N 38 38 34
Table 46.  Correlation matrix between oral functioning and doctor-patient 
communication. 
* Correlation is significant at the 0.05 level (2-tailed)
















-.021 .009 .101 .108
N 82 83 82 81
T2 FACTHN Pearson 
Correlation 
-.089 -.096 .262 .070
N 47 48 47 47
T3 FACTHN Pearson 
Correlation 
.023 -.075 .144 .052
N 38 38 35 35
Table 47.  Correlation matrix between oral functional status, beliefs about causes of 
illness, and coping. 
**  Correlation is significant at the 0.01 level (2-tailed). 


















.071 -.163 -.248* .081
N 82 79 81 83
T2 FACTHN Pearson 
Correlation 
-.191 -.272 -.120 .293*
N 47 46 47 47
T3 FACTHN Pearson 
Correlation 
.105 -.220 -.290 .079
N 39 38 38 39
Table 48.  Correlation matrix between oral functional status and illness perceptions at 
baseline. 
**  Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).















.113 .101 -.373** .214
N 51 47 49 51
T2 FACTHN Pearson 
Correlation 
-.024 -.033 -.275 .115
N 50 47 49 50
T3 FACTHN Pearson 
Correlation 
.273 .118 -.196 .183
N 24 21 23 25
Table 49.  Correlation matrix between oral functional status and illness perceptions at 
post-treatment. 
**  Correlation is significant at the 0.01 level (2-tailed). 
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-.066 -.163 -.352* -.030
N 43 43 43 43
T2 FACTHN Pearson 
Correlation 
.169 .005 -.325 .117
N 36 36 36 36
T3 FACTHN Pearson 
Correlation 
.028 -.097 -.480* .142
N 20 21 21 21
Table 50.  Correlation matrix between oral functional status and illness perceptions at 
follow-up. 
* Correlation is significant at the 0.05 level (2-tailed).
Baseline 
intentions 
T2 intentions T3 intentions 
Baseline FACTHN Pearson 
Correlation 
.255* .021 -.053
N 81 50 43
T2 FACTHN Pearson 
Correlation 
.083 -.220 -.350*





N 38 24 21
Table 51.  Correlation matrix between oral functional status and intentions to adhere at 
each time point. 
* Correlation is significant at the 0.05 level (2-tailed).
Oral care at 
baseline 












N 39 15 10
Table 52.  Correlation matrix between oral functional status and oral care at each time 
point. 
* Correlation is significant at the 0.05 level (2-tailed).
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N 37 25 13

















N 17 15 9
Table 53.  Correlation matrix between oral functional status, tobacco use, and alcohol use 
at each time point.  Correlations for smokeless tobacco at each time point and follow-up 
cigarette use could not be calculated.  Due to a small N, the variable ended up 
representing a constant. 
a Cannot be computed because at least one of the variables is constant. 
Baseline CESD T2 CESD T3 CESD 
Baseline FACTHN Pearson 
Correlation 
.049 -.075 .232
N 80 48 43
T2 FACTHN Pearson 
Correlation 
.224 .143 .115
N 45 47 37
T3 FACTHN Pearson 
Correlation 
.106 -.023 .267
N 35 25 20






Baseline FACTHN Pearson Correlation .177 .041 
N 47 42
T2 FACTHN Pearson Correlation -.124 -.047 
N 46 36
T3 FACTHN Pearson Correlation -.004 -.079 
N 22 20
Table 54.  Correlation matrix between oral functional status and self reported adherence 
at post-treatment and follow-up. 
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Oral functioning did not predict depression, coping, oral care, tobacco use, alcohol 
use, or overall self-reported adherence at post-treatment or follow-up.  There was a 
significant predictive relationship between oral functioning and the affective quality of 
doctor-patient communication at post-treatment, with the affective quality of doctor-
patient communication predicting post-treatment oral functioning (β = -.570, p < 0.05). 
That is, the less satisfied patients were with the affective quality of the communication, 
the more discomfort they reported at post-treatment.  Oral functioning at baseline 
emerged as a significant predictor of beliefs about susceptibility to future oral 
complications (β = -.386, p < 0.05).  That is, the more oral complications at baseline, the 
weaker the belief in the utility of the oral care regimen at post-treatment.  This 
relationship was also significant at follow-up (β = -.350, p < 0.05).  At post-treatment 
oral functioning predicted follow-up beliefs about utility of treatment (β = .401, p <
0.01), susceptibility to future complications (β = -.549, p < 0.01), and barriers to 
adherence (β = .352, p < 0.05).  Post-treatment oral functional status also predicted 
follow-up intentions to adhere (β = -.561, p < 0.01).   That is, the more complications at 
post-treatment, the less the intent to adhere at follow-up.   
Cancer Site
GLM univariate analyses were run to test the predictive value of cancer site on doctor-
patient communication, coping, and beliefs about the causes of illness at baseline.  No 
significant results were found with respect to any of the three variables.  GLM univariate 
analyses were also run for oral care at each time point, as N was too small for repeated 
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measures analyses.  No group differences emerged with respect to oral care.  Finally, 
univariate analyses were run at baseline for tobacco use and alcohol use, as N was too 
small for analyses at both post-treatment and follow-up.  There were no effects of cancer 
site on any of the two outcome variables. 
 GLM repeated measures analyses were conducted to examine the predictive value of 
cancer site on depression, oral functional status, illness perceptions, and intent to adhere. 
There were no group differences for depression at any time point.   With respect to oral 
functional status there was a main effect of cancer site (F (1,59) = 12.06, p < 0.01), so that 
patients with oral cancer (mean = 28.83) reported significantly less problems than those 
with oralpharyngeal cancer (mean = 32.05) at baseline, but not at post-treatment or 
follow-up.  The FACT-HN assesses symptoms for both the oral cavity and the throat, thus 
it is difficult to explain this finding.  Repeated measures analyses did not reveal any group 
differences by cancer site on illness perceptions or intent to adhere. 
Treatment Modality
GLM univariate analyses were run to test the predictive value of treatment modality 
on doctor-patient communication, coping, and illness perceptions at baseline.  No 
significant results were found for treatment modality with respect to doctor-patient 
communication, coping, or illness perceptions.  GLM univariate analyses were also run 
for oral care at each time point, as N was too small for repeated measures analyses.  No 
group differences emerged.  Finally, univariate analyses were run at baseline for tobacco 
use and alcohol use, as N was too small for repeated measures analyses at both post-
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treatment and follow-up.  There were no effects of treatment modality on any of the two 
outcome variables. 
 GLM repeated measures analyses were conducted for treatment modality with respect 
to depression, oral functional status, and illness perceptions.  There were no significant 
group differences for depression, oral functional status, illness perceptions, or intentions 
to adhere at any time point. 
Mediation Analyses 
It was hypothesized that patients’ illness perceptions would operate as a partial 
mediator of the relationship between patients’ perceptions of each aspect of the doctor-
patient communication (socio-emotional quality, affective quality, and instrumental 
information) and patient adherence.  Linear regression analyses were conducted between 
the independent variable, adherence, and dependent variable, doctor-patient 
communication, and between the independent variable and the proposed mediator to 
determine whether the relationships would be appropriate (i.e. were significant) for 
mediational analysis.      
 It was hypothesized that patients’ illness perceptions would emerge as a partial 
mediator of the relationship between patients’ perceptions of the socio-emotional quality, 
the affective quality, and the instrumental quality of the doctor-patient communication, at 
baseline, and each of the outcome variables.  There were no significant regressions 
between any of the three aspects of doctor-patient communication and oral care, tobacco 
use, or alcohol use at either post-treatment or follow-up, thus, according to Baron and 
Kenney (1986), mediational analysis was not deemed appropriate.  
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Moderation Analyses 
Patients’ adaptive coping was hypothesized to strengthen the relationship between 
each aspect of the doctor-patient communication (socio-emotional quality, affective 
quality, and instrumental information) and patient adherence.  Linear regression analyses 
were conducted to ensure that moderational analysis would be appropriate.  That is, there 
is a significant predictive relationship between the independent variable and the 
dependent variables.  According to Baron and Kenny (1986) it is also preferable that the 
moderator be uncorrelated with the independent variable and the dependent variable or, at 
the very least, that these relationships are weak.   
 It was hypothesized that patients’ coping would moderate the relationship between 
patients’ perceptions of each aspect of the doctor-patient communication, at baseline, and 
the adherence measures at post-treatment and follow-up.  The moderator, adaptive 
coping, was not significantly correlated with the independent variable, doctor-patient 
communication, or the any of the dependent variables, oral care, tobacco use, and alcohol 
use.  However, no significant predictive relationships were found for any of the three 
aspects of doctor-patient communication and any of the dependent variables at post-
treatment and follow-up. Nevertheless, moderation analyses were conducted.  No 
significant findings emerged.   
 Finally, exploratory questions had also aimed to investigate the effect of depression 
and functional status on the relationships between variables in the proposed model.  It was 
proposed that depression and oral functional status would each emerge as moderators 
between:    
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a. Patients’ perceptions of doctor-patient communication and patient adherence.
Linear regressions did not reveal any significant predictive relationship between
any of the aspects of doctor-patient communication and actual patient adherence at
post-treatment or follow-up.  Nonetheless, moderation analyses were performed.
There were no significant findings for either depression or oral functional status.
b. Patients’ illness perceptions and patient adherence.  Linear regressions revealed
significant predictive relationships between baseline beliefs about severity of
illness and oral care at post-treatment, baseline beliefs about severity of illness and
cigarette use at post-treatment, baseline beliefs about the utility of treatment and
cigarette use at post-treatment, baseline beliefs about barriers to adherence and
cigarette use at post-treatment, and baseline beliefs about barriers to adherence
and alcohol use at follow-up.  Regression analyses found that oral functional
status moderates the relationship between beliefs about the severity of illness and
actual oral care at post-treatment (β = -2.132, p < 0.05).  That is, when oral
functional status is good, beliefs about severity of illness is a good predictor of
adherence, whereas when oral functional status is poor, the predictive power of
beliefs about severity is diminished.  Analyses did not reveal moderation by either
depression or oral functional status of the relationships between baseline beliefs
about severity of illness and cigarette use at post-treatment, baseline beliefs about
the utility of treatment and cigarette use at post-treatment, baseline beliefs about
barriers to adherence and cigarette use at post-treatment, or baseline beliefs about
barriers to adherence and alcohol use at follow-up.
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Writing Intervention 
 The study had originally proposed a solution focused writing intervention to increase 
adherence.  However, concerns were raised at MD Anderson Cancer Center about testing 
the new intervention with a population as ill as these patients.  Therefore, the intervention 
was changed to a pilot study of the solution-focused writing.  Ten percent of the sample 
would be asked to complete the intervention.  In the end only 6 patients completed the 
task.  Such data is presented next. 
 The intervention was administered about 3 weeks into the radiation treatment.  Patients 
were asked to respond to 8 items written to start patients thinking about their oral care 
regimen, problems they were having, and possible solutions (see Appendix 2).  There 
were no group differences between the writing condition and the rest of the sample with 
respect to illness perceptions, intent to adhere, actual adherence, or oral functional status.  
At baseline there were no differences with respect to depression.  However, at both post-
treatment and follow-up the 6 patients in the writing condition were significantly more 
depressed than the rest of the sample (see tables 52 and 53).  Interestingly, depression 
scores were elevated for each of the six participants who completed the solution focused 
writing intervention. 
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Study condition Baseline CESD T2 CESD T3 CESD  
Questionnaire 
only 
Mean 8.4390 11.7609 8.1463
N 82 46 41
Std. Deviation 9.21231 8.33516 9.87310 
feedback Mean 11.8333 23.3333 25.0000
N 6 6 4
Std. Deviation 13.12123 13.45610 23.40940 
Total Mean 8.6705 13.0962 9.6444
N 88 52 45
Std. Deviation 9.46830 9.64316 12.22731 
Table 52.  Means table comparing depression between writing condition and the rest of 










64.415 1 64.415 .716 .400
Within 
Groups 
7735.028 86 89.942 
Total 7799.443 87
T2 CESD Between 
Groups 
710.816 1 710.816 8.815 .005
Within 
Groups 
4031.703 50 80.634 
Total 4742.519 51
T3 CESD  Between 
Groups 
1035.189 1 1035.189 8.030 .007 
Within 
Groups 
5543.122 43 128.910 
Total 6578.311 44
Table 53.  One-way ANOVA table comparing depression between writing condition and 
the rest of the sample at baseline, post treatment, and follow-up. 
Writing Intervention Vignettes 
The following is a sampling of the writing done by the six participants in the solution 
focused writing condition.  These vignettes are included because they capture aspects of 
patients’ thinking about their oral care that was not caught by the measures. 
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 “Fluoride treatments have been very hard due to gagging”
 “Dentist always seems backed up and running late.  Maybe if his workload was
not so heavy he could spend more time [with patients]”
 “[Most difficult has been] fluoride application because it is a life long
commitment and I am unsure of the side effects of fluoride when some is
swallowed”
 “I think more education on oral complications related to radiation therapy will
help us ask for oral care sooner before serious complications develop”
 “[Most difficult has been to] brush teeth because people are thrown when you do
it in public bathrooms or in parking lots”
 “It is not an easy task, but painful and downright uncomfortable.  However, I
realize I must cope with this since oral hygiene is very important towards my
health and a speedy recovery”
 “Counseling prior to and during treatment would probably ease tension and
reassure patients”
 “Routine and determination.  Once the new oral care is part of my routine for a
while it will become second nature to my daily routine.  I am determined to keep
my teeth and gums healthy”
 “Doctors can do a better job at discussing future problems if the oral care is not
followed.  This may help patients follow the routine”
 “The fluoride trays hurts your gums once you begin to get sores and blisters from
the radiation”
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CHAPTER 6: DISCUSSION 
Overview of Findings 
 The present study examined the role of doctor-patient communication, patients’ 
coping, and patients’ illness related cognitions about cancer on treatment adherence to an 
oral health regimen among patients being treated for head and neck cancer.  The oral 
health regimen encompassed three areas: adherence to a recommended oral care regimen, 
as well as patients’ abilities to refrain from tobacco and alcohol use, as these present 
additional risks for complications and relapse.     
 The study was a longitudinal investigation of several factors that may influence 
patients’ adherence to the oral health regimen.  Refer to Figure 1 (page 59) for a graphic 
depiction of the proposed model.  Doctor-patient interaction encompassed three aspects: 
instrumental information related to diagnosis, prognosis, and treatment; socio-emotional 
behaviors, which assesses physician’s non-verbal behavior; and affective quality which is 
a measure of physician interpersonal skills.  Patients’ illness related conceptions 
incorporated two areas: beliefs about illness related factors such as diagnosis, prognosis, 
and vulnerability, and beliefs about treatment related factors such cost vs. benefit of 
treatment and treatment efficacy. Adherence was measured in three areas: adherence to 
the oral care program, smoking cessation, and abstinence from alcohol.  Patients’ coping 
style was also examined in terms of adaptive versus maladaptive coping strategies. 
 Several significant relationships emerged, particularly involving illness perceptions 
and adaptive coping; however, the data did not support the proposed integrative model. 
Significant findings will be further discussed below. 
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The Function of Doctor-Patient Communication
Three aspects of doctor-patient communication were examined: the first component 
encompasses what has been termed socio-emotional behaviors and taps physician 
behaviors such as verbal attentiveness, showing concerns, and negative talk.  The second 
component has to do with the affective quality of the communication, i.e. is the doctor 
experienced as supportive, understanding, and caring by the patient.  The last component 
is concerned with the kinds and clarity of information that is exchanged during the 
consultation.   
 Doctor-patient communication has been shown to play a role in patient adjustment to 
illness (Rutter, Iconomou, & Quine, 1996; Mager, & Andrykowski, 2002); however, 
findings from studies examining the role of doctor-patient communication with respect to 
quality of life have produced unclear results (Rutter, Iconomou, & Quine, 1996; Ong, 
Visser, Lammes, & de Haes, 2000), and little research to date has examined the role of 
doctor-patient communication on treatment adherence (Gilbar, 1989; Henman et al, 
2002).  This study aimed to examine the role of doctor-patient communication with 
respect to depression, oral functioning, illness perceptions, intent to adhere, and treatment 
adherence.  Based on earlier research it was hypothesized that the more satisfied patients 
were with each component of the communication, the less depressed they would be, the 
fewer complications they would reports, the more optimistic, or realistic, their illness 
perceptions, the better their intent to adhere, and the more likely they would be to actually 
adhere.   
 As predicted, the instrumental quality of doctor-patient communication emerged as a 
significant predictor of beliefs about the utility of the oral care regimen at post-treatment 
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and also of intentions to adhere at follow-up.  The more satisfied patients were with the 
instrumental quality of the consultation, the stronger the belief in the utility of the 
regimen (this might reflect better understanding of reasons for the regimen) and the better 
the intentions to adhere (again this might reflect better understanding of the consequences 
of non-adherence) (Manne, Markowitz, Winawer, Meropol, Haller, Rakowski, Babb, & 
Jandorf, 2002;  Castellano, Wenger, and Graves, 2001;  Husaini, Sherkat, Bragg, Levine, 
Emerson, Mentes, & Cain, 2001;  Saidi, Sutton, & Bickler, 1998).   However, unlike 
previous research (Gilbar, 1989; Henman et al, 2002) this study found no relationships 
between instrumental quality of the communication and actual adherence.  The fact that 
the consequences of non-adherence are not immediate nor life threatening might explain 
this finding.   
 Consistent with hypotheses, the affective quality of doctor-patient communication 
emerged as a predictor of post-treatment oral functioning (Henman et al, 2002).  That is, 
the less satisfied the patient was with the affective quality of the communication, the more 
discomfort they reported at post-treatment.  Finally, the socio-emotional aspect of the 
communication was found to predict patients’ belief about their susceptibility to future 
complications (Kucera, Lu, Raju, & Nathanson, 2002; Manne, Markowitz, Winawer, 
Meropol, Haller, Rakowski, Babb, & Jorf, 2002).  That is, the more satisfied patients were 
with the physician’s behavior at baseline, the less susceptible they believed they were at 
follow-up.     
 Results from previous studies that have examined the link between physician behavior 
and adherence have suggested that being satisfied with, and having high confidence in, 
one’s physician is a good predictor of adherence (Gilbar, 1989, Henman et al, 2002). 
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However, the findings for doctor-patient communication in the present study did not 
support such research that exists on communication and adherence.   
The Role of Coping
Research suggests that patients, who employ coping styles that can be characterized by 
involvement in medical decision making and a desire to understand and gain information 
about their illness, tend to better adjusted than those who do not, and are more likely to be 
proactive in their interactions with physicians (Keltikangas-Jaervinen, 1986; Ong, Visser, 
Van Zuuren, Rietbroek, Lammes, & de Haes, 1999).  Whether these findings extend to 
treatment adherence is not known, and this question was part of the foundation of the 
present study.  Based on previous research it was hypothesized that there would be a 
positive relationship between patients’ adaptive coping and the variables in the model. 
That is, the more adaptive coping the better the less reported depression, the fewer oral 
complications reported, the better the intent to adhere, the better the adherence to oral care 
recommendations, the less tobacco and alcohol use, and the more optimistic the illness 
perceptions.   
 Integrative analyses revealed no significant relationships between adaptive coping and 
intent to adhere, oral care, tobacco use, or alcohol use.  However adaptive coping was 
found to predict beliefs about susceptibility to future complications at follow-up. That is, 
the more adaptive coping, the less susceptible a patient believes he/she is to future oral 
complications.  This finding is consistent with the hypothesis that adaptive coping would 
be related to a more optimistic outlook (Cohen, 2002; Arraras, Wright, Jusue, Tejedor, & 
Calvo, 2002).  There was also a significant predictive relationship between adaptive 
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coping and beliefs about barriers to treatment at post-treatment.  That is the more adaptive 
coping at baseline, the more barriers were perceived at post-treatment.  This was in the 
opposite direction from what had been predicted (Stanton, Danoff-Burg, & Huggins, 
1991).  This finding might reflect a realistic appreciation of the lengths one will have to 
go to, to successfully adhere to oral care recommendations.    
 While previous research has linked choice of coping strategy with subjective reports of 
physical and psychological side effects during treatment with adjuvant chemotherapy 
among women with breast cancer (Spairo, Boggs, Rodrigue, Urry et all, 1997), research 
as yet has not found any links between coping and treatment adherence.  The present 
study did not find any predictive relationship between coping and any of the outcome 
variables assessing adherence.  Neither did coping play a role as a moderator between 
independent and dependent variables in the model.  It appears that while coping strategy 
may play an important role in adjustment to illness, the function of coping in treatment 
adherence still warrants further investigation (Keltikangas-Jaervinen, 1986). 
The Function of Illness Perceptions 
Generally, research examining the effect of patients’ beliefs about their illness and 
treatment has suggested that there may be a link to treatment adherence.  Results from 
previous research (Matthews, Sellergren, Manfredi, & Williams, 2002) have suggested 
that the following components of illness perceptions may all be predictors of low 
treatment adherence: lack of knowledge about cancer and cancer treatment; beliefs about 
side effects; low expectations of treatment efficacy; poor understanding of causality, 
prognosis, and vulnerability; and a high cost/benefit ratio of treatment.   
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Illness perceptions, as measured in this study, encompass four different subscales: 
beliefs about utility of treatment, severity of illness, susceptibility to future complications 
or illness, and barriers to adherence.  It was hypothesized that illness perceptions would 
be related to each downstream variable in the model: intent to adhere, oral care, tobacco 
use, and alcohol use (Matthews, Sellergren, Manfredi, & Williams, 2002; Siminoff & 
Fetting, 1991; Gilbar, 1989; Tamaroff, Festa, Adesman, & Walco, 1992; Horne & 
Weinman, 1999).  While there were several significant correlations at different time 
points between three of the subscales (beliefs about utility, severity, and barriers) and 
intentions to adhere, there were no predictive relationships between illness perceptions 
and intent to adhere.  However, beliefs about the severity of oral complications at baseline 
significantly predicted oral care at follow-up.   Surprisingly this relationship was opposite 
from what was expected.  That is, the more severe the complications were perceived to 
be, the less likely a patient was to follow the oral care recommendations.   
 One previous study (Siminoff & Fetting, 1991) also found that patients who believed 
that side effects of treatment would be likely and severe were significantly more likely to 
be non-compliant.  It may be that patients who believed that oral complications would be 
severe also believed that there would be significant side effects and discomfort associated 
with the oral care regimen.  Another possible explanation is that patients give up in the 
face of what is perceived to be a severe complication.  Alternatively patients who 
correctly identify their illness as severe may suffer more treatment side effects, as a 
consequence of more prolonged and intense treatment, that in turn prevents adherence.     
 A similarly finding emerged for beliefs about the severity of illness, which were also 
found to be a significant predictor of cigarette use at post-treatment.   That is, the more 
154
severe the illness is perceived to be, the more the reported use of cigarettes.  Beliefs about 
the utility of treatment also predicted cigarette use at post-treatment.  Specifically, the 
higher the belief that treatment is useful, the more reported cigarette use.  Again, this is an 
unexpected finding.  Previous research has suggested the opposite relationship; that 
patients who reported low expectations of the treatment outcome (Gilbar, 1989) were 
significantly less likely to adhere to cancer treatment.  Similar findings emerged from 
another study by Horne and Weinman (1999).  Horne and Weinman (1999) found that 
patients who scored high in believing that the treatment was necessary were much more 
likely to be adherent, whereas having a high number of concerns about the treatment was 
correlated with lower reported adherence.   It is unclear why patients in the present study 
reported lower adherence in the face of believing that treatment would be beneficial.  It is 
possible that patients in this study believed that treatment was so powerful that it would 
cancel out the bad effects of smoking.  Similarly, patients may have believed that while 
treatment would be of value, it was not necessary.   
 While not consistent with hypotheses (Schnoll, 2002; Vander, DiNardo, & Oliver, 
1997; Ostroff et al, 1995), beliefs about barriers to adherence emerged as a significant 
negative predictor of post-treatment cigarette use.  The more barriers were perceived at 
baseline, the less was the reported use of cigarettes at post-treatment.  A similar 
relationship was found between beliefs about barriers to adherence and alcohol use at 
follow-up.  That is, the more barriers were perceived at baseline, the less alcohol use was 
reported at follow-up.  In other words, the more difficult the oral care regimen was 
perceived to be, the better patients did with respect to smoking and alcohol cessation.  It 
is possible that rather than perceived difficulty leading to non-adherence due to patients 
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feeling overwhelmed by the oral care regimen, the perceived difficulty may have 
underscored the importance of following through with the regime. 
 To better understand this finding one might look to previous research, which has 
suggested that patients’ illness perceptions are essential in creating the cognitive and 
psychological framework within which patients make treatment decision (Buick, 1997).  
A series of studies that attempted to link patients’ illness-related cognitions to treatment 
adherence found that limited knowledge and misinformation about cancer and cancer 
treatment side effects tended to predict poor adherence to health related behaviors among 
cancer patients (Matthews, Sellergren, Manfredi, & Williams, 2002; Tamaroff, Festa, 
Adesman, & Walco, 1992), whereas being well-informed was associated with better 
adherence.  These findings support the present results between perceived difficulty of the 
oral care regimen and adherence to smoking and alcohol cessation.  That is, high 
perceived difficult might actually reflect a better understanding of the regimen, which is 
demanding, that then results in better adherence.  Results from the cancer screening 
literature also support these findings.  Knowledge about cancer (Friedman, Moore, Webb, 
& Puryear, 1999; Champion & Miller, 1996;  Danigelis, Roberson, Worden, Flynn, et al, 
1995; Beeker, Kraft, Southwell, & Jorgensen, 2000) and beliefs about the potential 
severity of cancer as well as one’s perceived susceptibility to cancer are positively related 
to participation in screening (Lostao, Joiner, Pettit, Chorot, & S&in, 2001; Stark, Prince, 
Kucera, Lu, Raju, &  Nathanson, 2002; Manne, Markowitz, Winawer, Meropol, Haller, 
Rakowski, Babb, & J&orf, 2002;  Saidi, Sutton, & Bickler, 1998).   
 Similarly, results from studies examining beliefs about the value of cancer screening 
have indicated that patients who believe that the benefits (relief that one does not have 
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cancer) of screening outweigh the risks (finding out one has cancer) are significantly 
more likely to exhibit positive screening behaviors, as are those who believe that early 
detection might lead to a cure of their cancer (Husaini, Sherkat, Bragg, Levine, Emerson, 
Mentes, & Cain, 2001; Manne, Markowitz, Winawer, Meropol, Haller, Rakowski, Babb, 
& J&orf, 2002; Saidi, Sutton, & Bickler, 1998).   Future studies in this area would do well 
in collecting information that specifically assessed what patients understood about their 
illness, treatment, and potential side effects.   
Do Intentions to Adhere Matter?
There is little, if any, research examining the role of patients’ intentions to adhere with 
respect to actual adherence and what previous research there is has lumped intentions to 
adhere in with illness perceptions (DiMatteo, et al, 1993).  The present study examined 
intentions to adhere separately hypothesizing that other illness perceptions might shape a 
patient’s intent to adhere, which in turn would predict actual adherence.  As discussed 
earlier there were several significant correlations at across different time points between 
three of the subscales (beliefs about utility, severity, and barriers) and intentions to 
adhere, but no predictive relationships between illness perceptions and intent to adhere. 
This pattern of finding suggests that while there are correlations between baseline illness 
perceptions and post-treatment intentions to adhere, these relationships are not predictive 
in nature and some other variable(s) may be causing the observed correlations.   
 With respect to actual adherence it was hypothesized that baseline intent to adhere 
with doctors’ recommendations would be positively related to actual adherence to each of 
the outcome variables (oral care, tobacco, use, and alcohol use) as well as self-reported 
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overall adherence (Weerdt, I. de,, Visser, A. P., Kok, G. & van der Veen, E. A.,1990; 
Farquharson, Noble, & Barker, 2004).  In fact, there were no predictive relationships 
between intent to adhere and oral care at either post-treatment or follow-up, nor did 
intentions at post-treatment predict oral care at follow-up.   No significant results were 
found with respect to the predictive value of intent to adhere on tobacco use or alcohol 
use at any time point.  However, there was a significant predictive relationship between 
post-treatment intentions to adhere and follow-up self-reported adherence.  That is, the 
better the intentions to adhere at post-treatment, the better the self-reported adherence at 
follow-up.   
 It is interesting to note that, contrary to predictions (Toljanic, Heshmati,  & Bedard, 
2002; Epstein, 1995), there was no relationship between patients’ intentions to adhere and 
the actual decision to follow through with the recommended oral care regimen.  It seems 
possible that factors during treatment, such as side effects from radiation treatment and 
possibly being focused on curative treatment rather than preventative treatment might 
explain the lack of any significant relationships between intentions to adhere and actual 
adherence.  However, the fact that intentions to adhere do predict self-reported adherence 
suggests that intentions to adhere may not be predictive of actual adherence to 
recommendations, but rather predict patients’ estimation of how well they are following 
their doctor’s recommendation.  This would be consistent with previous research, which 
has suggested that among patients the perspective on adherence is related to what the 
patient themselves consider a reasonable effort in the context of perceived constraints 
(Roberson, 1992).    
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The Role of Depression
Results from research examining the effect of co-morbid psychiatric disorders, 
cognitive impairment, interpersonal dysfunction, and addiction in relation to treatment 
adherence (Kunkel, Woods, Rodgers, & Myers, 1997; Seddon, Zabora, & Smith, 1992; 
Goldberg, 1983) have suggested that both psychological and psychiatric complaints are 
linked with poor adherence.  Therefore, depression was examined in relation to each of 
the variables in the model. 
 As hypothesized baseline (Kunkel, Woods, Rodgers, & Myers, 1997; Seddon, Zabora, 
& Smith, 1992; Goldberg, 1983) depression did emerge as a significant predictor of 
illness perceptions.  However, there was only one such predictive relationship: baseline 
depression predicted post-treatment beliefs about susceptibility.  The less depression at 
baseline, the more susceptible the patient believed he/she was to future complications at 
post-treatment.  This is a rather unexpected finding as it had been predicted that less 
depression would lead to more optimistic beliefs about potential oral complications 
(Ayres, Hoon, Franzoni, Matheny, et al, 1994).  It might be that the presence of 
depressive symptoms lowers the threshold of what the patient can cope with.  As a 
consequence the importance of the oral care regimen and the potential for oral 
complications may be perceived as secondary to the cancer treatment and in the context 
of acute illness be suppressed, or avoided, until the patients is feeling less overwhelmed 
and better able to cope with additional demands.  If so, this would explain the ability of 
less depressed patients to better cope with the information as is.  It would also be 
consistent with the literature linking depression and maladaptive, or avoidant, coping 
(Carver, C. S. et al, 1993; Lazarus, R. S., & Folkman, S., 1984).  Another point to 
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consider is that though it was hypothesized that less depression would lead to more 
optimistic illness perceptions, it would actually be more adaptive for patients, in the long 
run, to assimilate the true significance of the potential complications they are at risk for 
and not deceive themselves into believing that consequences of non-adherence are 
benign. 
 As hypothesized, post-treatment depression was found to predict follow-up intentions 
to adhere (Ayres, Hoon, Franzoni, Matheny, et al, 1994; Seddon, Zabora, & Smith, 1992; 
Goldberg, 1983).  That is, the more depressed at post-treatment, the lower the intent to 
adhere at follow-up.  If it is assumed that intent to adhere is associated with actual 
adherence, then this finding is consistent with previous research, which has suggested that 
poor psychosocial adjustment is a predictor of non-adherence (Kunkel, Woods, Rodgers, 
& Myers, 1997; Seddon, Zabora, & Smith, 1992; Goldberg, 1983; Gilbar 1989). 
However, contrary to predictions, there were no predictive relationships between 
depression and oral care, tobacco use, and alcohol use.  That is, depression did not predict 
actual adherence.  Interestingly, the lack of findings with respect to adherence is 
consistent with one study examining the role of psychiatric complaints on treatment 
adherence among patients with head and neck cancer (Girardi, de Pisa, Cianfriglia, 
Perrino, et al, 1992).  Results from this previous study indicated that neither somatic 
disturbance, anxiety, insomnia, social dysfunction, nor depression predicted treatment 
adherence.   
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The Effects of Oral Functional Status
Research examining adherence to oral care among head and neck cancer patients has 
found that many patients have difficulty following the oral care recommendations made 
(Lockhart and Clark, 1994; Toljanic, Heshmati,  & Bedard, 2002).  It was hypothesized 
that one of the reasons for this might be that the radiation therapy these patients undergo 
often exacerbates oral discomfort and pain, making it painful and uncomfortable to brush, 
floss, and apply fluoride.    
 While oral functioning did not predict depression, coping, oral care, tobacco use, 
alcohol use, or overall self-reported adherence at post-treatment or follow-up, there were 
several significant predictive relationships between oral functional status and doctor-
patient communication, illness perceptions, and intent to adhere.  A predictive 
relationship emerged between oral functioning and the affective quality of doctor-patient 
communication at post-treatment, with the affective quality of doctor-patient 
communication predicting post-treatment oral functioning.  That is, the less satisfied 
patients were with the affective quality of the communication, the more discomfort they 
reported at post-treatment.   
 With respect to illness perceptions oral functioning at baseline emerged as a significant 
predictor of beliefs about susceptibility to future oral complications.  That is, the fewer 
oral complications at baseline, the stronger the belief that one would be likely to suffer 
oral complications in the future.  This relationship was also significant at follow-up.  This 
finding is contrary to expectations that a low number or oral complications would lead a 
person to expect fewer oral complications in the future.  It is possible that patients may 
have been told to expect oral complications by their doctor, and that the finding reflects 
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the belief that if one has few, or no, complications at baseline, the expectation is that these 
will soon develop.   
 At post-treatment oral functioning predicted follow-up beliefs about utility of 
treatment.  Specifically, the  (β = .401, p < 0.01), susceptibility to future complications (β
= -.549, p < 0.01), and barriers to adherence (β = .352, p < 0.05).   
 Post-treatment oral functional status also predicted follow-up intentions to adhere (β =
-.561, p < 0.01).   That is, the more complications at post-treatment, the less the intent to 
adhere at follow-up.   
 Moreover, contrary to what had been expected (Tavss, 1997; Kennedy & Erb, 2002), 
there were no predictive relationships between oral functioning and oral care, tobacco 
use, alcohol use, or overall self-reported adherence at any time point.  It had been 
hypothesized that patients who reported a high number of oral complications would have 
more difficulty following the oral care regimen.   In contrast, the present results indicate 
that oral functional status does not play a role in patients’ decision to adhere to the oral 
care regimen.  Given the extent of side effects to the mouth and throat, that at times 
necessitate a feeding tube, the lack of findings is surprising.  However, some interesting 
findings from previous research suggest that while treatment side effects have been 
shown to be predictors of non-adherence in other illnesses, side effects of cancer 
treatment, though highly adverse, do not predict adherence among cancer patients 
(Richardson, Marks, & Levine, 1988; O'Connor, Boyd, Warde, Stolbach, & Till, 1987). 
It would be interesting to further examine patients’ beliefs about the oral care regimen to 
find out if they perceive it as part of their cancer treatment or as a separate treatment all 
together. One other possible explanation is that some patients in the sample were also 
162
enrolled in a clinical trial of the drug Amifostine (Bensadoun, Schubert, Lalla, & Keefe, 
2006).  The drug was administered by injection prior to each radiation treatment and was 
being investigated for it’s purportedly protective qualities against the development of oral 
and pharyngeal side effects associated with radiation.  This may have lowered the number 
of patients experiencing severe side effects from radiation that would otherwise have 
made adherence to oral care difficult.  Unfortunately, data analyses were not able to 
control for this factor and examine the adherence rates of patients on the Amifostine trial 
versus those who were not part of the trial. 
 Finally, with respect to oral functional status at baseline, there was a group difference 
for cancer site.  Specifically, patients with oral cancer reported significantly more 
problems than those with oralpharyngeal cancer at baseline, but not at post-treatment or 
follow-up.  As the measure assessing oral functional status includes items for both the 
oral cavity and the throat, it is difficult to explain this finding unless having a cancer in 
one’s mouth is somehow more uncomfortable that having a cancer in one’s throat.   
Moderation by Oral Functional Status
Exploratory questions investigated whether depression and functional status might 
moderate the relationships between a) patients’ perceptions of doctor-patient 
communication and patient adherence, b) patients’ coping and patient adherence, and c) 
patients’ illness perceptions and patient adherence.  In accordance with Baron and 
Kenney’s (1986) stipulations for moderation that there be a significant regression between 
the dependent and independent variable, each set of variables were tested to see if this 
relationship was indeed present. Analyses did not reveal any significant predictive 
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relationships doctor-patient communication or adherence nor between coping and 
adherence.  However, there were significant predictive relationships between illness 
perceptions and adherence.  Integrative analyses revealed that by oral functional status 
moderated the relationship between baseline beliefs about the severity of illness and 
actual oral care at post-treatment.  That is, when oral functional status was good, beliefs 
about severity of illness were good predictors of adherence.  In contrast, when oral 
functional status was poor, the predictive power of beliefs about severity diminished.  In 
other words, the severity of oral side effects from radiation treatment might make the oral 
care regimen so uncomfortable and painful that even though the patient believes the 
complications are severe they still choose to not, or are not able to, follow 
recommendations. 
Limitations of the Study 
 Results from the current study failed to support the proposed integrative model.  There 
are several factors that deserve consideration when attempting to understand why the 
model did not work.   First, the study assumed that patients would be invested in 
following oral care recommendations, but failed to take into account that the oral care 
regimen may not have been considered of much importance in the context of treatment 
aimed directly at curing one’s cancer.  Second, radiation side effects cause burning and 
thinning of the mucosa in the mouth and throat, which may have made adherence to the 
oral care regimen extremely painful not only for the duration of treatment, but also at 
post-treatment and follow-up, as healing occurs only slowly.  
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Another fact that should be taking into consideration is, that while the measure was 
anchored on the dental oncologist, each patient saw their radiation oncologist on a weekly 
basis and worked closely with him/her throughout their radiation treatment, whereas they 
saw their dental oncologist once prior to treatment, and then again post-treatment.  The 
radiation oncologist reinforced oral care issues as well and had the measured been 
anchored on him/her results might have been different.  In other words, it may be 
important, when considering the doctor-patient relationship in the research setting, that 
we ask the patient which doctor he/she considers their primary doctor in the cancer team.   
 The cancer screening literature emphasizes the importance of this point.  Two of the 
strongest predictors of participation in cancer screening are related to the primary medical 
provider.  First, having a consistent source of care, such as a family physician or primary 
care physician who is seen on a regular basis, significantly predicts compliance with 
cancer screening (Mandelblatt, Gold, O'Malley, Taylor, Cagney, Hopkins, and Kerner, 
1999; Zambrana, Breen, Fox, and Gutierrez-Mohamed, 1999).  Further, patients whose 
physician specifically recommend and encourage cancer screening procedures are 
significantly more likely to comply with screening behaviors than those whose physician 
do not specify such procedures (Manne, Markowitz, Winawer, Meropol, Haller, 
Rakowski, Babb, and Jandorf, 2002; Castellano, Wenger, and Graves, 2001; Friedman, 
Moore, Webb, and Puryear, 1999; Champion and Miller, 1996; Costanza, Stoddard, Gaw, 
and  Zapka, 1992;  Allen, Sorensen, Stoddard, Peterson, and Colditz, 1999).  
 A possible explanation may also be found in a model proposed by Lepper, Martin, 
and DiMatteo (1995), which pertains to the nonverbal exchange between patients and 
physicians and is based on the expectations for patient involvement on behalf of both 
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patients and physicians.  Authors suggest that high patient treatment adherence is most 
likely in situations where both patient and physician expect patient involvement.  This 
study did not assess such expectations on behalf of patients or physicians. 
 Yet another thing that should be taken into consideration concerns measurement.  
Because was no existing measure of oral care at the time of the study a measure was 
created, consisting of face valid items asking patients to record the extend to which they 
were able to follow the specific oral care recommendations (See Appendix 1, page 197).  
Internal consistency was moderate, an indication that the measure may not have 
adequately assessed adherence, or at the very least that it might be productive to repeat 
analyses looking at each individual behavior separately.  Another study is currently being 
conducted at MDACC collecting more information about this measure. 
 There may also have been limitations associated with the measures chosen for tobacco 
and alcohol use.  It is possible that there were too many questions asked, when fewer 
would have sufficed.  This may explain why many patients chose to answer the 
questionnaires by drawing a line across the page to indicate that they did not use tobacco 
or alcohol over the past month.  Unfortunately, for coding purposes, such data was 
considered ‘lost’ and coded as ‘missing’ which resulted in significant missing data on 
these outcome measures. 
 Missing data presented a problem as pertaining to statistical power.  First of all, a 
number of patients felt too sick at post-treatment to fill out the 18-page questionnaire.  
Secondly, at follow-up patients often came in, for one day, from out of town.  This meant 
that, if the patient was not contacted during their appointment, data collection had to rely 
on mailing the questionnaire out.  Only about 50% of patients who received a 
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questionnaire by mail returned it.  This resulted in a very low N for the outcome variables 
at both post-treatment and follow-up, and a possibly skewed sample with those 
completing the questionnaire sharing some sort of characteristic not present in the rest of 
the sample.   
 Last, but not least, the sample in this study is hardly representative.  This sample was 
primarily Caucasian, male, married, middle aged to older, highly educated, and had a 
household income well above average.  Previous research has found age, marital status, 
level of education, and racial background are all predictors of cancer screening behavior. 
Such studies have found an interesting correlation between age and adherence to 
screening recommendations.  Generally, being older, greater than 50 years of age, is a 
positive predictor of screening adherence (Zambrana, Breen, Fox, & Gutierrez-Mohamed, 
1999; Husaini, Sherkat, Bragg, Levine, Emerson, Mentes, & Cain, 2001; Champion & 
Miller, 1996; Rimer, Conaway, Lyna, Rakowski, William, et al, 1996).  However, some 
studies have found that women above age 65 are significantly less likely to comply with 
cancer screening than their younger counterparts. (Mandelblatt, Gold, O'Malley, Taylor, 
Cagney, Hopkins, & Kerner, 1999; Rawl, Champion, Menon, & Foster, 2000).  This non-
linear relationship between age and screening behavior is of particular interest as the risk 
of developing cancer increases with age.  It is unclear whether this relationship is true for 
males as well.  Marital status and education are other indicators of screening adherence. 
Studies have found that being married increase adherence to recommended cancer 
screening, as does having a higher level of education (Zambrana, Breen, Fox, & 
Gutierrez-Mohamed, 1999; Amonkar, & Madhavan, 2002; Franco, Belinson, Casey, 
Plummer, Tamburrino, & Tung, 2000; Friedman, Moore, Webb, & Puryear, 1999; Rimer, 
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Conaway, Lyna, Rakowski, William, et al, 1996).  However, cancer-screening adherence 
is significantly lower among minority groups (Rawl, Champion, Menon, & Foster, 2000; 
Rojas, Mandelblatt, Cagney, Kerner, & Freeman, 1996).   
 All in all it would be expected that the current sample would be highly adherent.  The 
fact that the findings of this study did not support this expectation suggests that some 
other, unmeasured variable, interferes with adherence, or at least the measurement of 
adherence.  Certainly the vignettes from the six participants in the solution-focused 
writing condition suggests that patients were struggling with the oral care regimen to a 
higher degree than the data gathered through questionnaires indicated.  The writings also 
speaks to aspects of following the oral care regimen that the present study did not take 
into consideration such as awkwardness when performing oral care in public as well as 
having to tote around a toothbrush, toothpaste, and floss.  Finally, the possibility that the 
importance of the oral care regimen is overshadowed by the active cancer treatment phase 
was not assessed in the present study.   
Practical Applications of Findings 
The Role of the Interpersonal Environment
Doctor-patient communication was found to be a significant predictor of beliefs about 
the utility of the oral care regimen and of intentions to adhere.  Specifically, the more 
satisfied patients were with the instrumental quality of the consultation, the stronger the 
belief in the utility of the regimen and the better the intentions to adhere.   These findings 
suggest that the amount of information the doctor provides, the format in which the 
information is delivered, and the amount of time allotted to the patient for asking 
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questions all play an important role in patient understanding of the treatment regimen and 
that this understanding leads to stronger beliefs in the utility of the recommended 
treatment.  Thus, it is both in our own and our patients’ interest that we create an 
interpersonal environment that will facilitate such understanding. 
 The affective quality of doctor-patient communication emerged as a predictor of post-
treatment oral functioning.  That is, the less satisfied patients were with the affective 
quality of the communication, the more discomfort they reported at post-treatment.  This 
finding is consistent with previous research, which has found that low satisfaction with 
the affective quality of the doctor-patient communication leads to poorer adjustment, 
which in turn has been linked with a higher number of reported side effects ((Rutter, 
Iconomou, & Quine, 1996; Mager, & Andrykowski, 2002; Thuné-Boyle, Myers, & 
Newman, 2006; Alder & Bitzer, 2003). This relationship underscores the importance of 
creating an environment in which the patient feels supported, safe, and cared for by 
his/her doctor.  Such an atmosphere produces a framework within which the patient can 
assimilate information, cope with the implications of his/her illness, and go on to make 
the necessary adjustments.  
 Lastly, the socio-emotional aspect of the communication was found to predict patients’ 
belief about their susceptibility to future complications.  The more satisfied patients were 
with the physician’s behavior at baseline, the more susceptible they believed they were at 
follow-up.  It was speculated that positive behaviors on behalf of the physician might 
create a safe environment that allow patients to let down their defense and take the 
information provided more seriously.  If this is so, then this finding is consistent with 
other findings for doctor-patient communication, which have found that patients report 
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positive experiences when consultations that were characterized by an affective 
communication style, a comprehensive patient-centered approach and the promotion of a 
working relationship  (McWilliam, Brown, & Stewart, 2000; Ong, Visser, Lammes, & de 
Haes, 2000;  Hebert, Jenckes, Ford, O'Connor, &  Cooper, 2001).  This is an important 
finding because it illustrates that satisfaction with physician behavior does not necessarily 
lead a patient to have a positive outlook, but rather supports the patient in facing the 
reality of his/her illness, which will ultimately allow the patient to make appropriate 
decisions with respect to treatment.  Another implication is that, the fear that giving bad 
news will comprise the positive relationship doctors have with their patients may be 
unfounded.  If the information is given in an environment that is perceived as caring and 
supportive by the patients, the patients are not only is better able to face the bad news, 
they are still very satisfied with their doctors. 
Implications for Coping
While analyses revealed no significant relationships between adaptive coping and 
intent to adhere, oral care, tobacco use, or alcohol use, adaptive coping was found to 
predict beliefs about susceptibility to future complications at follow-up.  That is, the more 
adaptive coping, the less susceptible a patient believes he/she is to future oral 
complications.  This finding is consistent with the hypothesis that adaptive coping would 
lead to a more optimistic outlook.  There is, of course, always a fine line between the 
utility of adaptive coping and the extent to which adaptive coping might lead someone to 
view circumstances in a more positive way than is warranted.  That is, while we want to 
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foster adaptive coping in our patients we also want to make sure they are realistic about 
their diagnosis and treatment, so that they can make reasonable decisions.   
 There was also a significant predictive relationship between adaptive coping and 
beliefs about barriers to treatment at post-treatment.  That is the more adaptive coping at 
baseline, the more barriers were perceived at post-treatment.  This was in the opposite 
direction from what had been predicted.  It was speculated that this finding might reflect a 
pragmatic appreciation of the lengths one will have to go to, to successfully adhere to oral 
care recommendations.  In other words, it may be of value to assess patients’ coping 
strategies to help guide them in their ability to set sensible expectations with respect to 
their diagnosis, prognosis, and treatment as these influence medical decision making.  
Implications of Illness Perceptions
Beliefs about the severity of oral complications at baseline significantly predicted 
oral care at follow-up.  That is, the more severe the complications were perceived to be, 
the less likely a patient was to follow the oral care recommendations.  It was speculated 
that patients might give up in the face of what is perceived to be a severe complication, or 
that maybe patients who correctly identify their illness as severe suffer more treatment 
side effects, as a consequence of more prolonged and intense treatment, that in turn 
prevent adherence.  The finding emphasizes the importance of assessing patients’ own 
understanding of their diagnosis, prognosis, and treatment, as such perceptions can 
influence treatment decisions.  The focus of the consultation would then shift from a strict 
emphasis that the patient adhere to recommendations under all circumstances to working 
with the patient to overcome misunderstandings, or misgivings, and, when needed, to 
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work with the patient to reach a compromise that still allows the patient to get as much as 
possible out of the treatment.  This might seem like a radical shift from traditional 
medicine, but if the alternative is complete non-adherence, then meeting the patient where 
he/she is and creating a cooperative relationship that allows the patient to receive at least 
part of their treatment could present a satisfactory goal for both partners. 
 A similarly finding emerged for beliefs about the severity of illness, which were also 
found to be a significant predictor of cigarette use at post-treatment.   That is, the more 
severe the illness was perceived to be, the higher was the reported use of cigarettes. 
Beliefs about the utility of treatment also predicted cigarette use at post-treatment. 
Specifically, the higher the belief that treatment is useful, the more reported cigarette use. 
This finding suggests that believing a particular treatment will be useful is not necessarily 
predictive of actually engaging in the treatment.  It implies that a patient may understand 
what a treatment entails and agree that the treatment is likely to be of benefit, but still 
decide to not follow through with it.  The finding also highlights the importance of not 
assuming that, just because the patient expresses understanding and agreement, the patient 
will adhere.  In other words, as providers we may have to inquire to our patients’ 
intentions and plans and engage in problem solving strategies to address concerns and 
reluctance on behalf of the patient to better promote adherence to treatment 
recommendations.     
 While not consistent with hypotheses, beliefs about barriers to adherence emerged as a 
significant negative predictor of post-treatment cigarette use.  The more barriers were 
perceived at baseline, the less was the reported use of cigarettes at post-treatment.  A 
similar relationship was found between beliefs about barriers to adherence and alcohol 
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use at follow-up.  That is, the more barriers were perceived at baseline, the less alcohol 
use was reported at follow-up.  In other words, the more difficult the oral care regimen 
was perceived to be, the better patients did with respect to smoking and alcohol cessation. 
It was speculated that rather than perceived difficulty leading to non-adherence due to 
patients feeling overwhelmed by the oral care regimen, the perceived difficulty may have 
underscored the importance of following through with the regime.  This finding supports 
honesty and clarity when informing patients about treatment.  While the treatment might 
be perceived as difficult, these data makes the case that patients are able to handle it.  It 
also hints at some of the thinking that might be going on in patients: While the regimen as 
a whole is perceived to be difficult, it may be that in contrast to other treatment 
requirements quitting tobacco and alcohol is thought to be relatively easy.  Again, this 
suggests that patients try to do as much as they feel they are able to do within the current 
context even if it does not meet what we, as providers, would consider ideal.   
Applications of Intent to Adhere
There was a significant predictive relationship between post-treatment intentions to 
adhere and follow-up self-reported adherence.   That is, the better the intentions to adhere 
were at post-treatment, the better the self-reported adherence was at follow-up. 
However, intentions to adhere does not predict actual adherence.  The finding suggests 
that patients’ intentions to adhere predict patients’ own assessment of how well they are 
doing with respect to the oral care regimen, but not their actual adherence.  This is 
consistent with other findings in this present study, which have suggested that there is a 
discrepancy between what patients feel is adequate or feasible versus what we, as 
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providers, would like to see with respect to treatment adherence. It also emphasizes the 
point that if we want a picture of how well our patients are actually doing we need to ask 
specific questions related to adherence behaviors, rather than asking patients for their own 
global sense of how they are doing.  Finally, this finding suggests that something happens 
between a patient’s good intentions to adhere and actual adherence.  Maybe 
recommendations are harder to carry out than anticipated or perhaps other treatment 
related effects get in the way.  As providers we might do well in continuously assessing 
how patients are doing with respect to adherence and be prepared to problem solve as 
things come up. 
Implications for Depression
Baseline depression was found to predict post-treatment beliefs about susceptibility so 
that the less depression reported at baseline, the more susceptible the patient believed 
he/she was to future complications at post-treatment.  This was a rather unexpected 
finding as it had been predicted that less depression would lead to more optimistic beliefs 
about potential oral complications.  The finding suggests that the absence of depressive 
symptoms do not preclude the presence of negative illness perceptions. Practically this 
can be translated into remembering that while there is certainly value in screening patients 
for depression, we should not forget that patients who are not reporting depression might 
still have negative cognitions surrounding their cancer diagnosis and treatment. 
 Post-treatment depression was found to predict follow-up intentions to adhere.  That 
is, the more depressed a patient was at post-treatment, the lower the patient’s intent to 
adhere at follow-up.  These results are consistent with previous research, which has 
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suggested that poor psychosocial adjustment is a predictor of non-adherence (Ayres, 
Hoon, Franzoni, Matheny, et al, 1994; Gilbar, 1989).  The finding underscores the 
importance of a holistic approach to patient care in the medical setting.  It is well known 
that depression and other psychiatric disorders can interfere with patients’ ability to cope 
with and adjust to a new diagnosis, and that such patients struggle more when it comes to 
treatment adherence than do those who are not such afflicted.  This point highlights the 
importance of continued screening and assessment of depression among the medically ill. 
Practical Issues Related to Oral Functioning
Oral functioning at baseline emerged as a significant predictor of beliefs about the 
utility of treatment at post-treatment.  That is, the more oral complications reported at 
baseline, the weaker the belief in the utility of the oral care regimen was at post-treatment.  
This relationship was not significant at follow-up.  It makes sense that a patient who is 
already suffering from significant complications at baseline is less likely to see the utility 
of carrying out the oral care regimen.  In this instance, support from the primary provider 
might be important to help the patient understand the long-range goals of the oral care 
regimen, and to provide encouragement that the complications will diminish after 
treatment has ended.  This may be another situation that calls for a compromise with 
respect to the extent that the patient is able to follow the oral care regimen until oral 
discomfort abates. 
 A significant predictive relationship emerged between baseline oral functional status 
and post-treatment intent to adhere.  Specifically, the more complications were reported at 
baseline the less the intent to adhere was at post-treatment.  This association was not 
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found at follow-up.  The observed relationship is properly a function of the number of 
radiation related side effects patients experience during treatment.  If side effects are 
severe it is understandable that patients are less likely to plan future adherence to an oral 
care regimen that may well exacerbate oral and pharyngeal discomfort and pain.  Again, 
together the physician and the patient will need to negotiate which parts of the oral care 
regimen the patient will be able and willing to do until treatment side effects subside. 
 Interestingly, there was a group difference with respect to oral functional status at 
baseline.  Specifically, patients with oral cancer reported significantly more problems 
than those with oralpharyngeal cancer at baseline, but not at post-treatment or follow-up. 
Given the above finding, this suggests that patients with oral cancer might be at greater 
risk for non-adherence to the oral care regimen or, at least, that their intentions to adhere 
will be low.  If this finding turns out to be consistent in future research then a special 
intervention aimed at those patients with oral cancers might be in order to help them 
better manage their oral health during treatment.     
 Finally, analyses found that oral functional status moderated the relationship between 
baseline beliefs about the severity of illness and actual adherence.  That is, when oral 
functional status was good, beliefs about severity of illness were good predictors of 
adherence, whereas when oral functional status was poor, the predictive power of beliefs 
about severity was diminished.  In other words, the severity of oral side effects from 
radiation treatment might make the oral care regimen so uncomfortable and painful that 
even though the patient believes the complications are severe they still choose to not, or 
are not able to, follow recommendations.   
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This finding underscores the role of treatment related side effects on treatment 
adherence.  Basically, when side effects get severe other predictive variables fall by the 
wayside and the patient may become non-adherent until such side effects have been 
resolved.  Again, these results suggest that monitoring oral and oralpharyngeal discomfort 
and pain will be important so that efforts to ease those can be initiated and a modified oral 
care regimen can be implemented allowing patients to do as much as they can with 
respect to oral care.  As providers we can encourage patients that even if the can only 
tolerate parts of the oral care regimen, this is still better than doing nothing at all. 
Future Directions 
 Cleary more research is needed to better understand the factors that lead head and 
neck cancer patients to adhere, or not adhere, to recommendation for oral care, smoking 
cessation, and alcohol cessation. While the present study found some interesting 
relationships, research in this area is still searching for an integrative model explaining 
treatment adherence. 
 Areas for future study on treatment adherence include the incorporation of models on 
medical decision-making.  Such research might consider the kinds of information patients 
use when making a decision to adhere to a specific treatment, and how one’s ability to 
actually adhere provides feedback that might change the original decision.  Such models 
ought also to continue to broaden out understanding of the concept of adherence.  From a 
medical point of view the parameters of adherence are often clearly defined in terms of a 
patient following a prescribed treatment regimen.  However, as findings from the present 
study suggests that patients define adherence differently.  In the medical literature 
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treatment adherence has been defined as “the degree to which a patient ‘voluntarily’ 
follows the (treatment) regimen recommended by a (health care) provider” (Barofsky, 
1984).  Inherent in this definition is the point that treatment adherence involves both the 
health care provider and the patient.   Interestingly, most measures of treatment adherence 
fail to incorporate adherence as it is understood by the patients themselves.   For example, 
previous research among chronically ill patients has found that these patients describe 
adherence as ‘doing one’s best’ under the circumstances (Roberson, 1992).  Further, these 
patients often defined adherence in the context of their life (i.e. actual ability to follow 
through with recommendations) as well as their perception of what is reasonable and 
effective (Roberson, 1992).   Future research should aim to incorporate patients views of 
adherence in our effort to better understand what leads patient to follow a recommended 
treatment and how to improve adherence in way that makes sense to patients. 
 An additional important factor that the current study did not examine is the role of 
family, or social, support. Research from the cancer-screening literature has found that 
psychosocial predictors of compliance encompass social support (Husaini, Sherkat, 
Bragg, Levine, Emerson, Mentes, and Cain, 2001; Manne, Markowitz, Winawer, 
Meropol, Haller, Rakowski, Babb, and Jandorf, 2002) and the perception that one’s health 
status matters to others (Danigelis, Roberson, Worden, Flynn, et al, 1995).  That is, not 
only does it appears to be important have support from others that getting screened for 
cancer is the right thing to do; the support attained through the feeling that someone cares 
about one’s health increases the likelihood of adherence to screening recommendations. 
It is entirely feasible that social support may play a role in adherence to treatment as well, 
in particular when the treatment is unpleasant or time consuming.  Another aspect of 
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social support to consider is the impact of the illness on the healthy spouse.  Spouses of 
patients in the present study were often observed expressing much more distress in 
response to the cancer diagnosis and cancer treatment than patients themselves.  It is 
conceivable that the distress the spouse experience might influence the dynamics between 
the patient and the spouse in a less than constructive manner. 
 When discussing the change of health behaviors it is difficult to not briefly mention 
Prochaska and DiClemente’s (1992) stages of change model.  The model proposes five 
stages of change: pre-contemplation, contemplation, preparation, action, and 
maintenance.   Based on the model it is suggested that actual behavior change does not 
take place until at person is in the action stage.  Adherence to the oral care regimen 
among head and neck cancer patients is a lifelong commitment that represents a drastic 
change for most patients.  For many, this requires a radical transformation in how they 
think about their oral care.  What was enough before is no longer adequate.  Integration 
and implementation of such change most likely does not happen overnight, and gaining a 
sense of where patients are in their readiness to change is integral to understanding their 







1. What is your date of birth (mm/dd/yy)? ___________




4. What is your ethnic background?
1. Caucasian (white)
2. African American




5. What is your current marital status?
1. Never married
2. Married
3. Divorced or separated
4. Widowed
5. Other __________
6. Are you currently:
1. employed for wages, full-time
2. employed for wages, part-time
3. Self-employed
4. Out of work for more than 1 year




9. Disabled and unable to work
7. What is the highest grade or year of school you completed?
1. Eight grade or less
2. Some high school
3. High school or GED certificate
4. Some college
5. College graduate
6. Post graduate or professional degree
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8. Which of the following categories best describes your annual income
from all sources? 
1. Less than $5,000
2. $5,000 to $9,999
3. $10,000 to $14,999
4. $15,000 to $19,999
5. $20,000 to $24,999
6. $25,000 to $34,999
7. $35,000 to $49,999
8. $50,000 to 74,999
9. $75,000 or more
9. Do you belong to a church, temple, or other religious group
1. Yes
2. No




4. Other. Please specify ____________________________
5. None




4. Not at all
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Health information  
Smoking (cigarettes and/or pipe tobacco) 
1. Have you smoked at least 100 cigarettes (5 packs) in your entire life?
1. Yes
2. No (if the answer is “no” go to question 6 on the next page)
3. Don’t know/Not sure
2. Do you now smoke cigarettes everyday, some days, or not at all?
1. Everyday
2. Some days
3. Not at all
3. On the average, about how many cigarettes a day do you now smoke?
(1 pack =20) 
1. Number of cigarettes _______________/Day
2. Don’t know/Not sure




3. Don’t know/Not sure
5. About how long has it been since you last smoked cigarettes
regularly, that is, daily? 
1. Within the past week (0 to 7 days ago)
2. Within the past month (0 to 1 month ago)
3. Within the past 3 months (1 to 3 months ago)
4. Within the past 6 months (3 to 6 months ago)
5. Within the past year (6 to 12 months ago)
6. Within the past 5 years (1 to 5 years ago)
7. Within the past 15 years (5 to 15 years ago)
8. 15 or more years ago
9. Don’t know/Not sure
10. Never smoked regularly
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Smokeless Tobacco 
6. Have you ever used or tried any smokeless tobacco product such as
chewing tobacco or snuff? 
1. yes, chewing tobacco
2. yes, snuff
3. yes, both chewing tobacco and snuff
4. no (skip to question 12 on the next page)
7. Do you currently use any smokeless tobacco product, such as
chewing tobacco or snuff? 
1. yes, chewing tobacco
2. yes, snuff
3. yes, both chewing tobacco and snuff
4. no (skip to question 12 on the next page)




9. On the days that you use the smokeless tobacco product you indicated
above, how many times a day to use it? 
1. Number of chews/snuffs _________________/Day
2. Don’t know/not sure
10. During the past 12 months, have you quit using smokeless tobacco
for 1 day or longer? 
1. Yes
2. No
3. Don’t know/Not sure
11. About how long has it been since you last used smokeless tobacco
regularly, that is, daily? 
1. Within the past week (0 to 7 days ago)
2. Within the past month (0 to 1 month ago)
3. Within the past 3 months (1 to 3 months ago)
4. Within the past 6 months (3 to 6 months ago)
5. Within the past year (6 to 12 months ago)
6. Within the past 5 years (1 to 5 years ago)
7. Within the past 15 years (5 to 15 years ago)
8. 15 or more years ago
9. Don’t know/Not sure
10. Never smoked regularly
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Alcohol Use 
12. During the past month, have you had at least one drink of any
alcoholic beverage such as beer, wine, wine coolers, or liquor?  
1. Yes
2. No (if the answer is “no” go to question 1 on page 6)
3. Don’t know/Not sure
13. During the past month, how many days per month did you drink any
alcoholic beverages, on the average?  
1._____Days per month  
2._____Don’t know/Not sure  
14. On the days when you drank, about how many drinks did you drink
on the average?  
(A drink is 1 can or bottle of beer, 1 glass of wine, 1 can or bottle of 
wine cooler, 1 cocktail, or 1 shot of liquor) 
1. Number of drinks ____________
2. Don’t know/Not sure
15. Considering all types of alcoholic beverages, how many times
during the past month did you have 5 or more drinks on an occasion?  
1. Number of times _____________
2. Never




1. How long has it been since you last visited a dentist or a dental clinic for any
reason? 
1. Within the past year (1 to 12 months ago)
2. Within the past 2 years (1 to 2 years ago)
3. Within the past 5 years (2 to 5 years ago)
4. 5 or more years ago
5. Don’t know/Not sure
6. Never
2. How many of your permanent teeth have been removed because of tooth decay or
gum disease?  Do not include teeth lost for other reasons, such as injury or 
orthodontics.  
1. 5 or fewer
2. 6 or more but not all
3. All
4. None
5. Don’t know/Not sure
3. How long has it been since you had your teeth "cleaned" by a dentist or dental
hygienist? 
1. Within the past year (1 to 12 months ago)
2. Within the past 2 years (1 to 2 years ago)
3. Within the past 5 years (2 to 5 years ago)
4. 5 or more years ago
5. Don’t know/Not sure
6. Never
4. During the past week, how often did you brush your teeth?






5. In general, on the days when you brushed your teeth, how many times did you
brush? 
1. I brushed once a day
2. I brushed 2 times a day
3. I brushed 3 times a day
4. I brushed 4 times a day or more
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6. During the past week, how often did you floss your teeth?






7. In general, on the days when you flossed your teeth, how many times did you
floss? 
1. I flossed once a day
2. I flossed 2 times a day
3. I flossed 3 times a day
4. I flossed 4 times a day or more
8. Do you practice other dental care on a regular basis other than describe above, such
as the use of mouth rinse and fluoride applications? 
1. Yes
2. No
If yes, please describe: _________________________________________
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Oral health  
(Follow-up version) 
Questions about your oral health 
We are interested in learning more about how patients manage their oral health.  
Thinking back on the past week, please answer each of the questions below.  Please be 
as honest as possible.  Your answers will remain strictly confidential and your doctor 
will not see them. 
1. During the past week, was there ever a day when you completely skipped brushing
your teeth?        (please circle one answer) 
a. no (go to question #3)
b. yes
2. Below you will see a line for each day of the week.  On the days that you that you
skipped brushing your teeth, please tell us briefly the reason why you did not brush.  
(Some examples are: forgetting, feeling too tired, did not bring tooth brush or tooth 
paste, gums too sore, having difficulty opening my mouth, didn't feel like it, etc.)  On 








3.On a typical day when you did brush your teeth, which of the following did you do?
(Please circle all that apply to you).   
a. I brushed my teeth in the morning
b. I brushed my teeth in the evening before bed
c. I brushed after each meal I ate
d. I brushed after every snack
e. I brushed after some of the meals I ate, but not all
f. I brushed after some of the snacks I had, but not all
4. During the past week, was there ever a day when you completely skipped flossing
your teeth? (please circle one answer) 
a. no (go to question #6)
b. yes
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5. Below you will see a line for each day of the week.  On the days that you that you
skipped flossing your teeth, please tell us briefly the reason why you did not floss.  
(Some examples are: forgetting, feeling too tired, did not bring floss, gums too sore, 
having difficulty opening my mouth, didn't feel like it, etc.)  On the days when you did 








6. On a typical day when you did floss your teeth, which of the following did you do?
(Please circle all that apply to you).   
a. I flossed my teeth in the morning
b. I flossed my teeth in the evening before bed
c. I flossed after each meal I ate
d. I flossed after every snack
e. I flossed after some of the meals I ate, but not all
f. I flossed after some of the snacks I had, but not all
7. During the past week, was there ever a day when you skipped applying fluoride to
your teeth? (please circle one answer) 
a. no (go to question #9)
b. yes
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8. Below you will see a line for each day of the week.  On the days that you that you
skipped fluoride application, please tell us briefly the reason why you did not apply 
fluoride.  (Some examples are: forgetting, feeling too tired, did not bring fluoride, 
gums too sore, having difficulty opening my mouth, didn't feel like it, etc.)  On the 
days when you did apply fluoride write N/A on the line for that day. 
Monday ___________________________________________________________ 






9. On a typical day when you applied fluoride to your teeth, how many minutes
did  you wait before you:  
a. rinsed?
(Circle one answer): 5 min 10 min 15 min 20 min 25 min 30 min
b. ate again?
(Circle one answer): 5 min 10 min 15 min 20 min 25 min 30 min
c. drank again?
(Circle one answer): 5 min 10 min 15 min 20 min 25 min 30 min
10. During the past week, was there ever a day when you completely skipped rinsing
 your mouth with the solution your dentist recommended? (please circle one answer) 
a. no (go to question #12)
b. yes
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11. Below you will see a line for each day of the week.  On the days that you that you
skipped rinsing, please tell us briefly the reason why you did not rinse.  (Some 
examples are: forgetting, feeling too tired, did not bring floss, out of rinsing solution, 
didn't feel like it, etc.)  On the days when you did rinse write N/A on the line for that 
day. 
Monday ___________________________________________________________ 






12. On a typical day when you did rinse with the solution that your dentist
recommended   
which of the following did you do?   (Please circle all that apply to you).   
g. I rinsed my teeth in the morning
h. I rinsed my teeth in the evening before bed
i. I rinsed after each meal I ate
j. I rinsed after every snack
k. I rinsed after some of the meals I ate, but not all
l. I rinsed after some of the snacks I had, but not all
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Cancer Diagnostic Interview Scale (CDIS) 
We want to understand how you felt when your dental oncologist told you about your 
cancer and cancer treatment. Specifically we are interested in how you felt when your dental 
oncologist spoke to you about the potential for oral complications that you may develop from 
your radiation therapy. 
 Please try to recall what you were feeling and thinking, and then indicate the extent to 
which you agree with each of the following statements.  If you saw more than one doctor, 









1 My dentist understood my fears 
and concerns. 
1 2 3 4 5
2 I felt hopeful after talking to my 
dentist. 
1 2 3 4 5
3 My dentist did not take time to 
answer all my questions. 
1 2 3 4 5
4 My dentist was abrupt when he 
gave me the news. 
1 2 3 4 5
5 My dentist encouraged me to 
express my feelings. 
1 2 3 4 5
6 I was given a lot of information 
about my cancer and oral health.
1 2 3 4 5
7 I believed my dentist would do 
everything he/she could to 
maintain my oral health. 
1 2 3 4 5
8 My dentist discussed different 
treatments available for the oral 
complications. 
1 2 3 4 5
9 I came away from the dentist’s 
office feeling that I was in good 
hands. 
1 2 3 4 5
10 My dentist explained the need for 
tests and procedures. 










11 I did not understand the information 
my dentist gave me. 
1 2 3 4 5
12 My dentist seemed uncomfortable 
 when I became emotional. 
1 2 3 4 5
13 I wish the dentist had given me more 
time to ask questions about oral  
complications and the treatments  
that are available. 
1 2 3 4 5
14 I wish that my dentist had been more 
hopeful. 
1 2 3 4 5
15 I felt that my dentist cared about  
me as a person. 
1 2 3 4 5
16 I got the impression my dentist 
preferred to remain emotionally 
detached. 
1 2 3 4 5
17 My dentist appeared annoyed and 
impatient with my questions. 
1 2 3 4 5
18 My dentist is a warm and caring 
person. 
1 2 3 4 5
19 My dentist did a good job of 
explaining the reasons that I might 
develop oral complications. 
1 2 3 4 5
20 I was satisfied with the information  
my dentist provided about the kinds 
of things I can do to help reduce the 
oral complications. 
1 2 3 4 5
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We are also interested in learning about the kinds of information you were given and 
who else, beside your dentist may have given you information about your oral care. 
Please answer the questions below to the best of your ability. 
1. In the area of dental oncology, where you saw your dentist, please indicate who of the
following individuals gave you information about your oral care and the form of 
information that was given to (spoken, written, or both).  Please circle all that apply.  (For 
example, if a person gave you both spoken and written information circle the number for 
both those answers.) 
Spoke 
 to me 
Gave me written 
information 
Did not give 
me any 
information 
I don’t remember if this 
person gave me any 
information 
1 My dentist. 1 2 3 4
2 The dental assistant. 1 2 3 4
3 The dental hygienist. 1 2 3 4
2. In the area of radiation oncology, where you saw radiation oncologist and received
your radiation treatment, please indicate who of the following individuals gave you 
information about your oral care and the form of information that was given to (spoken, 
written, or both).  Please circle all that apply.  (For example, if a person gave you both 
spoken and written information circle the number for both those answers.) 
Spoke 
 to me 
Gave me written 
information 
Did not give 
me any 
information 
I don’t remember if this 
person gave me any 
information 
1 My doctor 1 2 3 4
2 The physician 
assistant. 
1 2 3 4
3 The nurse. 1 2 3 4
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Adherence Determinants Questionnaire (ADQ) 
We are interested in your views about your illness and the recommendations your dental oncologist has 
made about the oral care program and suggestions that you do not smoke or drink alcohol.
Please indicate the extent to which to agree or disagree with the following statements by circling the 
answer that best describes how you feel.  The phrase “treatment plan” below refers to the recommendations 












1 The benefits of my 
treatment plan outweigh 
any difficulty I might have 
following it. 
1 2 3 4 5
2 My treatment plan is too 
much trouble for what I get 
out of it. 
1 2 3 4 5
3 Because my treatment plan 
is too difficult, it is not worth 
following. 
1 2 3 4 5
4 Following my treatment plan 
is better for me than not 
following my treatment plan.
1 2 3 4 5
5 Following my treatment plan 
will help me to be healthy. 
1 2 3 4 5
6 I’ll be just as healthy if I 
avoid my treatment plan. 
1 2 3 4 5
7 I believe that my treatment 
plan will help to prevent 
further oral complications. 
1 2 3 4 5
8 It’s hard to believe that my 
treatment plan will help me. 
1 2 3 4 5
9 There are many conditions  
more severe than the kind of 
oral complications I am at 
risk for. 
1 2 3 4 5
10 The oral complications I am 
at risk for are not as bad as 
people say. 
1 2 3 4 5
11 The kind of oral 
complications I am at risk 
for are terrible. 













12 There is little hope for 
people with the kind of 
oral complications I am at 
risk for. 
1 2 3 4 5
13 The chances that I might 
develop oral complications 
are pretty high. 
1 2 3 4 5
14 I expect to be oral 
complications in the future. 
1 2 3 4 5
15 No matter what I do, there’s 
a good chance of developing 
Oral complications. 
1 2 3 4 5
16 My body will fight off oral 
complications in the future. 
1 2 3 4 5
17 I have made a commitment 
to follow my treatment 
plan. 
1 2 3 4 5
18 Following my treatment 
plan is not in my plans. 
1 2 3 4 5
19 I intend to follow my 
treatment plan. 
1 2 3 4 5
20 I have no intentions of 
following my treatment 
plan. 
1 2 3 4 5
21 Lots of things get in the way 
of following my treatment 
plan. 
1 2 3 4 5
22 I need more assistance in 
order to follow my 
treatment plan. 
1 2 3 4 5
23 I get the help I need to 
carry out my treatment 
plan. 
1 2 3 4 5
24 I am able to deal with any 
problems in following my 
treatment plan. 
1 2 3 4 5
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Illness Perceptions Questionnaire (IPQ) - Causes illness subscale 
We are also interested in what you consider may have been the cause of your illness. As 
people are very different, there is no correct answer for this question. We are most interested in 
your own views about the factors that caused your illness rather than what others including 
doctors or family may have suggested to you.  
Below is a list of possible causes for your illness. Please indicate how much you agree or 
disagree that they were causes for you by circling the appropriate number. 








1 Stress or worry. 1 2 3 4 5
2 Hereditary - it runs in my family. 1 2 3 4 5
3 A Germ or virus. 1 2 3 4 5
4 Diet or eating habits. 1 2 3 4 5
5 Chance or bad luck. 1 2 3 4 5
6 Poor medical care in my past. 1 2 3 4 5
7 Pollution in the environment. 1 2 3 4 5
8 My own behavior. 1 2 3 4 5
9 My mental attitude e.g. thinking 
about life negatively. 
1 2 3 4 5
10 Family problems or worries 
caused my illness. 
1 2 3 4 5
11 Overwork. 1 2 3 4 5
12 My emotional state e.g. feeling 
down, lonely, anxious, empty. 
1 2 3 4 5
13 Ageing. 1 2 3 4 5












15 Tobacco use. 1 2 3 4 5
16 Accident or injury. 1 2 3 4 5
17 My personality. 1 2 3 4 5
18 Altered immunity. 1 2 3 4 5
In the table below, please list in rank-order the three most important factors that you now 
believe caused YOUR illness. You may use any of the items from the box above, or you may 
have additional ideas of your own. 





Functional Assessment of Cancer Therapy – Head and Neck (FACT-HN) 
Often patients with head and neck cancers will experience physical changes 
involving the neck and face.  These changes may be directly related to the cancer or 
result from complications associated with cancer treatment.  Such physical changes 
may affect your appearance and/or your ability to perform basic functions involving 
the mouth and neck. 
Below, please indicate to what extent the following statements have been true for 










1 I am able to eat the foods that I like. 0 1 2 3 4
2 My mouth is dry. 0 1 2 3 4
3 I have trouble breathing. 0 1 2 3 4
4 My voice has is usual quality and 
strength. 
0 1 2 3 4
5 I am able to eat as much food as I want. 0 1 2 3 4
6 I am unhappy with how my face and 
neck looks. 
0 1 2 3 4
7 I can swallow naturally and easily. 0 1 2 3 4
8 I am able to communicate with others. 0 1 2 3 4
9 I can eat solid foods. 0 1 2 3 4
10. Do you have a feeding tube?
1. No
2. Yes
3. If yes, when did you get it _____________(date)
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Brief COPE 
We are interested in how people respond when they confront difficult or stressful 
events in their lives.  There are lots of ways to try to deal with stress.  This 
questionnaire asks you to indicate what you generally do and feel when you experience 
stressful events.  Obviously, different events bring out somewhat different responses, 
but think about what you usually do when you are under a lot of stress. 
Below is a list of responses that people typically use.  Please choose your answers 
carefully by circling the appropriate number.   Remember there are no “right” or 
“wrong” answers so choose the most accurate answer for YOU, that is what YOU do 
when you experience a stressful event.  Please try to answer every item. 
I don’t do 
this at all 
I do this a 
little bit 





1 I turn to work of other activities to take 
my mind of things. 
1 2 3 4
2 I concentrate my efforts on doing 
something about the situation I’m in. 
1 2 3 4
3 I say to my self “this isn’t real”. 1 2 3 4
4 I drink alcohol or take other drugs to 
make myself feel better. 
1 2 3 4
5 I try to get emotional support from 
others. 
1 2 3 4
6 I admit to myself that I cant’ deal with it 
and give up trying.  
1 2 3 4
7 I take action to try to make the situation 
better. 
1 2 3 4
8 I refuse to believe that it has happened. 1 2 3 4
9 I say things to let my unpleasant feelings 
escape. 
1 2 3 4
10 I use alcohol or other drugs to help me 
get through it. 
1 2 3 4
11 I try to see it in a different light, to make 
it seem more positive. 
1 2 3 4
12 I try to come up with a strategy about 
what to do. 
1 2 3 4
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13 I get comfort and understanding from 
someone. 
1 2 3 4
14 I give up trying to cope with it. 1 2 3 4
15 I to look for something good in what is 
happening. 
1 2 3 4
16 I make jokes about it. 1 2 3 4
17 I do something to make me think about it 
less, such as going to the movies, 
watching TV, reading, daydreaming 
sleeping, or shopping. 
1 2 3 4
18 I accept the reality of the fact that it has 
happened. 
1 2 3 4
19 I express my negative feelings. 1 2 3 4
20 I find comfort in my religion or spiritual 
beliefs. 
1 2 3 4
21 I learn to live with it. 1 2 3 4
22 I think hard about what steps to take. 1 2 3 4
23 I pray or meditate. 1 2 3 4
24 I make fun of the situation. 1 2 3 4
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Center for Epidemiologic Studies – Depression Scale (CES-D) 
On the line next to each statement, please circle the number of the answer on each line, 
which best describes how many times during the past week you felt the same way. 
During the past week: 
Rarely or 
none of the 
time  






Occasionally or a 
moderate amount of 
the time (3-4 days) 
Most or all 
of the time 
(5-7 days) 
1 I was bothered by things that 
usually don’t bother me. 
0 1 2 3
2 I did not feel like eating; my 
appetite was poor. 
0 1 2 3
3 I felt that I could not shake off 
the blues even with the help 
from my family or friends. 
0 1 2 3
4 I felt that I was just as good as 
other people. 
0 1 2 3
5 I had trouble keeping my 
mind on what I was doing. 
0 1 2 3
6 I felt depressed. 0 1 2 3
7 I felt that everything I did was 
an effort. 
0 1 2 3
8 I felt hopeful about the future. 0 1 2 3
9 I thought my life had been a 
failure. 
0 1 2 3
10 I felt fearful. 0 1 2 3
11 My sleep was restless. 0 1 2 3
12 I was happy. 0 1 2 3
13 I talked less than usual. 0 1 2 3
14 I felt lonely. 0 1 2 3
15 People were unfriendly. 0 1 2 3
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16 I enjoyed life.  0 1 2 3
17 I had crying spells.  0 1 2 3
18 I felt sad.  0 1 2 3
19 I felt that people dislike me. 0 1 2 3





As mentioned to you earlier we are doing this study to learn more about 
the kinds of problems patients may encounter in trying to follow their oral 
care program.  We know that the program is very demanding and time 
consuming.  We hope that by learning more about what it is like to try to 
follow the program during treatment we may be able to help future patients 
in following their program.   
This is your opportunity to tell us it about your personal experience with 
your dental care program.  You have a unique perspective on what it is like 
to try to carry out a dental care program that is certainly more involved than 
usual and can be very difficult to follow.    
Below you will be asked to describe your specific oral care program and 
provide more information on what it has been like for you to follow it.  We 
also ask you to provide us with some feedback about the program and 
suggestions for how to improve it.   
When answering the questions, please take some time to really think 
about and reflect on your experience, your insight and experience is very 
valuable to us! 
1. Please describe your dental care program as your doctor has explained











2. How do you feel about following the program so far?  For example, has it
been difficult or easy?  Do you find it bothersome or annoying? Or do you 





























5. Have you come up with any strategies, or plans, that have helped you in












6. Are there things you wish that your doctor or the hospital could have
done for you?  (Remember all your feedback will remain confidential and 









7. Do you have any ideas for how we can better help persons like yourself










8. Do you have any other comments or things you think we should know









Thank you so much for your time and input! 
209
REFERENCES 
Alden ME., O'Reilly RC., Topham A., Lowry L. D., Brodovsky H., & Curran WJ Jr., 
1996. Elapsed radiation therapy treatment time as a predictor of survival in patients 
with advanced head and neck cancer who receive chemotherapy and radiation therapy. 
Radiology, 201, 675-80. 
Alder, J. & Bitzer, J.  (2003).  Retrospective evaluation of the treatment for breast cancer: 
how does the patient's personal experience of the treatment affect later adjustment to 
the illness?  Achieves of  Women’s Mental Health 6, 91-7. 
Alferi, S. M., Carver, C. S., Antoni, M. H., Weiss, S., & Duran, R. E. (2001). An 
exploratory study of social support, distress, and life disruption among low-income 
Hispanic women under treatment for early stage breast cancer. Health Psychology, 20, 
41-46. 
Arman, M., Rehnsfelt, A., Carlsson, M., & Hamrin, E. (2001). Indications of change in 
life perspective among women with breast cancer admitted to complementary care. 
European Journal of Cancer Care, 10, 192-200. 
Arraras, J. I., Wright, S. J., Jusue, G., Tejedor, M., & Calvo, J. I. (2002). Coping style, 
locus of control, psychological distress and pain-related behaviors in cancer and other 
diseases. Psychology Health & Medicine, 7, 181-187. 
Audrain, J., Rimer, B., Cella, D., Stefanek, M., Garber, J., Pennanen, M., Helzlsouer, K., 
Vogel, V., Lin, T. H., & Lerman, C.  (1999).  The impact of a brief coping skills 
intervention on adherence to breast self-examination among first-degree relatives of 
210
newly diagnosed breast cancer patients.  Psycho-Oncology, 8, 220-229.  
Ayres, A., Hoon, P. W., Franzoni, J. B., Matheny, K. B., et al. (1994). Influence of mood 
and adjustment to cancer on compliance with chemotherapy among breast cancer 
patients. Journal of Psychosomatic Research, 38, 393-402. 
Bakker, D. A., Fitch, M. I., Gray, R., Reed, E., & Bennett, J. (2001). Patient-health care 
provider communication during chemotherapy treatment: The perspectives of women 
with breast cancer. Patient Education & Counseling, 43, 61-71. 
Balkrishnan, R. (1998). Predictors of medication adherence in the elderly. Clinical 
Therapeutics, 20, 764-771. 
Bancroft B., 1994. Immunology simplified. Seminars in Perioperative Nursing, 3, 70-8. 
Barofsky, I. (1984). Therapeutic compliance and the cancer patient. Health Education 
Quarterly, 10, 43-56. 
Bast, R. C., Zalutsky, M. R., Kreitzman, R. J., Sausville, E. A., & Frankel. A. R. (2000) 
Monoclonal serotherapy. In: R. C. Bast, D. W. Kufe, R. E. Pollock, R. R. 
Weichselbaum, J. E. Holland, & E. Frei (Eds.), Cancer Medicine. 5th ed. (pp. 860-
875). Baltimore, MD: Williams and Wilkins. 
Baum, Andrew and Posluszny, Donna M. (1999). Health psychology: Mapping bio-
behavioral contributions to health and illness. Annual Review of Psychology, 50, 137-
163.  
Bensadoun, R., Schubert, M. M., Lalla, R. V., &  Keefe, D.  (2006). Amifostine in the 
management of radiation-induced and chemo-induced mucositis.  Support Care 
Cancer, 14, 566-72. 
211
Ben-Zur, H., Gilbar, O., & Lev, S. (2001). Coping with breast cancer: Patient, spouse, and 
dyad models. Psychosomatic Medicine, 63, 32-39. 
Blay, J. Y., Bouhour, D., Carrie, C., Bouffet, E., Brunat-Mentigny, M., Philip, T., & 
Biron, P. (1995). The C5R protocol: A regimen of high-dose chemotherapy and 
radiotherapy in primary cerebral Non-Hodgkin’s lymphoma of patients with no 
known cause of immunosuppression. Blood, 86, 2922-2929. 
Block, K. I. (2000). Diet, exercise and natural killer cells. Advances in Mind-Body 
Medicine, 16, 4-5.  
Bloom, J. R., Stewart, S. L., Johnston, M., Banks, P., & Fobair, P. (2001). Sources of 
support and the physical and mental well-being of young women with breast cancer. 
Social Science & Medicine, 53, 1513-1524. 
Blot, W. J., McLaughlin, J. K., Winn, D. M., Austin, D. F., Greenberg, R. S., Preston-
Martin, S. et al. (1988). Smoking and drinking in relation to oral and pharyngeal 
cancer. Cancer Research, 48, 3282-7. 
Bonadonna, G., Gasparini, M., & Rossi, A., 1980. Adjuvant therapies of postsurgical 
minimal residual disease. Recent Results in Cancer Research, 74, 8-25. 
Bonadonna, G., & Valagussa, P. (1981). Dose-response effect of adjuvant chemotherapy 
in breast cancer. New England Journal of Medicine, 304, 10-5. 
Bremers, A. J., & Parmiani, G. (2000). Immunology and immunotherapy of human 
cancer: present concepts and clinical developments. Critical Reviews in Oncology-
Hematology, 34, 1-25. 
Browman, G. P., Wong, G., Hodson, I., Sathya, J., Russell, R., McAlpine, L., Skingley, 
212
P., & Levine, M. N. (1993). Influence of cigarette smoking on the efficacy of 
radiation therapy in head and neck cancer. New England Journal of Medicine, 328, 
159-63.    
Brown, E. R., Nichols, C. R., Turns, M., Williams, S. D., Loehrer, P. J., Roth, B. J. et al. 
(1994). Early salvage therapy for germ cells cancer using high dose chemotherapy 
with autologous bone marrow support. Cancer, 73, 1716-1720. 
Brownell, K. D., & Cohen, L. R. (1995). Adherence to dietary regimens. 1: An overview 
of research. Behavioral Medicine, 20, 149-54. 
Buick, D. L. (1997). Illness representations and breast cancer: Coping with radiation and 
chemotherapy. In K. J. Petrie & J. A. Weinman (Eds.), Perceptions of health and 
illness: Current research and applications (pp. 379-409). Amsterdam, Netherlands: 
Harwood Academic Publishers. 
Burke, M. B., Wilkes, G. M., Ingwersen, K., Bean, C. K., & Berg, D. Cancer 
Chemotherapy: A Nursing Process Approach (2nd ed.). Boston, Ma: Jones and 
Bartlett; 1996.  
Butow, P. N., Kazemi, J. N., Beeney, L. J., Griffin, A., Dunn, S. M., & Tattersall, M. H. 
N. (1996). When the diagnosis is cancer: Patient communication experiences and 
preferences. Cancer, 77, 2630-2637. 
Cameron, L. D., & Nicholls, G. (1998).  Expression of stressful experiences through 
writing:  Effects of a self-regulation manipulation for pessimists and optimists.  
Health Psychology, 17, 84-92. 
Camp-Sorrell D. (1997). Chemotherapy: Toxicity management. In S. L. Groenwald, M. 
213
H. Frogge, M. Goodman, & C. H. Yarbro (Eds.). Cancer Nursing: Principles and 
Practice (4th ed.). (pp. 387-425) Boston, Ma: Jones and Bartlett. 
Cancer Prevention & Early Detection. Facts & Figures 2003. American Cancer Society 
(2003). 
Cancer Prevention & Early Detection: Facts and Figures 2001. American Cancer Society 
(2001). 
Carver, C. S. (1997). You want to measure coping but your protocol's too long: Consider 
the Brief COPE. International Journal of Behavioral Medicine, 4, 92-100. 
Carver, C. S., Pozo, C., Harris, S. D., Noriega, Y., Scheier, M., Robinson, D., Ketcham, 
A., Moffat, E. L., & Clark, K. (1993).  How coping mediates the effect of optimism 
on distress: A study of women with early stage breast cancer.  Journal of Personality 
and Social Psychology, 65, 375-390.  
Carver, C. S., & Scheier, M. F. (1994). Situational coping and coping dispositions in a 
stressful transaction. Journal of Personality and Social Psychology, 66, 184-195. 
Carver, C. S; Scheier, M. F; & Weintraub, J K. (1989). Assessing coping strategies: A 
theoretically based approach. Journal of Personality & Social Psychology. Vol 56, 
267-283. 
Cathcart, C. S., Dunican, A., & Halpern, J. N. (1997). Patterns of delivery of radiation 
therapy in an inner-city population of head and neck cancer patients: an analysis of 
compliance and end results. Journal of Medicine, 28, 275-84. 
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A. et al. (1993). The 
Functional Assessment of Cancer Therapy scale: Development and validation of the 
214
general measure. Journal of Clinical Oncology, 11, 570-9. 
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance 
System Survey Questionnaire. Atlanta, Georgia: U.S. Department of Health and 
Human Services, Centers for Disease Control and Prevention, 1999. 
Chaitchik, S., Kreitler, S., Shaked, S., Schwartz, I., & Rosin R. (1992). Doctor-patient 
communication in a cancer ward. Journal of Cancer Education, 7, 41-54. 
Chambers, M. S., Toth, B. B., Martin, J. W., Fleming, T. J., & Lemon, J. C. (1995). Oral 
and dental management of the cancer patient: Prevention and treatment of 
complications. Journal of Supportive Care in Cancer, 3, 168-175. 
Chan, A., & Woodruff, R. K. (1997). Communicating with patients with advanced cancer. 
Journal of Palliative Care, 13, 273-283. 
Cheng, J. D., Rieger, P. T., von Mehren, M., Adams, G. P., & Weiner LM. (2000). Recent 
advances in immunotherapy and monoclonal antibody treatment of cancer. Seminars 
in Oncology Nursing, 16, 2-12. 
Cohen, L., & Baum, A. (2001). Targets for interventions to reduce cancer morbidity.  In 
A. Baum, & B. L. Andersen (Eds.). Psychosocial interventions for cancer, (pp. 321-
340). Washington, DC, US: American Psychological Association. 
Cohen, M. (2002). Coping and emotional distress in primary and recurrent breast cancer 
patients. Journal of Clinical Psychology in Medical Settings, 9, 245-251. 
Coia, L, & Moylan, D. Introduction to Clinical Radiation Oncology, 3rd ed. Madison, 
WI: Medical Physics Publishing; 1998. 
Courneya, K. S., & Friedenreich, C. M. 1999). Physical exercise and quality of life 
215
following cancer diagnosis: A literature review. Annals of Behavioral Medicine, 21, 
171-179. 
Courneya, K., Keats, M., & Turner, A., 2000.  Physical exercise and quality of life in 
cancer patients following high dose chemotherapy and autologous bone marrow 
transplantation.  Psycho-Oncology, 9, 127-136. 
Cox, L. S., Sloan, J. A., Patten, C. A, Bonner, J. A., Geyer, S. M., McGinnis, W. L., 
Stella, P. J., &  Marks, R. S. (2002).  Smoking behavior of 226 patients with diagnosis 
of stage IIIA/IIIB non-small cell lung cancer.  Psycho-Oncology, 11, 472-478.  
Cull, A. (1990). Invited review: Psychological aspects of cancer and chemotherapy. 
Journal of Psychosomatic Research, 34, 129-140. 
Cummings, C. W., Fredrickson, J. M., Harker, L.A., et al. (1998). Otolaryngology - Head 
and Neck Surgery. Saint Louis, Mosby-Year Book, Inc.   
Day, G. L., Blot, W. J., Shore, R. E., McLaughlin, J. K., Austin, D. F., Greenberg, R. S. et 
al. (1994).  Second cancers following oral and pharyngeal cancers: role of tobacco and 
alcohol.  Journal of the National Cancer Institute, 86, 131-7. 
Day, G. L., Blot, W. J., Shore, R. E., Schoenberg, J. B., Kohler, B. A., Greenberg, R. S. et 
al.  (1994). Second cancers following oral and pharyngeal cancer: patients' 
characteristics and survival patterns.  European Journal of Cancer, Part B, Oral 
Oncology, 30, 381-6. 
Day, T. A., Davis, B. K., Gillespie, M. B., Joe, J. K., Kibbey, M., Martin-Harris, B., 
Neville, B., Richardson, M. S., Rosenzweig, S., Sharma, A. K., Smith, M. M., 
Stewart, S., & Stuart, R. K. (2003). Oral cancer treatment. Current Treatment Options 
216
in Oncology, 4, 27-41. 
Des Rochers, C., Dische, S., & Saunders, M.I., 1992.  The Problem of cigarette smoking 
in radiotherapy for cancer in the head and neck.  Clinical Oncology, 4, 214-216. 
DiMatteo, M. R., Hays, R. D., & Sherbourne, C. D. (1992).  Adherence to cancer 
regimens: implications for treating the older patient. Oncology, 6, 50-7.  
DiMatteo, M. R., Hays, R. D., Gritz, E. R., Bastani, R., Crane, L., Elashoff, R., Ganz, P., 
Heber, D, McCarthy, W., & Marcus, A. (1993). Patient adherence to cancer control 
regimens: Scale development and initial validation. Psychological Assessment, 5, 
102-112. 
Dimeo, F., Bertz, H., Finke, J., Fetscher, S., Mertelsmann, R., & Keul, J. (1996).  An 
aerobic exercise program for patients with hematological malignancies after bone 
marrow transplantation.  Bone Marrow Transplant, 18, 1157-1160. 
Dimeo, F., Fetscher, S., Lange, W., Mertelsmann, R., and Keul, J. (1997).  Effects of 
aerobic exercise on physical performance and incidence of treatment related 
complications after high dose chemotherapy.  Blood, 90, 3390-3394. 
Dimeo, F., Tilmann, M. H. M., Bertz, H., Kanz, L., Mertelsmann, R., and Keul, J. (1997).  
Aerobic exercise in the rehavilitation of cancer patients after high dose chemotherapy 
and autologous peripheral stem cell transplantation.  Cancer, 79, 1717-1722. 
Dollinger, M, Rosenbaum, E. H, & Cable, G. (Eds) (1997).  Everyone’s Guide to Cancer 
Therapy: How cancer is diagnosed, treated, and managed day to day. (3rd Edition). 
Andrews  McMeel Publishing, Kansas City. 
Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et al. 
217
(2000). Communication styles in the cancer consultation: Preferences for a patient-
centered approach. Psycho-Oncology, 9, 147-156. 
Dreizen, S. (1990). Oral complications of cancer therapies. Description and incidence of 
oral complications. NCI Monographs 9, 11-5. 
Duckett, T. & Belldegrun, A. (1992). Immunology in cancer. Current Opinion in 
Oncology, 4, 149-55.  
Duffy, S. A., Terrell, J. E., Valenstein, M., Ronis, D. L., Copeland, L. A., Connors, M. 
(2002). Effect of smoking, alcohol and depression on the quality of life of head and 
neck cancer patients. General Hospital Psychiatry, 24, 140-147. 
Eakes, G. G., Rakfal, S. M., Keel, E., & Gaiser, J. E. (1996).  The cancer experience: 
Responses of patients receiving outpatient radiotherapy. Journal of Psychosocial 
Oncology, 14, 19-30. 
Eden, O. B., Stiller, C. A., & Gerrard, M. P. (1988).  Improved survival for childhood 
acute lymphoblastic leukemia: possible effect of protocol compliance.  Pediatric 
Hematology & Oncology, 5, 83-91. 
Ellis, P. M., & Tattersall, M. H. N. (1999). How should doctors communicate the 
diagnosis of cancer to patients? Annals of Medicine, 31, 336-341. 
Epstein, J. B., van der Meij, E. H., Emerton, S. M., Le, N. D., & Stevenson-Moore, P. 
(1995).  Compliance with fluoride gel use in irradiated patients.  Special Care in 
Dentistry, 15, 218-22 
Farquharson, L., Noble, L. M., & Barker, C.  (2004).  Health beliefs and communication 
in the travel clinic consultation as predictors of adherence to malaria 
218
chemoprophylaxis.  British Journal of Health Psychology,  9, 201-217. 
Feld, R., Rubenstein, L., Thomas, R. A., & the Lung Cancer Study Group. (1993). 
Adjuvant chemotherapy with cuclophosphamide, doxorubicin, and cisplatin in 
patients with completely resected Stage I non-small-cell lung cancer.  Journal of the 
National Cancer Institute, 85, 299-306. 
Ferguson, T. F., Stewart, K. E., Funkhouser, E., Tolson, J., Westfall, A. O., & Saag, M. S. 
(2002).  Patient-perceived barriers to antiretroviral adherence: Associations with race.  
AIDS Care, 14, 607-617.  
Fife, B. L. (1995). The measurement of meaning in illness. Social Science & Medicine, 
40, 1021-1028. 
Franciosi, V., Fumagalli, M., Biscari, L., Martinelli, R., Ferri, T., Bella, M. et al. (2003) 
Compliance and outcomes in locally advanced head and neck cancer patients treated 
with alternating chemo-radiotherapy in clinical practice.  Tumori, 89, 20-5. 
Fleming, I. D. et al. (Eds.) (1997).  American Joint Committee on Cancer.  Manual for 
Staging of Cancer.  Philadelphia: Lippingcott-Raven. 
Fleshner, N., Garland, J., Moadel, A., Herr, H., Ostroff, J., Trambert, R., O'Sullivan, M., 
& Russo, P. (1999).  Influence of smoking status on the disease-related outcomes of 
patients with tobacco-associated superficial transitional cell carcinoma of the bladder. 
Cancer, 86, 2337-45. 
Formenti, S. C., Meyerowitz, B. E., Ell, K., Muderspach, L., Groshen, S., Leedham, B., 
Klement, V., & Morrow, P. C. (1995).  Inadequate adherence to radiotherapy in 
Latina immigrants with carcinoma of the cervix. Potential impact on disease free 
219
survival. Cancer, 75, 1135-40. 
Gilbar, O. (1989). Who refuses chemotherapy? A profile. Psychological Reports, 64, 
1291-1297. 
Gilbar, O. (1990).  Is there a relationship between family environment and dropping out 
of chemotherapy? Journal of Psychosocial Oncology, 8, 99-107. 
Girardi, P., de Pisa, E., Cianfriglia, F., Perrino, A., et al. (1992). Compliance with 
treatment for head and neck cancer: The influence of psychological and 
psychopathologic variables: A longitudinal study. European Journal of Psychiatry, 6, 
40-50. 
Goldberg, R. J. (1983). Systematic understanding of cancer patients who refuse treatment. 
Psychotherapy & Psychosomatics, 39, 180-189. 
Green, M., & Hortobagyi, G. N. (2002).  Neoadjuvant chemotherapy for operable breast 
cancer. Oncology, 16, 871-84.  
Greenwald, P. (2002).  Division of Cancer Prevention, National Cancer Institute, and 
National Institutes of Health: Cancer prevention clinical trials.  Journal of Clinical 
Oncology, 20, 4S-22S. 
Grimm, E. A. (2000). Cytokines: Biology and applications in cancer medicine. In: R. C. 
Bast, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, J. F. Holland, & E. Frei (Eds.) 
(pp. 825-834). Cancer Medicine. 5th ed. Baltimore, MD: Williams and Wilkins. 
Hagedoorn, M. & Molleman, E.  2006).   Facial Disfigurement in Patients With Head and 
Neck Cancer: The Role of Social Self-Efficacy.  Health Psychology, 25, 643-647.  
Hampton, M. R., & Frombach, I. (2000). Women’s experience of traumatic stress in 
220
cancer treatment. Heath Care for Women International, 21, 67-76. 
Harris, L. B., Sessions, R. B., & Hong, W. K. (Eds). (1998). Head and Neck Cancer: A 
Multidisciplinary Approach. Philadelphia, Lippincott-Raven. 
Hebert, R. S., Jenckes, M. W., Ford, D. E., O’Connor, D. R., & Cooper, L. A. (2001). 
Patient perspectives on spirituality and the patient-physician relationship. Journal of 
General Internal Medicine, 16, 685-692. 
Henman, M. J, Butow, P. N, Brown, R. F, Boyle, F, & Tattersall, M. H. N. (2002).  Lay 
constructions of decision-making in cancer.  Psycho-Oncology, 11, 295-306.  
Hoagland, A. C., Morrow, G. R., Bennett, J. M., & Carnrike, C. L Jr. (1983). Oncologists' 
views of cancer patient noncompliance. American Journal of Clinical Oncology, 6, 
239-44.  
Holm, L. E., Nordevang, E., Ikkala, E., Hallstrom, L., & Callmer, E. (1990).  Dietary 
intervention as adjuvant therapy in breast cancer patients--a feasibility study. Breast 
Cancer Research & Treatment, 16, 103-9. 
Horne, R., & Weinman, J. (1999).  Patients' beliefs about prescribed medicines and their 
role in adherence to treatment in chronic physical illness.   Journal of Psychosomatic 
Research, 47, 555-567. 
Humfress, H., Igel, V., Lamont, A., Tanner, M., Morgan, J., & Schmidt, U. (2002). The 
effect of a brief motivational intervention on community psychiatric patients' attitudes 
to their care, motivation to change, compliance and outcome: A case control study.  
Journal of Mental Health, 11, 155-166. 
Hyland, J. M., et al. (1983). Problems of compliance with treatment among patients 
221
receiving radiotherapy. Journal of Psychosocial Oncology, 1, 65-71. 
Jansma, J., Vissink, A., Spijkervet, F. K., Roodenburg, J. L., Panders, A. K., Vermey, A., 
Szabo, B. G., & Gravenmade, E. J. (1992).  Protocol for the prevention and treatment 
of oral sequelae resulting from head and neck radiation therapy.  Cancer, 70, 2171-80. 
Jehn, U. (1994). Long-term outcome of postremission chemotherapy for adults with acute 
myeloid leukemia using different dose-intensities.  Leukemia and Lymphoma, 15, 99-
112. 
Jones, K. R., Lodge-Rigal, R. D., Reddick, R. L., et al. (1992).  Prognostic factors in the 
recurrence of stage I and II squamous cell cancer of the oral cavity. Archieves of  
Otolaryngol Head Neck Surgery, 118, 483-5 
Jones, L. W., & Courneya, K. S. (2002). Exercise counseling and programming 
preferences of cancer survivors. Cancer Practice, 10, 208-15. 
Jovanovic, A., Schulten, E. A., Kostense. P. J., Snow, G. B., & van der Waal, I. (1993). 
Tobacco and alcohol related to the anatomical site of oral squamous cell carcinoma. 
Journal of Oral Pathology & Medicine, 22, 459-62. 
Jurcic JG. & Scheinberg DA., 1994.  Recent developments in the radioimmunotherapy of 
cancer.  Current Opinion in Immunology, 6, 715-21. 
Kaplowitz, S. A., Campo, S., & Chiu, W. T. (2002). Cancer patients’ desires for 
communication of prognosis information. Health Communication, 14, 221-241. 
Katz, M., Kopek, N., Waldron, J., Devins, G. M., & Tomlinson, G.  (2004).  Screening 
for depression in head and neck cancer.  Psycho-Oncology, 13, 269-280. 
Keltikangas-Jaervinen, L. (1986). Psychological meaning of illness and coping with 
222
disease. Psychotherapy & Psychosomatics, 45, 84-90. 
Kennedy, J. & Erb, C. (2002). Prescription noncompliance due to cost among adults with 
disabilities in the United States. American Journal of Public Health, 92, 1120-1124. 
Kintzel, P. E., & Calis, K. A. (1991).  Recombinant interleukin-2: a biological response 
modifier. Clinical Pharmacy, 10, 110-28. 
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., et al. (2000). High- and low-dose 
Interferon alpha-2b in high-risk melanoma. Journal of  Clinical  Oncology, 18, 2444-
2458.  
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., et al. (2001). High-dose interferon alpha-
2b significantly prolongs relapse-free and overall survival compared with the GM2-
KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma. Journal of 
Clinical Oncology, 19, 2370-2380.  
Kirkwood, J. M., Strawderman, M.H., Ernstoff, M.S., et al. (1996). Interferon alpha-2b 
adjuvant therapy of high-risk resected cutaneous melanoma. Journal of Clinical 
Oncology, 14, 7-17.  
Kunkel, E. J., Shakin, Woods, C. M., Rodgers, C., & Myers, R. E. (1997). Consultation 
for “maladaptive denial of illness” in patients with cancer: Psychiatric disorders that 
result in noncompliance. Psycho-Oncology, 6, 139-149. 
Lenhard, R. E., Osteen, R. T., Gansler, T. (Eds.). (2001). Clinical Oncology. American 
Cancer Society, Atlanta.   
Lepper, H. S, Martin, L. R., & DiMatteo, M. R. (1995).  A model of nonverbal exchange 
in physician-patient expectations for patient involvement.  Journal of Nonverbal 
223
Behavior, 19, 207-222. 
Lewis, C., Linet, M. S., & Abeloff, M. D. (1983).  Compliance with cancer therapy by 
patients and physicians. American Journal of Medicine, 74, 673-8. 
Li, B. D., Brown, W. A., Ampil, F. L., Burton, G. V., Yu, H., & McDonald J. C. (2000). 
Patient compliance is critical for equivalent clinical outcomes for breast cancer treated 
by breast-conservation therapy.  Annals of Surgery, 231, 883-9. 
List, M. A., D'Antonio, L. L., Cella, D. F., Siston, A., Mumby, P., Haraf, D., & Vokes, E. 
(1996).  The Performance Status Scale for Head and Neck Cancer Patients and the 
Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility 
and validity.  Cancer. 77, 2294-301. 
Lockhart, P. B., & Clark, J. (1994).  Pretherapy dental status of patients with malignant 
conditions of the head and neck.  Oral Surgery, Oral Medicine, Oral Pathology, 77, 
236-41. 
Lowell, J. A., Parnes, H. L., & Blackburn, G. L. (1990). Dietary immunomodulation: 
beneficial effects on oncogenesis and tumor growth. Critical Care Medicine, 18, 145-
8. 
Lundberg, J. C., & Passik, S. D. (1997). Alcohol and cancer: A review for psycho-
oncologists.  Psycho-Oncology, 6, 253-266 
Mackillop, W. J., Stewart, W. E., Ginsburg, A. D., & Stewart, S. S. Cancer patients' 
perceptions of their disease and its treatment.  British Journal of Cancer, 58, 355-8. 
Mager, W. M., & Andrykowski, M. A. (2002). Communication in the cancer “bad news” 
consultation: Patient perceptions and psychological adjustment. Psycho-Oncology, 11, 
224
35-46. 
Mann, T. (2001).  Effects of future writing and optimism on health behaviors in HIV-
infected women.  Annals of Behavioral Medicine, 23, 26-33. 
Manne, S. L., Pape, S. J., Taylor, K. L., & Dougherty, J. (1999). Spouse support, coping, 
and mood among individuals with cancer.  Annals of Behavioral Medicine, 21, 111-
121. 
Mashberg, A., Boffetta, P.,  Winkelman, R., & Garfinkel, L. (1993).  Tobacco smoking, 
alcohol drinking, and cancer of the oral cavity and oropharynx  among U.S. veterans. 
Cancer, 72, 1369-75. 
Matthews, A. K., Sellergren, S. A., Manfredi, C., & Williams, M. (2002). Factors 
influencing medical information seeking among African American cancer patients. 
Journal of Heath Communication, 7, 205-219. 
McCaul, K. D., Sandgren, A. K., King, B., O’ Donnell, S., Branstetter, A., & Foreman, G. 
(1999). Coping and adjustment to breast cancer. Psycho-Onology, 8, 230-236. 
McMasters, K. M., & Swetter, S. M. (2003). Current management of melanoma: Benefits 
of surgical staging and adjuvant therapy.  Journal of Surgical Oncology, 82, 209-216. 
McWilliam, C. L., Brown, J. B., & Stewart, M. (2000). Breast cancer patients’ experience 
of patient-doctor communication: A working relationship. Patient Education & 
Counseling, 39, 191-204. 
Meng, L., Maskarinec, G., Lee, J., & Kolonel, L. N. (1999).  Lifestyle factors and chronic 
diseases: Application of a composite risk index.   Preventive Medicine, 29, 296-304.  
Miaskowski, C., & Lee, K. A. (1999). Pain, fatigue, and sleep disturbances in oncology 
225
outpatients receiving radiation therapy for bone metastasis: a pilot study. Journal of 
Pain & Symptom Management, 17, 320-32. 
Moadel, A. B., Lederberg, M. S., & Ostroff, J. S. (1999). Nicotine dependence and 
withdrawal in an oncology setting: A risk factor for psychiatric comorbidity and 
treatment non-adherence. Psycho-Oncology, 8, 264-267. 
Moadel, A., Morgan, C., Fatone, A., Grennan, J., Carter, J., Laruffa, G., et al. (1999). 
Seeking meaning and hope: Self-reported spiritual and existential needs among an 
ethnically-diverse cancer patient population. Psycho-Oncology, 8, 378-385. 
Mocellin S., Panelli M., Wang E., Rossi CR., & Marincola FM., 2002. Tumor 
microenvironment: what have we learned studying the immune response in this 
puzzling battlefield? Tumori, 88, 437-44. 
Mocellin, S., Rossi, C. R., Lise, M., & Marincola. F. M. (2002). Adjuvant immunotherapy 
for solid tumors: from promise to clinical application. Cancer Immunology & 
Immunotherapy, 51, 583-95. 
Mock, V., Pickett, M., Ropka, M. E., Muscari, E., Stewart, K. J., Rhodes, V. A., et al. 
(2001). Fatigue and quality of life outcomes of exercise during cancer treatment. 
Cancer Practice, 9, 119-127.  
Moertel, C. G., Fleming, T. R., MacDonald, J. S., Haller, D. G., Laurie, J. A., Goodman, 
P. J., et al. (1990).  Levamisole and fluorouracil for adjuvant therapy of resected colon 
carcinoma.  New England Journal of Medicine, 322, 352-358. 
Mustian, K. M., Katula, J. A., & Gill, D. L. (2002).  Exercise: Complementary therapy for 
breast cancer rehabilitation. Women & Therapy, 25, 105-118.  
226
Naftzger, C., & Houghton, A. N. (1991). Tumor immunology. Current Opinion in 
Oncology, 3, 93-9. 
Nieman, D. C. (1997). Immune response to heavy exertion. Journal of Applied 
Physiology, 82, 1385-94. 
O’ Connor, A. M., Boyd, N. F., Warde, P., Stolbach, L., & Till, J. E. (1987). Eliciting 
preferences for alternative drug therapies in oncology: influence of treatment outcome 
description, elicitation technique and treatment experience on preferences.  Journal of 
Chronic Diseases, 40, 811-818. 
Oggins, J. (2003).  Notions of HIV and medication among multiethnic people living with 
HIV.  Health & Social Work, 28, 53-62.  
Omne-Ponten, M., Holmber, L., & Sjoden, P. O. (1994).  Psychological adjustment 
among women with breast cancer stages I and II:  Six-year follow-up of consecutive 
patients.  Journal of Clinical Oncology, 12, 1778-1782. 
Ong, L. M. L., De Haes, J. C. J. M., Hoos, A. M., & Lammes, F. B. (1995).  Doctor-
Patient Communication: A Review of the Literature.  Social Science and Medicine, 
40, 903-918. 
Ong, L. M. L., Visser, M. R. M., Lammes, F. B., & de Haes, J. C. J. M. (2000). Doctor-
patient communication and cancer patients’ quality of life and satisfaction. Patient 
Education & Counseling, 41, 145-156. 
Ong, L. M., Visser, M. R., van Zuuren, F. J., Rietbroek, R. C., Lammes, F. B., & de Haes, 
J. C. (1999). Cancer patients' coping styles and doctor-patient communication.  
Psycho-Oncology, 8, 155-66. 
227
Onoda, N., Nehmi, A., Weiner, D., Mujumdar, S., Christen, R., & Los, G. (2001).  
Nicotine affects the signaling of the death pathway, reducing the response of head and 
neck cancer cell lines to DNA damaging agents. Head & Neck, 23, 860-70. 
Ostroff, J. S., Jacobsen, P. B., Moadel, A. B., Spiro, R. H., Shah, J. P., Strong, E. W., 
Kraus, D. H., & Schantz, S. P. (1995).  Prevalence and predictors of continued 
tobacco use after treatment of patients with head and neck cancer.  Cancer, 75, 569-
76. 
Pardoll, D. M., & Topalian, S. L. (1998). The role of CD4+ T cell responses in antitumor 
immunity.  Current Opinion in Immunology, 10, 588-94. 
Partridge, A. H., Avorn, J., Wangs, P. S., & Winer, E. P. (2002). Adherence to therapy 
with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652-661. 
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003).  Nonadherence to 
adjuvant tamoxifen therapy in women with primary breast cancer.  Journal of Clinical 
Oncology, 21, 602-6. 
Pavol, M. A., Meyers, C. A., Rexer, J. L.. Valentine, A. D., Mattis, P. J., & Talpaz, M. 
(1995).  Pattern of neurobehavioral deficits associated with interferon alfa therapy for 
leukemia. Neurology, 45, 947-50. 
Payne, S., Jarrett, N., & Jeffs, D. (2000).  The impact of travel on cancer patients' 
experiences of treatment: a literature review. European Journal of Cancer Care, 9, 
197-203. 
Pazdur, R., Coia, L. R., Hoskins, W. J., Wagman, L. D. (Eds.). (1996). Cancer 
Management: A Multidisciplinary Approach, Medical Surgical and Radiation 
228
Oncology. Huntington, NY. 
Peleg-Oren, N., & Sherer, M. (2001). Cancer patients and their spouses: Gender and its 
effect on psychological and social adjustment. Journal of Health Psychology, 6, 329-
338. 
Peterman, A. H., & Cella, D. F. (1998). Adherence issues among cancer patients. In S. A. 
Shumaker, E. B. Schron, et al. (Eds.), The handbook of health behavior change (pp. 
462-482). New York, NY: Springer Publishing Co, Inc. 
Pickett, M., Ropka, M. E., Cameron, L., Coleman, M., & Podewils, L. (2002).  Adherence 
to moderate-intensity exercise during breast cancer therapy.   Cancer Practice, 10, 
284-292.  
Pignon, J. P., Bourhis, J., Domenge, C., et al. (2000).  Chemotherapy added to 
locoregional treatment for head and neck squamous-cell carcinoma: three meta-
analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis 
of Chemotherapy on Head and Neck Cancer. Lancet, 355, 949-55. 
Post-White J., 1996. The immune system.  Seminars in Oncology Nursing, 12, 89-96. 
Prochaska, J. O. & DiClemente, C. C. (1992).  Stages of change in the modification of 
problem behaviors.  Progress in Behavior Modification, 28, 183-218. 
Pruzinsky, T., Levine, E., & Persing, J. A.  (2006).  Facial Trauma and Facial Cancer.  In 
D. B. Sarwer, T. Pruzinsky, T. F. Cash, R. M. Goldwyn, & J. A. Persing, (Eds.), 
Psychological aspects of reconstructive and cosmetic plastic surgery: Clinical, 
empirical, and ethical perspectives. (pp. 125-143).  Philadelphia, PA: Lippincott 
Williams & Wilkins Publishers.  
229
Ptacek, J. T., Pierce, G. R., & Ptacek, J. J. (2002). The social context of coping with 
prostrate cancer. Journal of Psychosocial Oncology, 20, 61-80. 
Radloff, L. S. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population.  Applied Psychological Measurement, 1, 385-401. 
Richardson, J. L., Marks, G., & Levine, A. (1988). The influence of symptoms of disease 
and side effects of treatment on compliance with cancer therapy. Journal of Clinical 
Oncology, 6, 1746-1752. 
Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L. et al. 
(eds).  (2003). SEER Cancer Statistics Review, 1975-2000, National Cancer Institute. 
Bethesda, MD.  
Rivkin, S. E., Green, S., Metch, B., Jewell, W. R., Costanzi, J. J., Altman, S. J., Minton, J. 
P., O’Bryan, R. M., & Osborne, C. K. (1993). One versus 2 years of CMFVP adjuvant 
chemotherapy in axillary node-positive and estrogen receptor negative patients: A 
Southwest Oncology Group Study.  Journal of Clinical Oncology, 11, 1710-1716. 
Robbins, K. T., Kumar, P., Wong, F. S. H., Hartsell, W. F., Flick, P., Palmer, R., et al. 
(2000).  Targeted Chemoradiation for Advanced Head and Neck Cancer: Analysis of 
213 Patients.  Head & Neck, 22, 687-693. 
Roberson, M. H. (1992). The meaning of compliance: Patient perspectives. Qualitative 
Health Research, 2, 7-26. 
Roberts, C. S., Cox, C. E., Reintgen, D. S., Baile, W. F., & Gibertine, M. (1994).  
Influence of physician communication on newly diagnosed breast cancer patients’ 
psychological adjustment and decision-making.  Cancer, 74, 336-341. 
230
Rojas, M., Mandelblatt, J., Cagney, K., Kerner, J., & Freeman, H. (1996). Barriers to 
follow-up of abnormal screening mammograms among low-income minority women. 
Ethnicity & Health, 1, 221-228. 
Royak-Schaler, R. (1991). Psychological processes in breast cancer: A review of selected 
research. Journal of Psychosocial Oncology, 9, 71-89. 
Rudman, L. A., Gonzales, M. H., & Borgida, E. (1999). Mishandling the gift of life: 
Noncompliance in renal transplant patients. Journal of Applied Social Psychology, 29, 
834-851. 
Rutter, D. R., Iconomou, G., & Quine, L. (1996). Doctor-patient communication and 
outcome in cancer patients: An intervention. Psychology & Health, 12, 57-71. 
Salgaller, M. L. (2000). Immune adjuvants. In: S. A. Rosenberg (Ed.) Principles and 
Practice of the Biologic Therapy of Cancer. 3rd ed. (pp. 584-601). Lippincott 
Williams & Wilkins. Philadelphia, Pa. 
Sanders, B. G., & Kline, K. (1995). Nutrition, immunology and cancer: an overview. 
Advances in Experimental Medicine & Biology, 369, 185-94. 
Schnoll, R. A., Malstrom, M., James, C., Rothman, R. L., Miller, S. M., Ridge, J. A., 
Movsas, B., Unger, M., Langer, C., & Goldberg, M. (2002). Correlates of tobacco use 
among smokers and recent quitters diagnosed with cancer. Patient Education & 
Counseling, 46, 137-45. 
Schnoll, R. A., James, C., Malstrom, M., Rothman, R., Wang, H., Babb, J., Miller, S., 
Ridge, J., Movas, B., Langer, C., Unger, M., & Goldberg, M. (2003).  Longitudinal 
Predictors of Continued Tobacco Use Among Patients Diagnosed With Cancer.  
231
Annals of Behavioral Medicine, 25, 214-221. 
Schull, W. J. (1991). The segregation of cancer-causing genes in human populations. 
Mutation Research, 247, 191-8. 
Schuller, D. E., Grecula, J. C., Agrawal, A., Rhoades, C. H., Orr, E. A., Young, D. C., 
Malone, J. P., & Merz, M. (2002). Multimodal Intensification Therapy for Previously 
Untreated Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity, 
Oropharynx, or Hypopharynx.  Cancer, 94, 3169-3178. 
Schumacher, M., Bastert, G., Bojar, H., Hubner, K., Olschewski, M., Sauerbrei, W., 
Schmoor, C., Beyerle, C., Neumann, R. L. A., & Rauschecker, H. F. for the German 
Breast Cancer Study Group. (1994). Randomized 2 x 2 trial evaluating hormonal 
treatment and the duration of chemotherapy in node-positive breast cancer patients.  
Journal of Clinical Oncology, 12, 2086-2093. 
Seddon, C. F., Zabora, J. R., & Smith, E. D. (1992). Cancer and addictions: The potential 
for family and staff collusion. Journal of Psychosocial Oncology, 10, 83-97. 
See, D., Mason, S., &  Roshan R. (2002).  Increased tumor necrosis factor alpha (TNF-
alpha) and natural killer cell (NK) function using an integrative approach in late stage 
cancers.  Immunological investigations, 31, 137-53. 
Shapiro, D. E., Boggs, S. R., Rodrigue, J. R., Urry, H. L., Algina, J. J., Hellman, R., & 
Ewen, F.  (1997). Stage II breast cancer: differences between four coping patterns in 
side effects during adjuvant chemotherapy.  Journal of Psychosomatic Research, 43, 
143-57. 
Sher, T. G., Cella, D., Leslie, W. T., Bonomi, P., Taylor, S. G., & Serafian, B. (1997). 
232
Communication differences between physicians and their patients in an oncology 
setting. Journal of Clinical Psychology in Medical Settings, 4, 281-293. 
Shifren, K. (2003).  Women with heart disease: Can the common-sense model of illness 
help? Health Care for Women International, 24, 355-368. 
Silberfarb, P. M., Philibert, D., & Levine, P. M. (1980). Psychosocial aspects of 
neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer 
patients. American Journal of Psychiatry, 137, 597-601. 
Silverman, S. Jr. (2001).  Demographics and occurrence of oral and pharyngeal cancers.  
The outcomes, the trends, the challenge.  Journal of American Dental Association, 
132, 7-11. 
Silverman, S. Jr., & Shillitoe, E. F. (1998).  Etiology and predisposing factors.  In: S. Jr. 
Silverman (Ed.) Oral Cancer, 4th ed. (pp. 7-24). BC Decker Inc. Hamilton, Ontario. 
Silverman, S., Greenspan, D., & Gorsky, M.  (1993). Tobacco usage in patients with head 
and neck carcinomas: a follow-up study on habit changes and second primary 
oral/oropharyngeal cancers.  Journal of American Dental Association, 106, 33-35. 
Silverman, S. Jr. (1990). Oral Defenses and Compromises: An Overview. NCI 
Monographs, 9, 17-19. 
Siminoff, L. A., & Fetting, J. H. (1991). Factors affecting treatment decisions for a life-
threatening illness: The case of medical treatment of breast cancer. Social Science & 
Medicine, 32, 813-818. 
Simmons, K., & Lindsay, S. (2001). Psychological influences on acceptance of 
postsurgical treatment in cancer patients. Journal of Psychosomatic Research, 51, 355-
233
360. 
Simone, C. B., Simone, N. L., & Simone, C. B. II. (1997). Nutritional and lifestyle 
modification to augment oncology care: An overview. Journal of Orthomolecular 
Medicine, 12, 197-206. 
Sleath, B., Rubin, R., & Huston, S. A. (2003).  Hispanic ethnicity, physician-patient 
communication, and antidepressant adherence.  Comprehensive Psychiatry, 44, 198-
204.  
Smith, M. J., & Khayat, D. (1992). Residual acute confusional and hallucinatory 
syndromes induced by interleukin-2/alpha-interferon treatment. Psycho-Oncology, 1, 
115-118. 
Spitz, M. R. (1994). Epidemiology and risk factors for head and neck cancer.  Seminar in 
Oncology, 21, 281-8. 
Stanton, A. L., Danoff-Burg, S., & Huggins, M. E. (2002). The first year after breast 
cancer diagnosis: Hope and coping strategies as predictors of adjustment. Psycho-
Oncology, 11, 93-102. 
Steer, R. A., Ball, R., Ranieri, W. F., & Beck, A. T. (1997).  Further evidence for the 
construct validity of the Beck Depression Inventory-II with psychiatric outpatients. 
Psychological Reports, 80, 443-446. 
Stockhorst, U., Klosterhalfen, S., & Steingrueber, H. (1998). Conditioned nausea and 
further side-effects in cancer chemotherapy: A review. Journal of Psychophysiology, 
12, 14-33. 
Swango, P. A. (1996).  Cancers of the oral cavity and pharynx in the United States: An 
234
epidemiologic overview.  Journal of Public Health Dentistry, 56, 309-18. 
Tamaroff, M. H., Festa, R. S., Adesman, A. R., & Walco, G. A.  (1992). Therapeutic 
adherence to oral medication regimens by adolescents with cancer. II. Clinical and 
psychological correlates.  Journal of Pediatrics, 120, 812-7. 
Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, 
C., Perrault, D., & Sutherland, H. (1988). A randomized trial of two dose levels of 
cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with 
metastatic breast cancer.  Journal of Clinical Oncology, 6, 1377-87. 
Tavss, E. A., Bonta, C. Y., Joziak, M. T., Fisher, S. W., & Campbell, S. K. (1997).  High-
potency sodium fluoride: a literature review.  Compendium of Continuing Education 
in Dentistry, 18, 31-6. 
Taylor, S. E., Lichtman, R. R., & Wood, J. V. (1984). Compliance with chemotherapy 
among breast cancer patients. Health Psychology, 3, 553-562. 
Thompson, S. C., & Pitts, J. S. (1993). Factors relating to a person’s ability to find 
meaning after a diagnosis of cancer. Journal of Psychosocial Oncology, 11, 1-21. 
Thuné-Boyle, I. C. V., Myers, L. B., & Newman, S. P.  (2006).  The role of illness 
beliefs, treatment beliefs, and perceived severity of symptoms in explaining distress in 
cancer patients during chemotherapy treatment.   Behavioral Medicine, 32, 19-29. 
Toljanic, J. A., Heshmati, R. H., & Bedard, J. F. (2002).  Dental follow-up compliance in 
a population of irradiated head and neck cancer patients.  Oral Surgery, Oral 
Medicine, Oral Pathology, Oral Radiology, & Endodontics, 93, 35-8. 
Tomatis, L. (1998).  Environmental cancer risk factors. A review. Acta Oncologica, 27, 
235
465-72. 
van Dongen, G. A., & Snow, G. B. (1997). Prospects for future studies in head and neck 
cancer.  European Journal of Surgical Oncology, 23, 486-91. 
Vander, A. W., DiNardo, L. J., & Oliver, D. S. (1997).  Factors effecting smoking 
cessation in patients with head and neck cancer.  Laryngoscope, 107, 888-892. 
Verdonck, L. F., Dekker, A. W., de Gast, G. C., van Kempen, M. L., Lokhorst, H. M., & 
Nieuwenhuis, H. K. (1992).  Salvage therapy with ProMACE-MOPP followed by 
intensive chemoradiotherapy and autologous bone marrow transplantation for patients 
with Non-Hodgkin’s lymphoma who failed to respond to first-line CHOP.  Journal of 
Clinical Oncology, 10, 1949-1954. 
Verhoef, M. J., & White, M. A. (2002). Factors in making the decision to forgo 
conventional cancer treatment. Cancer Practice, 10, 210-207. 
Vickberg, S. M. J., Duhamel, K. N., Smith, M. Y., Manne, S. L., Winkel, G., 
Papadopoulos, E. B., et al. (2001). Global meaning and psychological adjustment 
among survivors of bone marrow transplant. Psycho-Oncology, 10, 29-39. 
Walker, L. G., Walker, M. B., Heys, S. D., Lolley, J., Wesnes, K., & Eremin, O. (1997). 
The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. 
Psycho-Oncology, 6, 290-301. 
Wang, C. C. (Ed). (1990). Radiation Therapy for Head and Neck Neoplasms: Indications, 
Techniques and Results. 2nd ed. Littleton, John Wright-PSG, Inc. 
Weinman, J., Petrie, K. J., Moss-Morris, R., & Horne, R. (1996).  The illness perception 
questionnaire: A new method for assessing the cognitive representation of illness. 
236
Psychology and Health, 11, 431-445. 
Winn, D. M. (1995).  Diet and nutrition in the etiology of oral cancer.  American Journal 
of Clinical Nutrition, 61, 473-445. 
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., 
Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R. et al. (1994).  Dose and dose 
intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.  New 
England Journal of Medicine, 330, 1253-9. 
Wynder, E. L., Mushinski, M. H., & Spivak, J. C. (1977). Tobacco and alcohol 
consumption in relation to the development of multiple primary cancers. Cancer, 40, 
1872-8. 
